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IMBALANCE BETWEEN NEUTROPHIL ELASTASE AND ELAFIN PROMOTES 
BREAST CANCER GROWTH AND PROGRESSION 
 
Joseph Anthony Caruso, B.S. 
Supervisory Professor:  Dr. Khandan Keyomarsi, Ph.D. 
 
Abstract: Elafin, an endogenous serine protease inhibitor, is a critical component of 
the epithelial barrier against neutrophil elastase (NE) activity. The central hypothesis 
examined in this dissertation was that elafin has tumor suppressive properties in breast 
cancer. In support of this hypothesis, immunohistochemical (IHC) analysis revealed that 
elafin was downregulated in the majority of invasive breast tumors and a subset of pre-
invasive ductal carcinoma in situ (DCIS) compared to elafin expression in the normal 
mammary epithelium. To understand the role of elafin in the mammary epithelium and 
the impetus for its downregulation during breast tumorigenesis, primary and 
immortalized human mammary epithelial cells (HMECs) were utilized as a model 
system. Elafin was highly expressed in G0-arrested HMECs, suggesting a previously 
unrecognized role for elafin in growth control. Stable knockdown (KD) of elafin 
compromised the ability of HMECs to maintain G0-arrest during long-term growth factor 
deprivation. This effect was reversed by re-expression of wild-type elafin but not elafin-
M25G lacking protease inhibitory function, suggesting a role for deregulated protease 
activity. Elafin KD HMECs demonstrated enhanced sensitivity to NE-induced 
proliferation. Mechanistically, activation of the ERK signaling pathway downstream of 
toll-like receptor 4 (TLR4) was essential to the mitogenic effect of NE in this system. 
Compared to HMECs, the majority of breast cancer cell lines lack endogenous elafin 
expression. Adenoviral-mediated expression of elafin was utilized to evaluate the tumor 
suppressive properties of elafin in breast cancer cell lines. Rb-status was identified as 
the critical factor governing the anti-tumor effect of elafin in this system. In breast 
cancer cell lines expressing functional Rb, the expression of elafin triggered Rb-
dependent cell cycle arrest. However, in breast cancer cell lines lacking functional Rb, 
elafin expression induced caspase-3 dependent apoptotic cell death. Elafin is a critical 
counterbalance against NE-activity. IHC analysis revealed that high levels of NE-
expressing tumor-associated neutrophils (TAN) were associated with reduced 
 viii 
recurrence-free survival, high tumor grade, and triple-receptor negative breast cancer 
(TNBC). ERK-catalyzed phosphorylation of p90RSK (T359/S363) and Rb 
phosphorylation (S807/811) were significantly enriched in NE-positive breast tumors, 
suggesting that NE-induced ERK signaling and proliferation may be relevant to human 
breast cancer. The in vivo role of deregulated NE in breast tumorigenesis was 
examined in the C3(1)TAg mouse model of TNBC. Knockout of NE in C3(1)TAg mice 
significantly reduced tumor growth and proliferation. Elafin has tumor suppressive 
properties in the context of breast cancer and is a critical counterbalance against the 
growth promoting effect of NE in vitro and in vivo. Deregulated NE-activity is a viable 
therapeutic target in breast cancer. 
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Chapter 1: Introduction 
 
Cancer is fundamentally a genetic disease. The accumulation of genetic and 
epigenetic alterations drives unrestrained proliferation and the invasive capacity of 
tumor cells (1). However, genomic derangement alone is insufficient for unabated tumor 
growth and progression. Post-mortem histological examination of adult tissues reveals a 
high frequency of occult tumors, held in stasis by a non-permissive microenvironment 
(2). Experimental evidence suggests that the ability of tumor cells to recruit and 
manipulate non-malignant cell types, including fibroblasts, endothelial cells, and 
leukocytes, governs their malignant growth potential (3-6). The interdependency of 
tumor cells and the surrounding stromal microenvironment in which they evolve (7) 
provides a strong rationale for the therapeutic targeting of essential crosstalk. The 
cellular constituents of the tumor microenvironment are not susceptible to the selective 
pressures driving resistance in tumor cells; therefore therapeutic modalities targeting 
microenvironmental factors may yield durable anti-tumor responses.  
Extracellular proteases are powerful modifiers of stromal-epithelial crosstalk. 
Deregulated protease activity is implicated in the etiology (8) and progression of cancer 
(9). Consequently, endogenous protease inhibitors are critical to the maintenance of 
tissue homeostasis, while imbalance in protease-inhibitor stoichiometry is a significant 
component of protease deregulation during tumor progression (9, 10). Neutrophil 
elastase (NE) is a potent serine protease implicated in the pathogenesis of a wide 
variety of inflammatory diseases (11). High levels of NE, largely contributed by activated 
neutrophils in the tumor microenvironment, are prognostic of poor survival in human 
cancer (12). Elafin is a serine protease inhibitor produced by epithelial cells as a 
counterbalance against the deleterious effects of excessive NE activity (13). 
Permutations in elafin expression affect the integrity of the anti-protease shield and 
dramatically alter the pathogenesis of inflammatory disease (14-20). Elafin is 
downregulated in squamous cell carcinomas of the skin, head/neck, and esophagus 
(21, 22) as well as tumor-derived cell lines (23-27), suggesting that elafin loss is a 
feature of malignant progression. 
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The central hypothesis examined in this dissertation was that elafin has tumor 
suppressive properties in breast cancer. Based on the canonical function of elafin as an 
endogenous NE inhibitor, this hypothesis implicitly questions the tumor-promoting 
activity of deregulated NE in breast tumorigenesis. Chapter One is a review of three 
major topics relating to the research described in this dissertation: (1) the biology of the 
normal mammary gland, breast tumorigenesis, and the clinical management of breast 
cancer, (2) the physiological role of NE and the consequences of deregulated NE 
activity, and (3) the control of NE activity by elafin. In Chapter Two, the expression of 
elafin during breast cancer progression, the normal regulation of elafin in human 
mammary epithelial cells (HMECs), and the consequences of disequilibrium between 
elafin and NE were examined. In Chapter Three, the tumor suppressive properties of 
elafin following expression in breast cancer cell lines were investigated. In Chapter 
Four, NE expression in human breast tumors and the role of NE in a mouse model of 
breast cancer were explored. Chapter Five discusses the findings reported within this 
dissertation, the potential clinical application of the results presented, and the future 
directions for this research. 
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BREAST CANCER 
Epidemiology of Breast Cancer 
Breast cancer is the most frequently diagnosed malignancy and a leading cause 
of cancer mortality in women worldwide, accounting for 23-percent of female cancer 
diagnoses (1,380,000 cases; 2008) and 14-percent of female cancer fatalities (458,000 
breast cancer deaths; 2008). Breast cancer disproportionately affects women in 
economically developed, westernized nations. The incidence of breast cancer is two- to 
three-fold higher in the developed countries of Western Europe and North America 
compared to the developing countries of Asia, South America, and Africa (28). Greater 
access to advanced mammographic screening technology exaggerates breast cancer 
incidence in developed nations and has contributed to the overall increase in breast 
cancer incidence observed since the late 1970s (29). However, the statistical anomaly 
created by breast cancer screening cannot completely rationalize the distribution and 
trends in breast cancer incidence over the last several decades. Lifestyle and 
environmental factors remain significantly associated with the increased incidence of 
breast cancer and observed geographical disparities. The increasing incidence of 
breast cancer within the population presents significant clinical, social, and economic 
challenges. 
Despite rising incidence, breast cancer mortality has decreased in the United 
States and several other developed countries since the early 1990s. In 1991, the age-
standardized breast cancer mortality rate in the United States was 32.7/100,000 per 
year; fifteen years later it had decreased to 23.4/100,000 per year (30). The overall five-
year relative survival rate of women diagnosed with breast cancer between 2001 and 
2007 was 90.0-percent, up from 75.1-percent for women diagnosed between 1975 and 
1977 (31). Breast cancer survivorship has benefited from early detection by widespread 
mammographic screening, optimization of chemotherapeutic regimens, the 
standardized assessment of prognostic/predictive markers, and the introduction of 
targeted therapeutics. However, progress against breast cancer is unevenly distributed 
within the population. The age-standardized mortality of Caucasian women 
(28.3/100,000 per year) is significantly less than that of African American women 
(36.4/100,000 per year). Socioeconomic factors, access to screening, treatment 
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disparities, and fundamental genetic differences influence the unbalanced burden of 
breast cancer mortality (31, 32). 
In the United States, one in eight women will be diagnosed and treated for 
breast cancer within her lifetime. Despite declining mortality rates over the last several 
decades (31), breast cancer remains a significant public health problem especially in 
economically developed countries.  
Hereditary Susceptibility to Breast Cancer 
Those affected by breast cancer or troubled by its prevalence are typically 
concerned with causality. However, no single factor can account for an individual’s risk 
of developing breast cancer. Epidemiological evidence convincingly demonstrates that 
all common cancer types have a familial component (33, 34). Compared to the general 
population, the incidence of breast cancer is between two- and three-fold higher in the 
first-degree relatives of the cancer stricken (35). The aggregation of breast cancer 
within families is largely attributable to heritable factors (36, 37). In women diagnosed 
with breast cancer and treated by mastectomy, the rate of breast cancer incidence in 
the contralateral breast is two- to three-fold higher than the general population, 
suggesting that the majority of breast cancer occurs within genetically predisposed 
women. This association is seen regardless of the stage of the original tumor indicating 
that incidence of contralateral breast cancer was not a recurrence of the original tumor 
(38, 39). The study of cancer incidence in twins provides the most compelling evidence 
of a role for genetic factors in breast cancer susceptibility. In the monozygotic twins of 
women diagnosed with breast cancer, the incidence of breast cancer is three- to four-
fold higher than in dizygotic twins or first-degree female relatives and six- to ten-fold 
higher than breast cancer incidence within the general population (35, 37). 
  Mutations in the highly penetrant breast cancer susceptibility genes, BRCA1 and 
BRCA2 (Table 1), are emblematic of hereditary breast cancer. Sub-populations with 
high frequencies of BRCA1 and BRCA2 mutations have been described, including 
Ashkenazi Jewish (40) and Bahamian (41) women. Women of African and Hispanic 
ancestry also have slightly higher frequencies of mutant BRCA1- and BRCA2-related 
breast cancers compared to woman of European or Asian descent (42, 43). In addition 
to BRCA1 and BRCA2 mutations, highly penetrate mutations in TP53 (Li-Fraumeni 
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syndrome), PTEN (Cowden syndrome), and STK11/LKB1 (Peutz-Jegher syndrome) are 
association with high breast cancer incidence (Table 1) (44-48). Together BRCA1, 
BRCA2, TP53, PTEN, and STK11/LKB1 mutations account for less than 25% of 
hereditary susceptibility to breast cancer (35, 49-51).  
The majority of hereditary breast cancer susceptibility is believed to be 
polygenic, such that the genetic component of breast cancer risk is dependent on the 
combinatorial effect of several moderate and low penetrance gene variants. These 
alleles are not necessarily rare within the population, as is the case with mutations in 
BRCA1, BRCA2, TP53, PTEN, and STK11/LKB1 (49-51). The contribution of individual 
loci to cancer susceptibility is typically small, generally less than 1.3-fold, however the 
combinatorial effect can be significant.  
Low penetrance polymorphisms at breast cancer susceptibility loci cannot be 
resolved by traditional genetic linkage studies, which relies on the mendelian 
inheritance of a rare disease-causing allele (52). Testing the association of 
polymorphisms in large cohorts of breast cancer patients versus controls is a powerful 
methodology to detect disease susceptibility loci. Pioneering association studies were 
limited by existing technology to the examination of candidate genes implicated in the 
etiology of breast cancer (53).  
The sequencing of the human genome has cataloged over 10 million single 
nucleotide polymorphisms (SNPs) with allele frequencies greater than one-percent (54-
56). The mapping of haplotypes, sets of SNPs that are statistically associated due to 
inheritances as a discrete unit (linkage disequilibrium blocks), allows the selection of a 
subset of genetic markers that define the majority of human genetic variability (56). 
These advances have facilitated the development of high throughput technologies 
capable of simultaneously assessing a great deal of common genetic diversity. 
Utilization of these technologies in association studies, referred to as genome-wide 
association studies (GWAS), has dramatically enhanced the capacity to detect disease 
susceptibility loci within the population. Large-scale genotyping remains an expensive 
and logistically challenging undertaking. GWAS generally employs a tiered design, 
beginning with a discovery phase that utilizes a relatively small cohort of cases and 
controls to identify potential susceptibility loci and followed by a validation phase 
utilizing much larger cohorts of case and controls (52). 
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High penetrance mutations in BRCA1 and BRCA2 account for a relatively small 
percentage of hereditary breast cancer susceptibility. GWAS studies have identified a 
significant number of low and moderate penetrance breast cancer susceptibility loci 
(Table 1). Individually these loci are associated with very modest increases in breast 
cancer susceptibility, however in combination their effect is pronounced. The majority of 
loci contributing to breast cancer susceptibility are located in intergenic and intronic 
chromosomal regions. The relevance of these regions is often unknown and functional 
significance is generally ascribed to the proximal gene based on the assumption that 
the majority of these loci fall within cis-regulatory elements (57).  
Breast cancer is an extremely heterogeneous disease. Hereditary factors can 
influence susceptibility to particular biological subtypes of breast cancer. Women of 
African descent demonstrate increased susceptibility to aggressive, triple-receptor 
negative breast cancer (TNBC; estrogen receptor [ER] negative, progesterone receptor 
[PR] negative, and human epidermal growth factor receptor 2 [HER2] negative), 
suggesting the enrichment of TNBC susceptibility loci in this population (32, 58-60). 
BRCA1 and BRCA2 mutations are associated with the development of TNBC (61, 62). 
Knockout of Brca1 and Trp53 in the mouse mammary gland generates tumors with 
features of TNBC (63-65). Polymorphisms at the TERT-CLPTM1L (58), 19p13 (59), 
16q12 (66), 5q11 (66), 11p15 (66), and 2q35 (66) loci are associated with the 
development of TNBC and some of these loci have been associated with women of 
African descent. ER-positive breast cancer susceptibility loci have also been identified 
in FGFR2 (67), TNRC9 (67), 8q24 (67), 2q35 (68), 16q12 (68) 9q31.2 (69), 5p12 (70), 
10q26 (66), 3q24 (66), and 17q25 (66). The association of susceptibility loci with rare 
breast cancer subtypes is more difficult to ascertain due to the inability to generate 
adequately powered cohorts (66). Sufficient evidence exists that an individual’s 
genotype plays a role in the genesis of specific breast cancer subtypes. Studies in 
larger cohorts are likely to identify more subtle associations between genetic variability 
and the genesis of breast cancer susceptibility. 
Although cancer is a disease of somatically acquired genetic and epigenetic 
alterations, the underlying genotype of the individual also influences tumor biology. A 
recent study, utilized quantitative trait locus (eQTL: loci that regulate gene expression) 
based analysis to evaluate the contribution of germline eQTLs to tumor gene 
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expression. Using the cancer genome atlas (TCGA) database, cis-acting eQTLs were 
found to be responsible for 1.2% of the absolute variance in gene expression within 
breast tumors. Taking into account the effect of somatic genetic and epigenetic factors 
within tumors, the authors examined the effect of fifteen known breast cancer 
susceptibility loci, hypothesized to exist within cis-acting elements, on gene expression. 
Polymorphisms at 9q31, 8p24, and 9q31.2 were significantly associated with the 
expression level of ESR1, MYC, and KLF4 respectively (57). This study is notable in its 
ability to connect polymorphic loci with a functionally relevant change in gene 
expression.  
The majority of breast cancer incidence likely occurs within a genetically 
susceptible subpopulation of women (36-39). Estimates suggest that about a third of the 
loci responsible for heritable breast cancer susceptibility have been identified, including 
high penetrance mutations (Table 1) (52, 53, 71-76). With rare exception, the 
contribution of individual polymorphisms to the etiology and progression of breast 
cancer is unknown. Building a comprehensive understanding of hereditary influences on 
breast cancer susceptibility is essential to understanding the etiology of breast cancer 
and more importantly identifying women at high risk of developing breast cancer who 
could benefit from the application of preventative medicine to this population.  
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Symbol Name Function Penetrance Disease 
BRCA1 (77) Breast cancer 
one, early onset 
DNA repair: 
homologous 
recombination 
High penetrance: 
mutant alleles 
also increase 
susceptibility to 
ovarian cancer 
50-65% of women with 
deleterious mutation 
develop breast cancer 
by age 70 (78).  
BRCA2 (79) Breast cancer two, 
early onset 
DNA repair: 
homologous 
recombination 
High penetrance: 
mutant alleles 
also increase 
susceptibility to 
ovarian cancer 
40-57% of women with 
deleterious mutation 
develop breast cancer 
by age 70 (78). 
TP53 (80) Tumor protein 53 Genome integrity, 
DNA damage 
response, 
apoptosis, cell 
cycle control, etc. 
High penetrance: 
mutant alleles 
also increase 
susceptibility to 
leukemia, 
sarcomas, brain 
tumors etc. 
TP53 mutations cause 
Li-Fraumeni 
syndrome. 49% of 
women with 
deleterious mutation 
develop breast cancer 
by age 60 (81). 
PTEN (46) Phosphatase and 
tensin homolog 
Control of PI3K- 
signaling, which 
regulates 
proliferation, cell 
survival, cell 
growth, 
metabolism, etc.  
High penetrance: 
mutant alleles 
increase 
susceptibility to 
thyroid, 
endometrial, 
colon, kidney 
cancer etc. 
PTEN mutations 
cause Cowden 
Syndrome. 81% of 
women with 
deleterious mutation 
develop breast cancer 
by age 70 (82) 
STK11 (LKB1) 
(83) 
Serine-threonine 
kinase 11 
Apoptosis and cell 
cycle regulation 
High penetrance: 
mutant alleles 
also increase risk 
of 
gastrointestinal, 
pancreatic, 
ovarian, uterine, 
lung cancer, etc.  
STK11 mutations 
cause Peutz-Jeghers 
syndrome. 32-54% of 
women with 
deleterious mutation 
develop breast cancer 
by age 60 
CDH1 (84, 85) E-cadherin Cell adhesion Moderate 
penetrance: 
mutant alleles 
also increase risk 
of colorectal and 
gastric cancer 
Associated with the 
development of lobular 
carcinoma of the 
breast. 40-54% of 
women with 
deleterious mutation 
develop breast cancer 
by age 70. 
PALB2 (86) Partner and 
localizer of 
BRCA2 
DNA repair, 
homologous 
recombination 
Moderate 
penetrance 
PALB2 mutations 
cause Fanconi anemia 
ATM (87, 88) Ataxia 
telangiectasia 
mutated 
DNA damage 
checkpoint, double 
stranded breaks, 
DNA repair 
Moderate 
penetrance 
ATM mutations cause 
ataxia telangiectasia  
CHEK2 (71, 89) Checkpoint kinase 
2 
DNA damage 
checkpoint, double 
Moderate 
penetrance 
1100delC 
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stranded breaks, 
DNA repair 
BRIP1 (90) BRCA1 interacting 
protein c terminal 
helicase 1 
DNA Repair: 
homologous 
recombination 
Moderate 
penetrance 
BRIP1 mutations 
causes Fanconia-
anemia 
RAD51C (76, 90) RAD51 homolog C DNA Repair: 
homologous 
recombination 
Moderate 
penetrance 
RAD51C mutations 
cause Fanconia-
anemia like phenotype 
XRCC2 (91) X-ray repair 
complementing 
defective repair in 
chinese hamster 
cells 2 
DNA Repair: 
homologous 
recombination 
Moderate 
penetrance  
 
FGFR2 (74) Fibroblast growth 
factor receptor 2 
Receptor tyrosine 
kinase involved in 
mitogenic 
signaling, and 
differentiation 
Low penetrance 
 
Breast cancer 
associated variants 
cluster within intron 
two among punitive 
transcription factor 
binding sites.  
TNRC9 (putative 
gene affected by 
1612.1 variants) 
(68, 74, 92) 
Trinucleotide-
repeat-containing 
9 
DNA repair, gene 
transcription, 
poorly defined 
Low penetrance  
MAP3K1 
(putative gene 
affected by 
5q11.2 variants) 
(74) 
Mitogen-activated 
protein kinase 
kinase kinase one  
Mitogenic 
signaling, 
component of the 
ERK signaling 
pathway 
Low penetrance  
LSP1 (putative 
gene affected by 
11p15.5 variants) 
(74) 
Lymphocyte-
specific protein 
one 
F-actin binding 
protein, expressed 
by lymphocytes, 
neutrophils, and 
macrophages, 
may have a role in 
adhesion and 
motility of these 
cell types 
Low penetrance Cluster in intron 10 
H19 (74)  Untranslated 
mRNA, regulated 
insulin-like growth 
factor two 
Low penetrance: 
significance may 
be associated 
with linkage to 
LSP1 variants 
Long non-coding RNA, 
maternally imprinted.  
RAD51L1 
(RAD51B) 
(putative gene 
affected by 
14q24.1 variants) 
(93) 
RAD51-like 1 DNA repair: 
homologous 
recombination 
Low penetrance  
CASP8 (53, 94) Caspase 8 Apoptosis Low penetrance D302H 
Shown to reduce 
breast cancer 
susceptibility. 
 10 
ESR1 (putative 
gene affected by 
6q25.1 variants) 
(69, 95) 
Estrogen receptor 
alpha 
Hormone 
signaling, 
mammary gland 
development, and 
breast cancer 
Low penetrance  
MYC (putative 
gene affected by 
8q24.21 
variants)(96) 
V-Myc 
myelocytomatosis 
viral oncogene 
homolog 
Transcriptional 
regulation of cell 
proliferation, 
metabolism etc.  
Low penetrance  
KLF4 (putative 
gene affected by 
9q31.2 
variants)(96) 
Kruppel-like factor 
4 
Transcriptional 
regulation, stem 
cell marker 
Low penetrance  
TERT (putative 
gene affected by 
5p15 variants) 
(58) 
Telomerase 
reverse 
transcriptase 
Maintenance of 
telomere repeats 
Low penetrance Intron 4 polymorphism 
identified in women of 
African descent. 
Variant alleles 
associated with 
increased risk of 
developing ER-
negative breast cancer 
TGFβ1(94) Transforming 
Growth Factor 
Beta 1 
Pleiotropic 
cytokine with pro- 
and anti- tumor 
properties 
Low penetrance L10P 
PTHLH (putative 
gene affected by 
12p11 variants) 
(97) 
Parathyroid 
hormone-like 
hormone isoform 1 
Mammary gland 
and bone 
development  
Low penetrance  
NRIP1 (putative 
gene affected by 
21q21 variants) 
(69, 97) 
Nuclear receptor-
interacting protein 
1 
Transcriptional 
repressor of 
nuclear receptors 
including ER 
Low penetrance  
COX11 (putative 
gene affected by 
17q23.2 variants) 
(98) 
Cytochrome c 
oxidase assembly 
homolog 11 
Mitochondrial 
respiration, 
catalyzes electron 
transfer from 
cytochrome c to 
oxygen 
Low penetrance  
SLC4A7/ NEK10 
(putative genes 
affected by 3p24 
variants) (98) 
Solute carrier 
family 4, sodium 
bicarbonate 
cotransporter, 
member 7 
 
Never-in mitosis 
related kinase 10 
SLC4A7: 
extracellular pH 
 
NEK10: mitosis? 
Low penetrance  
 
Table 1: Breast Cancer Susceptibility Genes.  
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Non-Heritable Breast Cancer Risk Factors 
Non-heritable, environmental and physiological factors can also significantly 
affect the risk of breast cancer development. The mammary epithelium undergoes 
frequent and repeated remodeling events in the context of the female reproductive cycle 
and pregnancy (99). Despite the evolution of robust tumor suppressor pathways, 
dynamic tissues, such as the mammary gland, are inherently sensitive to 
transformation. Many environmental and physiological factors influence an individual 
susceptibility to breast cancer, including gender, age, estrogen exposure, childbearing, 
and lifestyle. The interplay between these factors and the underlying genetic 
susceptibility in the development of breast cancer is poorly defined.  
Gender and Age 
Breast cancer is 100-times more common in women than in men. Age is the 
greatest risk factors influencing breast cancer development in women. In European and 
North American countries, the cumulative incidence of breast cancer in women is 2.7-
percent by 55 years of age, nearly doubling to 5-percent by 65 years of age, and 
increasing to 7.7 percent by 75 years of age (100). Following tumor initiation, the 
accrual of an adequate mutational spectrum capable of facilitating tumor 
growth/progression can take years or decades. The somatic mutation rate is believed to 
be the major factor limiting carcinogenesis. Under-recognized age-related changes in 
tissue architecture and the composition of the ECM may also play an important role in 
susceptibility to cancer by generating a microenvironment permissive of malignant cell 
expansion (101). Chronic low-grade inflammation and cytokine production are also 
associated with advanced age and significantly enhance the development of breast 
cancer (102). Rising life expectancy and aging populations in the United States, 
Western Europe, and elsewhere in the developed world will continue to increase the 
absolute incidence of breast cancer.  
Estrogen Exposure 
High-fidelity control of hormone levels is essential to the coordination of 
proliferation, differentiation, and apoptosis, processes that facilitate remodeling of the 
glandular architecture. Factors influencing hormone signaling are particularly important 
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determinants of breast cancer risk. Estrogen promotes growth and development of the 
mammary gland and also plays a central role in the etiology of breast cancer. The 
cumulative lifetime exposure of a woman to estrogen is consistently associated with the 
likelihood of breast cancer development (103). Early menarche (<12 years versus >16 
years) and late menopause (>55 years versus <45 years) are significant breast cancer 
risk factors (104, 105). High levels of serum estrogen in post-menopausal women are 
associated with increased breast cancer incidence (106, 107). The pharmacological use 
of estrogen as a component of hormone replacement therapy (100) and to a lesser 
extent in contraceptives (108-110) increases breast cancer risk. Estrogen analogs 
increase the prevalence of breast cancer in heavily exposed populations. Estrogenic 
activity is a common property of industrial byproducts, herbicides, pesticides, and other 
synthetic products (111-114).   
Childbearing 
Pregnancy is associated with drastic changes in hormone signaling that can 
have confounding affects on breast cancer incidence. In the short term, high levels of 
serum estrogen can promote the progression of small pre-existing tumors and expand 
the pool of susceptible stem/progenitor cells, increasing breast cancer incidence in the 
years directly following pregnancy (104). In experimental models, pregnancy and 
lactation can induce changes in stromal ECM composition enhancing the invasive and 
metastatic capacity of breast tumor cells (115, 116) However, early-pregnancy (<20 
versus >30) and multiple pregnancies greatly reduces long-term chances of developing 
breast cancer (104). Pregnancy is associated with high, sustained levels of circulating 
progesterone, inducing differentiation of mammary stem and progenitor cells, which is 
thought to underlie the long-term protective effect of pregnancy. Experimentally, 
carcinogen transformed mammary epithelial cells fail to form tumors in the stromal fat 
pad of uniparous rats, but readily form tumors in virgin rats. The factors responsible for 
the enhanced tumor suppressive properties of the post-partum mammary stroma are 
uncharacterized (117). Changes in the stroma and the stem/progenitor cell population 
within the mammary gland likely underlie long-term reductions in breast cancer risk 
following pregnancy. Lactation and prolonged breast-feeding are also known to reduce 
the risk of breast cancer, however the mechanism is undefined (118).  
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Obesity and the Western Lifestyle 
Characterized especially by dietary overconsumption and a lack of physical 
activity, the western lifestyle encompasses a wide range of behavioral patterns and 
lifestyle choices known to promote several tumor types. Western women tend to give 
birth at relatively older ages and to fewer children, forgoing the protective benefit of 
early and repeated childbearing (119). A high fat diet and lack of physical activity are 
significant risk factors for breast cancer, especially in post-menopausal women (120). 
Resultant high body mass index (BMI) is strongly associated with breast cancer 
incidence (121-123). In post-menopausal women, the synthesis of estrogen is catalyzed 
in peripheral adipose tissue by the aromatase enzyme (CYP19). Dietary fat intervention 
studies demonstrate that reducing the percentage of calories consumed as fat 
significantly decreases circulating estrogen levels and breast cancer incidence, 
suggesting that increased estrogen signaling partially underlies breast cancer risk due 
to obesity (122, 124). In obese individuals, sub-clinical chronic inflammation is 
commonly observed in the visceral and subcutaneous adipose tissue. Dead adipocytes 
elicit an inflammatory response resulting in the recruitment of macrophages, which 
produce pro-inflammatory mediators known to promote tumor development and 
progression (125-128). In animal models, obesity induces significant inflammation of the 
mammary gland characterized by activation of the NF-κB pathway, elevated pro-
inflammatory cytokine production, and enhanced aromatase expression (129). Alcohol 
consumption increases estrogen levels and breast cancer risk in a dose-dependent 
fashion (130). Perturbed hormonal homeostasis may be a significant mechanism by 
which the western lifestyle influences breast cancer incidence. 
The western lifestyle may partially account for regional disparities in breast 
cancer incidence. Breast cancer incidence is more than three times higher in the United 
States than in Asian countries, including China, Japan, and the Philippines. Following 
migration to the United States, the incidence of breast cancer in Asian women from 
these countries shifts precipitously towards that of other Americans, reaching 
significance after only a decade; even when controlling for regional differences in heath 
care and surveillance. After two generations of residence in the United States, the 
relative risk of breast cancer is indistinguishable when comparing the descendants of 
Asian immigrants to other groups living in the United States (131). Increased breast 
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cancer incidence in recent immigrants and the overall trend of rising incidence among 
women in rapidly developing countries have been largely attributed to the 
westernization of these populations (132).  
Breast cancer risk factors either increase the somatic mutation rate within the 
mammary epithelium and/or facilitate the aberrant growth and progression of breast 
cancer to clinical relevance. A comprehensive understanding of the environmental and 
hereditary factors influencing breast cancer susceptibility does not exist. The 
mechanisms underlying the effect of known risk breast cancer factors is largely absent 
or conjecture. Building a multivariate risk model for breast cancer could increase the 
efficiency of breast cancer screening programs and guide cancer-preventative 
strategies. 
The Mammary Gland  
The mammary gland is the defining characteristic of the class, Mammalia; 
evolutionarily designed, as an epidermal appendage, to provide for the rapid growth, 
development, and immunological defense of live-born offspring (133). The mammary 
gland is architecturally defined by ductal branching, a distinction that applies to several 
organs, including the kidney, salivary gland, vascular system, and lung. Most organs 
are patterned embryonically and maintain their basic structure throughout adulthood. 
Uniquely, the mammary gland experiences the majority of its growth and development 
after puberty and is subject to continual remodeling throughout the reproductive lifespan 
of the individual (134). Many of the same properties that make the mammary gland 
functional and responsive to the nutritional needs of offspring, also make it susceptible 
to tumorigenesis.  
The labyrinthine molecular networks coordinating cell fate decisions, the 
proliferation of stem/progenitor cells, the initiation of context dependent differentiation 
programs, and maintenance of tissue homeostasis within the mammary gland are only 
partially understood. Essential paradigms of signaling are persistently observed, 
including the importance of stromal-epithelial interaction in the normal development and 
function of the mammary gland. Many of the developmental processes and molecular 
circuitry that shape the adult mammary gland, also play a role in promoting or inhibiting 
breast tumorigenesis and progression.  
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Murine Mammary Gland as a Model System 
  The availability of human breast tissue at discrete developmental stages is 
limited. The relatively few studies of human mammary gland development are restricted 
to histology, ultrastructure, and immunohistochemistry (135). In vitro culture systems 
have been developed that recapitulate some aspects of human mammary gland biology 
(136). However, mammary gland development and function is dependent on 
simultaneous interactions between a broad array of cell types and ECM elements, 
limiting the utility of in vitro systems. Therefore, the mouse has become the 
predominate model of mammary gland development. The transplantability of the adult 
mouse mammary gland makes it an ideal system for the examining the interaction 
between stromal and epithelial elements. 
Despite 65-75 million years of divergent evolution, eighty-percent of human 
genes have direct orthologs within the mouse genome (137). Since their introduction in 
1980s, transgenic (138, 139) and knockout (140-142) mouse models have significantly 
contributed to our understanding of the genetic and biological basis of mammary gland 
development and tumorigenesis. However, significant morphological, functional, and 
developmental differences exist between the mouse and human mammary gland, 
complicating the interpolation of observations made in the mouse to human physiology 
and disease (135, 143). 
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Figure 1: Critical Elements of the Signaling Network Regulating the Development of the Mouse 
Mammary Gland 
 
The development of a ductal system capable of producing and delivering milk to 
offspring at parturition is a highly regulated process. The embryonic mouse mammary 
gland is formed by the invagination of epidermal cells from circular placodes into the 
dermal mesenchyme. Mammary cell fate decisions within the placode are dependent on 
Wnt and Fgf signaling as well as the Tbx3 transcription factor. Reciprocal paracrine 
exchange with the developing mesenchyme directs the development of the mammary 
bud; essential factors include Pthrp, hedgehog, and Wnt signaling as well as the 
Msx1/Msx2 transcription factors. At puberty, estrogen and GH drive branching 
morphogenesis through paracrine signaling intermediates including Egf, amphiregulin, 
and Igf1. Progesterone, prolactin, and placental lactogens drive lobuloalveolar 
differentiation through a series of paracrine intermediates, including Wnt-4, Stat5a, and 
Rankl. Upon parturition, high levels of prolactin and declining levels of progesterone, 
estrogen, and placental lactogens stimulate milk production. Oxytocin stimulates 
contraction of myoepithelial cells, triggering lactation. Following weaning, Lif-induced 
Stat3 synergizes with C/ebpδ to induce pro-apoptotic signaling and drive involution of 
the redundant epithelium. 
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Embryonic Mammary Gland Development 
The initial stage of mammary gland development, as defined in the mouse, is 
the formation of bilateral milk lines; a multilayered epithelial ridge within the single 
layered embryonic epidermis. Nascent mammary epithelial cells then migrate to circular 
placodes, later forming the nipples, at regular intervals along the milk line (135, 144). 
Wnt/β-catenin signaling (145), fibroblast growth factor (Fgf) signaling (146), and the 
Tbx3 transcription factor (147, 148) are critical components of the molecular network 
directing early cell fate decisions at the mammary placode (Figure 1). Induction of 
Wnt/β-catenin signaling is among the earliest events at the mammary placode. 
Overexpression of the secreted Wnt inhibitor, Dickkopf 1, in the epidermis of mice 
abrogates mammary placode formation (145). Similarly, Fgf10, Fgfr2, and Tbx3 
knockout mice cannot form embryonic placodes (146-148). Wnt/β-catenin (149, 150), 
Fgf (74, 151, 152), and Tbx3 (152, 153) pathways are commonly deregulated in breast 
cancer through overexpression, amplification, and in the case of some FGF-receptors, 
somatic mutation. Hyperactivity of these pathways been shown to enhance 
stem/progenitor cell populations and facilitate breast tumorigenesis in animal model 
(149, 150, 153). 
The mammary bud is formed by the invagination of cells from the epidermal 
placode into the underlying dermal mesenchyme. The development of the mammary 
bud is dependent on reciprocal, paracrine exchange with the mammary mesenchyme 
(99, 154). The influence of mesenchymal signals on glandular epithelial development is 
very significant, such that transplantation of embryonic mammary epithelial cells into 
salivary gland mesenchyme results in the generation of salivary gland-like structures 
(155). The embryonic mammary mesenchyme even has the capacity to induce 
differentiation of mammary carcinoma cells (6). The importance of cellular context to 
mammary epithelial cells has also been demonstrated in vitro using three-dimensional 
culture on reconstituted basement membrane. Three-dimensional culture systems are 
capable of inducing functional differentiation of mammary epithelial cells and 
normalizing tumor cells, largely through epigenetic reprogramming (136, 156). 
Several factors have been shown to drive mammary bud development, including 
Wnt/β-catenin signaling (157), parathyroid hormone related peptide (Pthrp) (158, 159), 
hedgehog signaling (160-162), and the Msx1/Msx2 transcription factors (163, 164) 
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(Figure 1). Pthrp signaling exemplifies paradigmatic stromal-epithelial crosstalk during 
mammary gland development. The mammary epithelial bud expresses Pthrp, while 
mesenchymal cells express the Pthrp receptor (Pth1r). Pthrp/Pth1r signaling drives the 
specialization of mesenchymal cells, the formation of the nipple, and suppresses hair 
follicle formation around the nipple. Pthrp has no direct effect on the developing 
mammary epithelium. Instead, Pthrp stimulates the expression of secreted 
mesenchymal factors essential to epithelial growth and differentiation, including bone 
morphogenetic protein 4 (Bmp4), neuregulin 3, and Fgf10. Pthrp knockout mice are 
incapable of maintaining the mammary bud (158, 159, 164, 165). 
The hedgehog pathway also plays a prominent role in the development of the 
mammary bud. Similar to Pthrp, hedgehog ligands are exclusively expressed by the 
mammary epithelium. Haploinsufficiency of the Patched-1 hedgehog receptor  (Ptc-1) is 
sufficient to disrupt early mammary gland development; evidenced by ductal 
hyperplasia and dysplasia. Transplantation of Ptc-1 +/- epithelium into a Ptc-1 +/+ 
stromal compartment completely reverses the phenotype, further evidencing the 
importance of stromal signaling during mammary epithelial development through 
paracrine feedback (161, 162). The hedgehog transcriptional affecter, Gli2, is 
exclusively expressed within the mammary mesenchyme. Knockout of Gli2 completely 
inhibits formation of the epithelial bud, corroborating the importance of stromal 
hedgehog signaling (160).  
Embryonic mammary gland development is heavily dependent on reciprocal 
paracrine exchange between the epithelial and stromal compartments. The wnt, 
hedgehog, and Pthrp pathways are commonly deregulated in breast cancer and have 
pleiotropic roles in the tumor initiation and progression (166-172).  
Post-Pubertal Mammary Gland Development 
Relatively little is known about the molecular mechanisms governing embryonic 
ductal outgrowth and formation of the rudimentary mammary ductal tree evident at birth. 
Although embryonic mammary epithelial cells express hormone receptors in the 
presence of maternal hormones, knockout of hormone receptor fails to diminish the 
embryonic ductal outgrowth, indicating that embryonic ductal morphogenesis is 
hormone independent (144). The ductal tree remains virtually growth arrested 
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(undergoing only isometric growth) from birth until circulating ovarian hormones trigger 
profound expansion at puberty.  
The importance of steroid and peptide hormones in the regulation of adolescent 
mammary gland development is well known. In rats, ovariectomy prevents ductal 
outgrowth of the mammary gland; administration of estrogen rescues this deficiency 
(173). Hypophysectomized (pituitary gland removal) rats require growth hormone (GH) 
and estrogen supplementation for mammary gland development (174). Estrogen 
receptor alpha (ERα) knockout mice and GH receptor knockout mice are incapable of 
ductal morphogenesis (175-178). Knockout of the estrogen receptor beta (ERβ), 
progesterone receptor (PR), and prolactin receptor do not significantly affect branching 
morphogenesis (178). 
ERα is primarily expressed in the epithelial compartment of the mammary gland, 
displaying a heterogeneous distribution (179, 180). Despite the role of estrogen in the 
proliferation of the mammary gland, ERα expressing epithelial cells rarely proliferate 
due to TGF-β blockade (181). Transplantation of ERα -/- mammary epithelial cells into 
an ERα +/+ stroma does not rescue the ability of these cells to undergo branching 
morphogenesis (182). Conditional ERα knockout within the mammary epithelium is 
sufficient to abrogate ductal morphogenesis (175). Therefore, only epithelial ERα 
activity is required for mammary gland development. ERα-/- mammary epithelial cells, 
transplanted with ERα +/+ cells, are capable of proliferation and contribute to ductal 
elongation, evidencing a predominately paracrine mechanism of mammary gland 
development upon estrogen stimulation (182).  
Amphiregulin is strongly induced by estrogen signaling in the mammary gland 
and is required for ductal morphogenesis (Figure 1). The protease ADAM17 is required 
for amphiregulin shedding and is also essential for ductal morphogenesis (183). 
Knockout and transplantation studies demonstrate that the epidermal growth factor 
receptor (EGFR), for which amphiregulin is a ligand, is active in the stromal 
compartment and required for ductal morphogenesis. Exogenous EGFR-ligands rescue 
ductal branching in ovariectomized mice (184). Downstream factors expressed in 
response to EGFR activation in the stromal compartment, include matrix 
metalloproteinase 2 (MMP-2) and FGFs. Knockout of MMP2 or conditional knockout of 
FGFR2 within the mammary epithelium impairs branching morphogenesis (185, 186). 
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The available evidence suggests that a paracrine feedback loop exists between ERα-
induced, epithelial amphiregulin and stromal EGFR-induced paracrine factors (183, 
187).  
In contrast to ERα, the GH receptor (GHR) is expressed in the mammary 
stroma. Knockout of GHR in the mammary epithelium does not impair mammary gland 
development, however complete knockout of the GH signaling in both the epithelial and 
stromal compartments completely abolishes ductal outgrowth (188-191). GH drives the 
expression of insulin-like growth factor 1 (IGF-1) in stromal cells (Figure 1). Complete 
knockout of IGF-1 or knockout of its receptor in the mammary epithelium prevents 
ductal morphogenesis. Administration of IGF-1 to hypophysectomized rats or GHR-
knockout mice restores growth of the mammary ductal tree, however administration of 
GH and estrogen to IGF-1 knockout mice does not rescue ductal morphogenesis (174, 
190, 192).  
Hormone signaling is essential to the development and function of the mammary 
gland. Estrogen and GH play a central role in the ductal elongation and morphogenesis. 
The human mammary gland undergoes constant remodeling during the reproductive 
lifespan of an individual. Hormone levels fluctuate during the menstrual cycle. 
Depending on the stage of the menstrual cycle, between four- and twenty-percent of 
luminal mammary epithelium expresses the ERα (180, 193). High estrogen levels drive 
mammary epithelial proliferation during the menstrual cycle. The proliferative fraction of 
mammary epithelial cells reaches 35% during the luteal phase, evidencing the scale of 
cyclic epithelial turnover. As estrogen levels decline, equivalent levels of apoptotic cell 
death counterbalanced the increased cellularity of the mammary gland (194, 195). The 
high levels of proliferation stimulated by estrogen underlie breast cancer risk associated 
with the lifetime exposure to estrogen. 
In addition to its critical role in normal mammary gland development, estrogen is 
essential to tumor growth and progression. Three-quarters of breast tumors express 
ERα and are largely dependent on estrogenic stimulation for growth and progression. 
Tumors lacking ERα may also arise from estrogen responsive lesions in the breast 
(196, 197).  
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Mammary Gland Architecture 
The mouse mammary ductal tree grows from terminal end buds (TEBs), multi-
layered, club-shaped structures situated at the tips of the immature ducts. TEBs contain 
mammary stem/progenitor cells, which differentiate into two, morphologically unique cell 
layers, an outer layer of cap cells and interior body cells. Proliferation within the TEBs 
forces invasion into the mammary stroma and ductal elongation. The mammary tree 
fans out through the stroma by bifurcation of the TEBs and lateral side branching from 
ducts. Branching continues until the TEBs reach the peripheral extent of the mammary 
fat pad, at which point TEBs arrest and disappear largely due to the TGF-β signaling 
(198, 199). Apoptosis clears the cells within the duct forming a central lumen, a process 
dependent on upregulation of the pro-apoptotic regulator, Bim (200). Mature mammary 
ducts are bi-layered tubes; a single layer of columnar epithelial cells line a central lumen 
(luminal cells), supported by a layer of contractile myoepithelial cells (basal cells) (201). 
The cap cells of the TEB become the basal layer of the duct and body cells become the 
luminal layer.  
The human mammary gland develops similarly as a branched network of ducts 
and has a comparable epithelial composition. The most significant morphological 
difference is the presence of lobules at the end of each duct, resembling an aggregate 
of grapes on a stem. This function unit of the human mammary gland is referred to as 
the terminal ductal lobular units (TDLU). Lobules within the TDLU consist of spherical 
alveoli are separated by connective tissue (Figure 2). The alveoli within the TDLU 
become the milk producing units of the mammary gland during lactation. 
The epithelium of the TDLU is responsive to ovarian hormone stimulation and 
contains a pool of proliferative mammary stem/progenitor cells. These properties are 
retained during the reproductive lifespan of the individual, facilitating the structural 
remodeling of the mammary epithelium during the reproductive cycle and pregnancy. 
Consequently, the TDLU is the major site of breast tumorigenesis. The mouse 
equivalent of the TDLU is the lobuloalveolar unit. In contrast to the TDLU, lobuloalveolar 
units form at the terminus of regularly space tertiary side branches, which sprout from 
the mature ducts in response to cyclic exposure to ovarian hormones (143, 202).  
 22 
 
Figure 2: Terminal Ductal Lobular Unit 
 
The function unit of the adult human mammary gland is TDLU, which is composed of 
the terminal duct and the lobule. The lobule is tightly bound collection of alveoli, which 
are hollow spheroids connected to the terminal duct. A single layer of epithelial cells 
lines the lumen of the alveoli and ducts. A layer of contractile myoepithelial cells and a 
layer of basement membrane surround the luminal epithelial layer. During lactation, 
functional differentiation of the alveoli produces the constituents of milk. Contraction of 
the myoepithelial layer forces the milk through the ducts and out the nipple. The 
epithelium of the TDLU is responsive to ovarian hormone stimulation and contains a 
pool of proliferative mammary stem/progenitor cells, making it the preferential site of 
breast tumorigenesis. 
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The Mammary Stroma 
 The mammary parenchyma exists within a complex stromal compartment. The 
mammary stroma consists of ECM and various cell types, including adipocytes, 
fibroblasts, endothelial cells, myofibroblasts, and immune/inflammatory cells (203). The 
mammary stroma is not simply a structural unit. Stromal derived signals are essential to 
the growth, differentiation, and maintenance of the mammary gland. Transplantation of 
mammary epithelial cells between mouse strains demonstrates that strain-specific 
differences in branching patterns are dependent on stromal factors (204). 
Mammographically dense breast tissue is a significant risk factor for human breast 
cancer development, suggesting that breast composition may influence tumorigenesis. 
(105, 205, 206).  
  Mechanical properties associated with ECM density and signaling molecules 
secreted by stromal cells significantly influence mammary epithelial cell behavior. A 
critical difference between the mouse and human mammary glands is the composition 
of the stromal compartment. Within the human breast, the mammary epithelium is 
embedded within a thick layer of highly collagenous connective tissue, separating it 
from the adipose tissue within the breast. Comparatively small amounts of fibrous 
connective tissue separate the mouse mammary epithelium from the adipose tissue 
(143, 202). Experimentally, the mammary fat pad of immunocompromised mice must be 
pre-injected with human fibroblasts and ECM to generate a stromal microenvironment 
conducive to the transplantation of human mammary epithelial tissue (207).  
The mammary epithelium is surrounded by a layer of basement membrane 
(BM). Physical connection between mammary epithelial cells and BM components is 
critical for the control of apical-basal polarity, epithelial architecture, proliferation, and 
differentiation (208-210). Critical components of the mammary BM include collagen type 
IV, laminin 1, 5, 10, and 11, fibronectin, and heparin sulfate proteoglycans. The 
composition and thickness of the BM varies relative to the mammary duct (211). The 
composition and distribution of the BM significantly influences elongation, branching, 
and lumen clearance (101, 212). Transmembrane proteoglycans, integrins and non-
integrin receptors expressed by the mammary epithelium detect the BM composition, 
dictating response. The cellular constituents of the mammary gland express several 
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dimeric integrin receptors capable of specifically detecting ECM elements, including 
collagen (α1β1 and α2β1), laminin (α3β1 and α6β4), and fibronectin (α5β1 and α5β3). 
Knockout of α2-integrin reduces ductal branching, (213), collagen receptor discoidin 
domain receptor 1 (DDR1) knockout mice are incapable of ductal elongation (208), and 
β1-integrin knockout disrupts alveologenesis (214-216). These results demonstrate the 
essential role of interactions between the BM and epithelium to the development and 
function of the mammary gland.  
Inflammatory signaling networks and effectors of the inflammatory processes 
are important components of mammary gland elongation and development. 
Macrophages are recruited by the developing TEB, contributing angiogenic factors, 
proteases, cytokines, and growth factors. Colony-stimulating factor 1 (CSF-1) knockout 
mice are deficient in mature macrophages and demonstrate impaired branching 
morphogenesis (217). MMPs are critical to stromal remodeling and are known to 
dramatically affect invasion, elongation, and branching patterns. MMP-3 and MMP-2 are 
of particular importance in branching morphogenesis; MMP-2 knockout mice are 
incapable of invasion at TEBs, while MMP-3 knockout mice are deficient in lateral side 
branching (186). MMPs have a critical role in invasion and metastasis in breast cancer. 
Overexpression of MMPs, results in disruption of normal mammary gland development, 
hyperplasia, and in some cases is sufficient to initiate tumorigenesis (8, 218-221).  
The composition of the mammary stroma is essential to the growth, 
differentiation, and function of the mammary gland (99, 154). Tumor progression is 
highly dependent on the ability of the tumor epithelium to recruit and manipulate non-
malignant stromal cell types, including fibroblasts, endothelial cells, and leukocytes (3-
6).  
Pregnancy, Lactation, and Involution 
During pregnancy, the mammary gland undergoes a dramatic increase in size 
and structural complexity, facilitating lactation at parturition. The fundamental 
component of the lactating mammary gland is the alveolus, a hollow spheroid with a 
central lumen. A single layer of secretory epithelial cells lines the alveoli lumen, which is 
surrounded by myoepithelial cells (222). Progesterone and prolactin drive lobuloalveolar 
differentiation. Progesterone receptor (PR) knockout mice demonstrate impaired 
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alveolar development (223, 224). PR (existing as two isoforms PR-A and PR-B) is 
expressed in both the stromal and epithelial compartments. In chimeric mammary 
glands, PR-/- epithelial cells are able to contribute to alveologenesis in the presence of 
PR+/+ epithelial cells, evidencing a paracrine mechanism of action. Essential 
downstream secreted factors include Wnt-4 and Rankl (receptor activated by NF-κB 
ligand) (Figure 1) (224, 225). Overexpression of Rankl rescues lobuloalveloar 
development in PR-knockout mice (226, 227). Prolactin receptor (PLR) knockout mice 
are similarly deficient in lobuloalveolar differentiation and lactation (228). Following 
prolactin stimulation, PLR and Jak2 associate resulting in the activation of Stat5a 
(Figure 1). Knockout of Stat5a displays the same defect in lobuloaveolar differentiation 
seen in prolactin knockout mice (229-231). Stat5a and PLR are both capable of 
enhancing Rankl  transcription. Rankl knockout, Rankl knockout, or IκB knockin mice 
demonstrate failure of lobuloaveolar proliferation and differentiation, evidencing a role 
for the NF-κB pathway in growth and differentiation of the secretory epithelium (232). 
Rankl is frequently deregulated during breast cancer progression and plays a critical 
role in metastasis to the bone (233-235). 
At parturition, functional differentiation of the secretory epithelium and lactation 
occurs in response to declining estrogen and progesterone levels, loss of placental 
lactogens, and high levels of prolactin. During lactation, the secretory epithelium 
produces the constituents of milk, secreting them into the alveoli lumen. Stimulated by 
oxytocin, myoepithelial cells contract, forcing the milk through progressively larger 
ducts, and eventually the nipple (Figure 1) (222, 236, 237).  
Following weaning, the milk-producing epithelium involutes through extensive 
apoptosis returning the mammary ductal tree to its original size and complexity (238). 
Involution of the mammary epithelium is dependent on Stat3, induced by leukemia 
inhibitory factor (LIF) (239). Knockout of Stat3 inhibits apoptosis of the secretory 
mammary epithelium following forced weaning (240, 241). Stat3 induces the expression 
of c/ebpδ, synergy between these two transcription factors potently induces pro-
apoptotic gene expression (Figure 1), including Bak, Igfbp5, and death receptor ligands 
(tnfα, FasL, Trail, and Tweak) (242-244). Stat3 activation also inhibits Akt survival 
signals by upregulating PI(3)Kinase regulatory subunits p55 α and p50 α (245). As the 
redundant mammary epithelial undergoes apoptosis, the activation of inflammatory 
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pathways leads to expression of MMPs and serine proteases. Protease activation 
enhances apoptosis through the removal of matrix attachment and is necessary for 
mammary gland remodeling. Apoptotic cells are cleared by recruited immune cells and 
adipoctyes replace the epithelium (246).  
The mammary gland is capable of repeated cycles of alveologenesis, lactation, 
and involution following subsequent pregnancies, facilitated by stem and progenitor cell 
maintained within the TDLU (247). Ultimately, at the conclusion of the reproductive 
lifespan of the individual, menopause, the levels of ovarian hormones decline and the 
functional elements of the mammary gland atrophy. In mammals, significant efficiency 
in energy utilization is derived from tightly coupling mammary gland development and 
function with reproduction (154, 248, 249).  
The high levels of proliferation throughout the reproductive lifespan and the 
essential role of stem/progenitor cells in mammary gland remodeling are believed to 
sensitize the mammary gland to tumorigenesis. The majority of breast tumors occur in 
post-menopausal women. Sustained estrogen stimulation due to the extra-ovarian 
synthesis of estrogen is critical to the development of breast tumors in post-menopausal 
women (120). 
Breast Tumor Histopathology 
Histological examination of breast tumors reveals a great deal of heterogeneity. 
Greater than 90% of breast cancers are carcinomas, however several sarcomas are 
known to occur within the breast. Invasive ductal carcinoma (IDC) of the breast, arising 
from the terminal duct, is the most common form of breast cancer, accounting for 65-
80% of cases. Ductal carcinoma in situ (DCIS), a non-invasive accumulation of 
neoplastic cells within the duct, is generally accepted to be a precursor of invasive 
breast cancer (250, 251). Invasive lobular carcinoma (ILC) of the breast, arising from 
the lobules, accounts for approximately 8-14% of breast tumors, while 3-6% of breast 
tumors display mixed lobular/ductal histology. Despite significant molecular difference 
between IDC and ILC, clinical outcomes are similar in multivariate analysis. Loss of e-
cadherin expression appears to be a critical factor in the development of ILC. Lobular 
carcinoma in situ (LCIS) is not a necessarily a precursor lesion, however it is predictive 
of subsequent development of breast cancer (either IDC or ILC) (252, 253). Several 
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additional subtypes of breast cancer commonly observed based on histological 
features. Tubular carcinoma (4%), invasive cribriform carcinoma, and mucionous 
carcinoma (2%) generally have a good relative prognosis. Medullary carcinoma (2%) 
has an intermediate prognosis. Metaplastic carcinoma (<1%), signet-ring carcinoma 
(<1%), inflammatory carcinoma (<1%), and lipid rich carcinoma (<1%) have a relatively 
poor prognosis. The molecular characteristics and origins of the rare histological 
subtypes are currently not well understood and the majority of research attention is 
directed at IDC given its prevalence. 
Mammary Stem and Progenitor Cells  
The regenerative capacity of the mammary gland is contingent on a stem and 
progenitor cell population capable of continuously replenishing the mammary 
epithelium. Mammary stem and progenitor cells are a prominent topic of research 
investigation not only because of their role in mammary morphogenesis and tissue 
homeostasis, but also because they provide a rich set of targets for transformation. 
Murine Mammary Stem and Progenitor Cells 
The existence of stem cells in the mouse mammary gland was established by 
pioneering studies in which normal mammary gland fragments or disassociated 
mammary epithelial cells were transplanted into the cleared mammary fat pad of 
syngeneic mice (254). A complete and functional mammary gland can be generated 
using mammary epithelial cells from any portion of the donor ductal tree, regardless of 
donor age or parity (255, 256). Reconstitution of the mammary gland following serial 
transplantation evidences a capacity for self-renewal, a critical property of stem cells. 
However, unlike neoplastic tissue, the regenerative capacity of normal mammary 
epithelial cells in serial transplantation studies is limited (between five and seven 
iterations) (257, 258). Transplantation of retrovirally labeled mammary epithelial cells 
demonstrated that a single cell can repopulate the entire mammary ductal tree 
indicating multipotency (the ability to differentiate into multiple cell types), another 
critical characteristic of stem cells (259). Serial transplantation of cells at limiting 
dilutions and examination of mammary repopulating efficiency is the gold standard 
methodology for verifying stem cell properties and establishing their frequency (260, 
261).  
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Long-term label retaining cells can be identified by bromodeoxyuridine (BrdU) or 
3H-thymidine pulse and chase experiments, suggestive of infrequent and asymmetric 
divisions, providing additional evidence of a stem cell population with the adult 
mammary gland (261, 262). Ultrastructure and histological studies identified several 
populations of undifferentiated cell types within the mouse mammary glands, which 
have been hypothesized to be stem and progenitor cells (255).  
Isolation of stem cell populations is difficult due to their rarity and failure to 
maintain their phenotype in culture. Using cell surface markers and fluorescence-
assisted cell sorting several impressive studies have overcome the barriers to 
mammary stem cell purification from disassociated mouse mammary glands. The 
authors of one study were able to generate a functional mammary gland at limiting 
dilution with cells expressing CD24 (heat stable antigen) and high levels of CD49f (α6-
integrin) (260). Similarly, another group was able to reconstitute the mammary gland 
using a single cell expressing CD24 and high levels of CD29 (β1-integrin) (261). In both 
studies, serial transplantation into the cleared mammary fat pad of secondary recipient 
mice reconstituted the mammary gland, demonstrating the hallmark capacity for self-
renewal. The ability of the reconstituted mammary glands to form milk producing 
lobuloalveolar units during pregnancy confirms the ability of the identified mammary 
stem cells to differentiate into the critical lineages comprising the mammary gland (260).  
Bi-potent and lineage restricted progenitors have been identified in the mouse 
mammary gland suggesting a hierarchical organization of mammary stem and 
progenitor cells. Committed luminal progenitors can be purified based on high 
expression of CD61 (β3-integrin), low levels of CD133 (prominin-1), and low levels of 
Sca-1. Differentiation into mature luminal cells is accompanied by loss of CD61, 
increased CD133, and increased Sca-1 (263-265). The number of intermediates, their 
nature, and the relationships between them are not fully understood. Characterization of 
individual progenitor cells is challenging. Cell surface markers are an imperfect means 
to consistently segregate pure populations of progenitors. Specific cell surface markers 
have not been identified for myoepithelial progenitor. Plasticity likely exist within the 
mammary stem and progenitor cell hierarchy further complicating their purification and 
characterization ex vivo. 
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Lineage Tracing of Murine Stem and Progenitor Cells 
Lineage tracing is an important tool for the examination of stem and progenitor 
cell hierarchy in vivo. Using the K14 promoter to drive YFP expression, a mutipotent 
progenitor can be identified in the embryonic mouse mammary gland. However, 
postnatal lineage tracing using inducible K14-YFP reporter mice find a K14 expressing, 
lineage restricted subpopulation of progenitor cells capable of generating cells of the 
myoepitelial, but not luminal lineage cells. Inducible-YFP expression under the K5 and 
Lgr5 promoters, confirms the existence of unipotent myoepithelial progenitor cells in the 
mature mouse mammary gland. Using inducible-K8-YFP reporter mice, a subpopulation 
of progenitor cells were identified that can give rise to the luminal lineage alone. These 
results argue that in the adult mammary gland, luminal and myoepithelial lineages are 
derived independently from distinct lineage-restricted progenitor cell populations. 
Interestingly, transplantation of the unipotent myoepithelilal (but not luminal) progenitor 
alone into a cleared mammary fat pad forces them to become multipotent and 
reconstitute both the luminal and myoepithelilal compartments. Transplantation of 
myoepithelilal progenitors with luminal progenitors maintains their unipotent nature 
(247). This indicates that plasticity exists between the myoepithelial progenitor and 
mammary stem cell populations and possibly explains the discordant results of lineage 
tracing and transplantation experiments. 
Lineage-tracing using WAP-Cre and Rosa26LacZ reporter mice has also been 
used to identify a long-lived sub-population of parity-identified mammary epithelial cells 
(PI-MECs) (266). PI-MECs proliferate during pregnancy and give rise to the alveolar 
structures (267). PI-MECs express high levels of CD49 (268), suggesting that they are 
a component of the population shown to repopulate the mammary gland (260).  
Mouse mammary stem and progenitors cells are arranges in a hierarchical 
manner (Figure 3). The relationship between individual stem and progenitor cells 
identified by lineage tracing and cell surface markers is unclear. The number of 
intermediates and organization of the hierarchy is unknown.  
Human Mammary Stem and Progenitor Cells 
Similar to mice, the human mammary gland also contains a population of stem 
cells (Figure 3). Examination of X-chromosome inactivation patterns in the normal, 
human mammary gland suggests that entire ducts and lobules, containing both luminal 
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epithelial and myoepithelial components, are clonally derived from a single cell (269). 
Immunohistochemistry and FACS analysis of stem cell markers identifies putitive stem 
cells in the human mammary gland (265, 270-274). Low levels of epithelial cell 
adhesion molecule (Ep-CAM) and high levels of CD49f identifies a subpopulation of 
human mammary epithelial cells capable of generating mammary gland-like structures 
in severely immunocompromised mice. These experiments require “humanization” of 
the stromal microenvironment, achieved by pre-injection of either the cleared mammary 
fat pad or highly vascularized renal capsule with ECM components and irradiated 
fibroblasts. The resulting mammary structures contained both ductal and lobular 
structures composed of myoepithelial and luminal lineage cells. Serial transplantation 
demonstrates that these cells are capable of self-renewal (65, 275, 276). However, this 
system is limited by inefficiency.   
Subpopulations of bipotent and lineage restricted progenitor cells have been 
identified in human breast tissue using in vitro clonogenic assays, evidencing a 
hierarchical organization of mammary epithelial precursors (271, 277, 278). Stem and 
progenitor cells are resistant to anoikis and can be propagated under non-adherent 
conditions, resulting in floating multicellular structures termed mammospheres. Serial 
passaging of mammospheres is an accepted surrogate test of self-renewal (260, 265, 
270-274, 279). Disassociated mammospheres plated at clonal densities in adherent 
monolayer culture can give rise to colonies containing myoepithelial cells (markers 
include: K5, K14, and α-smooth muscle actin), luminal epithelial cells (markers include: 
K8, K18, K19, MUC-1, ER, and PR), or both cell types. 
Using these assays the mammary precursor population isolated based on 
expression of EpCAM and CD49f can be further subdivided into a uncommitted/bi-
potent population (Muc-1-, CD24-, CD133-, Thy1+, and CD10+) and luminal-restricted 
population (Muc-1+, CD24+, CD133+, Thy1-, and CD10-) (65, 274, 275, 279-281). Bi-
potent progenitor cells within the human mammary gland can also be identified by 
double positivity for myoepithelial K14 and luminal K19 (274). Specific markers of 
myoepithelial-restricted precursors have not been identified, however myoepithelial-
restricted colony forming cells have been identified in vitro (281, 282)  
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Figure 3: Simplified Mammary Stem and Progenitor Cell Hierarchy 
Mouse and human stem and progenitor cells are organized in a hierarchical manner. In 
this simplified diagram, a multipotent stem cell gives rise to a bipotent progenitor, which 
in turn generates two lineage restricted progenitor populations, luminal-restricted and 
myoepithelial-restricted. Through a series of intermediates these progenitors give rise to 
the differentiated populations making up the mammary gland. The number of 
intermediates and the relationship between them are unknown. 
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Stem and Progenitor Cell Niche 
In the mammary gland stem and progenitor cells exist within a specific 
microenvironmental niche and are not randomly distributed throughout the bulk of the 
epithelium. In the developing mouse mammary gland, stem and progenitor cells reside 
within the TEB, however in the mature mammary gland these cells are located within 
specialized regions of the duct as observed by immunohistochemical analysis of stem 
cells markers and the spatial arrangement of lobule structures during pregnancy (267, 
283, 284). Microdissection of the human mammary organoids from reduction 
mammoplasty and validation of stem cell properties in vitro revealed the stem cell niche 
is in the terminal duct (274).  
Self-renewal and the ability to differentiate into multiple cells types are 
advantageous traits for tumor cells. Cell extrinsic control of stem cell activity may have 
evolved to prevent unrestrained, cell autonomous self-renewal and carcinogenesis 
(285). In the absence of self-renewal signals from the niche, stem cells differentiate 
making it difficult to study the factors influencing mammary stem cell biology in vitro.  
Regulation of Stem and Progenitor Cells 
Although the existence of stem and progenitor cells is well accepted, the 
molecular mechanisms underlying their maintenance and differentiation remains 
unclear. Paracrine signaling downstream of hormone receptors and microenvironmental 
factors are critical to the maintenance and differentiation of normal mammary stem and 
progenitor cells.  
Mammary stems cells can be enriched based on the expression of integrins, 
particularly α6-(CD49f) and β1-(CD29). Heterodimeric integrin complexes, such as 
α6/β1, directly anchor cells to the ECM and are critical to communication with the 
stromal microenvironment. Deletion of β1-integrin in the basal compartment (using K5-
Cre) eliminates the mammary repopulating capacity in serial transplantation 
experiments. The mammary glands of these mice also display abnormal ductal 
branching, atypical polarity, and disequilibrium between the myoepithelial and luminal 
lineages. β1-integrin mediated interactions with the ECM are critical to maintenance and 
cell fate decisions in mammary stem cells (286).  
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Ovarian hormone exposure and reproductive history profoundly influence breast 
cancer risk. Although mammary stem and progenitor cells are generally ER and PR 
negative (only a subset, 6-10%, of luminal progenitors express hormone receptors) 
hormone dynamics dramatically affect the frequency and activity of these cell 
populations (154). Ovariectomy dramatically reduces the number of stem/progenitor 
cells, while treatment with estrogen and progesterone restore their numbers (287). 
Pregnancy enhances the stem/progenitor pool ten-fold (288). The downstream effectors 
of ERα and PR, amphiregulin, Wnt-4, and Rankl, are critical paracrine factors affecting 
mammary stem and progenitor cell dynamics (287, 289, 290) Fluctuations in the 
frequency and activity of stem and progenitor cells in the context of reproductive cycle 
and pregnancy likely underlies the complicated relationship between breast cancer risk 
and ovarian hormone exposure (105). The estrogen receptor target gene, Gata3, plays 
a specific role in the evolution of the luminal lineage. Conditional knockout of Gata3 in 
the mouse mammary gland results in expansion of the luminal progenitor population 
and defective differentiation. Overexpression of Gata3 in mammary stem cells forces 
differentiation into alveolar luminal cells (264). GATA3 is an important marker and is 
essential to the development of luminal breast cancer (291). 
Transcriptional profiling of human mammary bi-potent progenitors and luminal 
restricted progenitors suggests that the NOTCH, WNT, and NF-κB pathways are of 
particular importance in the regulation of stem/progenitor cell function. The NOTCH 
signaling pathway is critical to stem cell maintenance and the specification of cell fate in 
diverse tissues. NOTCH receptor 4 was highly expressed in the bi-potent progenitor 
population, while NOTCH receptor 3 was enriched in the luminal progenitor populations, 
suggesting a role for differential NOTCH signaling in regulating the stem cell hierarchy 
(280). Disruption of Cbf-1/Rbpκ, a critical component of the Notch transcriptional 
complex, alters the cellular composition of the mouse mammary gland during 
pregnancy (292). Downregulation of Notch signaling in mammary stem cells results in 
expansion of the stem and progenitor cell pool, suggesting that Notch is required for cell 
fate decisions and the regulation of the stem and progenitor cell pool within the 
mammary gland. In progenitor cells, constitutive activation of Notch-1 results in 
preferential selection of luminal cell fate resulting in the accumulation of luminal 
progenitors, hyperplasia, and tumorigenesis (293-295). In breast cancer patients, 
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NOTCH1 and JAG1 overexpression have been observed and are prognostic of poor 
outcome (296).  
The Wnt/β-catenin pathway is critical to mammary stem cell self-renewal. Wnt 
ligands expand the pool of mammary progenitors, however they fail to significantly alter 
cell fate (297). Overexpression of Wnt ligands in the mammary gland is associated with 
a six-fold increase in the mammary stem cell population (261). Overexpression of MMP-
3 enhances the mammary stem cell population and induces hyperplasia by binding the 
non-canonical wnt, Wnt5b, which is known to inhibit the canonical Wnt/β-catenin 
pathway (298).  MMP-3 knockout mice demonstrate a marked decrease in the 
mammary stem cell activity (298). Wnt/β-catenin is commonly deregulated in breast 
cancer (299-302). The hedgehog pathway also appears to regulate the stem cell 
population within the mammary gland; expression of constitutively activated 
smoothened was shown to increase the pool of stem and progenitor cells (303).  
The factors governing the maintenance, proliferation, and differentiation of 
mammary stem and progenitor cell is poorly understood. Stem and progenitor cell 
populations are long-lived, compared to fully differentiated cell types. Proliferation of 
mammary stem and progenitor cell population in the context of mammary gland 
remodeling exposes them to the accumulation of transforming mutations over the 
lifespan of the individual. Mammary stem and progenitor cells are likely cellular targets 
of oncogenesis in breast cancer.  
Cancer Stem Cells 
According the cancer stem cell hypothesis, breast tumors are organized in a 
hierarchical manner, similar to normal breast tissue. In this model, only a small 
subpopulation of tumor cells, termed cancer stem cells, drive tumor growth, 
progression, recurrence, and therapeutic resistance. Cancer stem cells have been 
hypothesized to originate from normal tissue stem cells that have acquired a limitless 
proliferative capacity. Alternatively, a more differentiated cell acquires the cancer stem 
cell phenotype.   
High levels of CD44 and low levels of CD24 enrich for breast cancer stem cells 
capable of recapitulating tumors in immunocompromised mice following serial 
transplantation at limiting dilutions (304). Gene expression analysis of cells isolated 
 35 
using these markers identifies a gene signature highly enriched in stem cell 
regulators/markers identified in other organ systems and prognostic of poor patient 
outcome in breast cancer (305, 306). High activity of aldehyde dehydrogenase (ALDH) 
and the ability to form mammospheres in a non-adherent culture system are similarly 
capable of identifying cancer stem cells. Furthermore, ALDH1 expression is prognostic 
of poor patient outcome (307). Many genes and pathways associated with stem cell 
function, such as Wnt, NOTCH, NF-κB, hormone receptor signaling, are deregulated in 
tumors.  
Breast Cancer Progression  
Post-mortem histological examination of adult tissues reveals a high frequency 
of tumors that fail to progress to clinical relevance despite the expression of strong 
oncogenes (2). Occult tumors are observed in the breast tissue of approximately 40% of 
young and middle-aged women (20-54 years of age) (308). The high relative frequency 
of microscopic tumors compared to actual clinical diagnoses suggests the existence of 
robust tumor suppressive mechanisms limiting tumor growth and progression. 
Understanding the barriers to tumor growth/progression and the mechanisms utilized by 
tumors to circumvent them are essential to the development of novel therapeutic 
strategies and predictive/prognostic markers. 
Oncogenes and Tumor Suppressors 
Tumorigenesis is driven by genetic and epigenetic alterations. In 1982, several 
groups simultaneously reported the discovery of activated and transforming ras, the first 
oncogene (309-311). Oncogenes are normal cellular genes constitutively or 
inappropriately activated by chromosomal translocation, gene amplification, or mutation. 
In 1986, loss of heterozygosity at the retinoblastoma susceptibility locus led to the 
identification of the first tumor suppressor gene, Rb (312). Tumor suppressors are 
genes rendered insufficiently active or inactive by deletion, insertion, mutation, or 
epigenetic silencing. Except in rare cases where haploinsufficiency provides a selective 
advantage during tumorigenesis (i.e. PTEN), tumor suppressors generally require loss 
of both alleles (313, 314).  
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Multiple safeguards have evolved in mammals to impede tumorigenesis. To 
circumvent these safeguards, the activation of multiple oncogenes and/or loss of 
multiple tumor suppressors are typically required for transformation (315, 316). Tumor 
initiation occurs within a single cell. Stem and progenitor cell are believed to be 
preferential targets of transformation within the mammary epithelium.  
Clonal Selection Model of Tumor Progression 
Following initiation, the accumulation of additional somatic mutations is essential 
to tumor growth and progression. Cancer develops over many years following the 
initiating event, reflecting the time required for accumulation of mutations. 
Tumorigenesis is theorized to be an evolutionary process, driven by the selection and 
expansion of tumor clones with advantageous traits from a heterogeneous population. 
The identification of cancer stem cells suggests that only a small subset of cells are 
responsible for tumor growth and progression giving rise to a phenotypically diverse 
population of non-tumorigenic progeny cells through an aberrant differentiation 
program. Given that the differentiated progeny of the cancer stem cells are incapable of 
contributing to disease progression the clonal selection may occur exclusively among 
the cancer stem cells. Alternatively, plasticity between the cancer stem cell 
compartment and more differentiated progeny making up the bulk of the tumor may 
allow clonal selection and expansion across the broader tumor cell landscape to 
influence the disease progression. 
Histopathological examination of tumor progression has defined a model in 
which several intermediate stages exist between initiation and a malignant tumor. In 
some tumor types, the acquisition of specific mutational events coincides transition 
between histologically defined stages. For example, colon cancer progression is 
characterized by the sequential accumulation of genetic alterations: APC/β-catenin 
mutation results in crypt dysplasia, the activation of K-RAS drives progression to an 
intermediate adenoma, the activation of DCC/SMAD4/SMAD2 coincides with transition 
to a late adenoma, and finally the loss of p53 occurs at the transition to invasive colon 
carcinoma (317). Breast cancer, on the other hand, demonstrates much greater 
heterogeneity in tumor progression and as a result very few recurrent genetic 
alterations have been identified in breast cancer (85, 318, 319).  
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Ductal Carcinoma In Situ 
Strong molecular, epidemiological, and histopathological evidence suggests that 
DCIS is antecedent to the majority of invasive breast carcinomas. Pre-malignant 
atypical ductal hyperplasia (ADH) is the precursor to DCIS (320). Both ADH and DCIS 
are characterized by the proliferation and accumulation of neoplastic cells within the 
lumen of mammary ducts. ADH lesions are smaller and lack some histological features 
of DCIS, but are contiguous with low grade.  
DCIS is a genetically advanced lesion, demonstrating a high degree of 
cytogenetic abnormalities (321). Many of the genetic alterations evident in invasive 
carcinoma are already established in pre-invasive DCIS (322-324). Comparison of 
DCIS and adjacent invasive carcinoma finds significant continuity between many 
molecular markers, including amplification of HER-2, ERα, cyclin D1, and Myc and 
mutations of PI3KCA and p53 (325). The intrinsic subtypes of breast cancer can be 
identified in pre-malignant breast tissue, suggesting the existence of distinct avenues of 
breast cancer progression (326). Gene expression profiling of large cohorts of DCIS 
and invasive breast tumors cannot resolve stage-specific differences in gene 
expression (318, 327-329). Based on the available evidence, specific genetic events 
are unlikely to facilitate the progression of DCIS to invasive carcinoma. The majority of 
mutational events driving tumor progression are likely acquired prior to DCIS. 
Metastatic Breast Cancer 
The underlying cause of death among breast cancer patients is the metastatic 
spread of tumors to distant organ sites, especially the bone, lungs, brain, and liver. The 
five-year relative survival rate of women diagnosed with localized breast cancer is 98.6 
percent, decreasing to 83.3 percent for patients with regional spread, and 23.3 percent 
for patients with distant metastasis (31). Metastatic breast cancer can develop at any 
time, years or even decades after the original diagnosis and remains virtually 
untreatable using current therapies (330). Following surgical excision of the primary 
breast tumor, 20-30% of breast cancer patients will experience a metastatic recurrence 
over a 15-year period (331). 
No reproducible genetic events can differentiate metastatic lesions from the 
primary tumor. Gene expression signatures predicting the development of metastatic 
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disease can be derived from early stage breast cancer patients (332, 333). Circulating 
tumor cells can be detected in a subset of these patients. Metastases can be generated 
from these genetically ‘primitive’ clones of the primary tumor (334-336). These results 
indicate that metastatic propensity is likely programed early during breast 
tumorigenesis, by many of the same genetic and epigenetic events that drive 
proliferation and clonal expansion (337). Multistep progression models predict that 
alteration in metastasis genes late in tumorigenesis triggers dissemination. These 
models provide the rationale for mammographic screening and early intervention in 
breast cancer. However, the available data suggests that the manifestation of breast 
cancer as a metastatic lesion is unlikely to be a result of additional mutational events 
late in tumorigenesis (332-336).  
Role of the Microenvironment in Breast Cancer Progression 
Accumulating evidence suggests that the normal microenvironment has tumor 
suppressive properties. Injection of fully malignant mammary carcinoma cells into the 
embryonic mammary mesenchyme can suppress tumor formation and induce 
differentiation (6). Malignant teratocarcinoma cells injected into a normal developing 
mouse blastocyst give rise to phenotypically normal chimeric mice (5). Similarly, 
chicken embryos infected with Rous Sarcoma Virus (RSV) develop normally despite 
constitutive expression of the v-src oncogene. Dissociation of the embryo alleviates 
restraints on transformed growth (4). Tumor formation in RSV-infected chickens 
requires wounding, suggesting a role for an altered microenvironment in tumor 
progression (3). Even genotoxic agents target the normal microenvironment in animal 
models of carcinogenesis. The cleared mammary fat pad of carcinogen-exposed rats 
enhances the tumorigenicity of transplanted mammary epithelial cells exposed to 
carcinogens in vitro. By comparison, the mammary fat pad of un-exposed rats 
suppressed the tumorigenic potential of identically in vitro transformed mammary 
epithelial cells instead resulting in the formation of a normal mammary ductal tree (338). 
The focus on mutational events within the tumor epithelium as the primary 
drivers of tumor progression has largely obscured the importance of the stromal 
microenvironment. The ability of tumor cells to recruit and manipulate non-malignant 
cell types, including fibroblasts, endothelial cells, pericytes, adipocytes, mesenchymal 
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cells, and leukocytes, governs their malignant growth potential. In mouse models, 
injection of tumor cells into different anatomical sites, with varying stromal compositions, 
dramatically affects proliferation, invasion, metastasis, and therapeutic sensitivity (339-
343). Depletion of specific non-malignant cell types or contributed factors can 
profoundly effect tumor progression (344-347). Many microenvironmental changes are 
permanent, breast tumor-derived stromal fibroblast maintain their abnormal phenotype 
in culture (348). Epigenetic reprogramming of stromal cell types has been shown to 
account for the alterations in gene expression (349). Genetic alterations have been also 
noted within the stromal compartment (350-352).  
Critical modes of communication between tumor cells and the stromal 
microenvironment include, the composition of the ECM, cell-to-cell contact, and 
paracrine signaling molecules. Comparison of distinct cell types within the normal 
breast, DCIS, and invasive breast cancer, reveals significant changes in stromal-
epithelial crosstalk during breast tumor progression (353). Gene expression analysis of 
the breast tumor stroma identifies a robust prognostic signature, evidencing the 
importance of stromal signaling especially in metastatic proclivity (7). In breast cancer 
xenograft models, the gene signature of cells migrating to the bone, lung, or brain is 
heavily populated by secreted or cell surface proteins, including cytokines/chemokines, 
MMPs, and cell adhesion molecules (354-356). 
Changes in the interaction between tumor cells and the microenvironment are 
critical to the transition from pre-invasive DCIS to invasive breast cancer. The 
disappearance of myoepithelial cells as a continuous entity surrounding the duct is the 
critical histological distinctions of invasive disease (357, 358). Abnormalities in 
myoepithelial cells results in the expression of MMPs resulting in the degradation of the 
basement membrane (353, 357).  
Deregulated interaction between the tumor epithelium and the tumor stromal are 
essential to tumor progression. Breast cancer progression cannot be defined by solely 
focusing on genetic changes within the tumor epithelium. The identification of 
microenvironmental factors that promote breast cancer progression is essential to the 
design of novel therapeutic strategies and continued progress against breast cancer 
mortality. 
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Inflammation and Breast Cancer Progression 
Inflammation and the presence of leukocytes in the tumor microenvironment are 
regarded as essential components of malignant progression. Tumors resemble “wounds 
that do not heal” (359). In many tumor types, chronic inflammatory stress due to viral or 
bacterial infection, autoimmune disease, or environmental irritants promotes the 
development and progression of tumors. Helicobacter pylori infection dramatically 
increases risk of developing gastric cancer (360). Autoimmune inflammatory bowel 
disease greatly enhances colon cancer development (361). Prostatitis increases the risk 
of developing prostate cancer (362). Asbestos and silica particles induce chronic 
inflammation essential to the development of mesothelioma (363). Long-term usage of 
non-steroidal anti-inflammatory drugs decreases the overall burden of cancer (364-
366). Systemic markers of inflammation are prognostic of poor overall and disease-free 
survival in breast cancer patients (367). 
Many factors contribute to the inflammatory tumor microenvironment. Tumor 
cells secrete cytokines, chemokine, and toll-like receptor ligands downstream of 
oncogenes, such as RAS and MYC (368-371) and in response to stress conditions, 
including hypoxia, necrosis, chemotherapy, and ionizing radiation (372-374). Tumor 
associated fibroblast significantly contribute to the inflammatory microenvironment. 
Gene expression characteristic of activated fibroblasts defines a wound healing 
signature that is prognostic of poor survival and the development of metastasis (375). 
Co-injection of tumor cells with activated fibroblast is routinely used to enhance the 
establishment of xenograft tumors (376).  
The inflammatory mileu surrounding the developing tumor results in the 
recruitment of leukocytes. Both innate and adaptive immune cells are evident in the 
tumor stroma including macrophages, dendritic cells, neutrophils, myeloid derived 
suppressor cells, mast cells, natural killer cells, T-lymphocytes, and B-Lymphocytes. 
Leukocytes can participate in either a tumor-promoting inflammatory response 
(demonstrated for all except natural killer cells (377)) or an anti-tumor immune 
response. The pro/anti-tumor properties of leukocytes are largely programmed by 
secreted factors and heterotypic interactions within the tumor microenvironment. In 
malignant tumors the balance is largely tilted in favor of a tumor-promoting inflammatory 
response. Many mechanisms play a role in immunosuppression within tumors including 
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the cytokine, TGF-β1 (378). Targeting immunosuppressive receptors expressed by T-
cells, PD-1 and CTLA-4, is a promising therapeutic strategy and highlights important 
efforts to reactivate anti-tumor immunity (379-382).  
Tumor-associated macrophages (TAMs) are among the most abundant immune 
cells within the tumor microenvironment. TAMs are essential to angiogenesis, invasion, 
and metastasis contributing cytokines, proteases, and growth factors to the tumor 
microenvironment. Within breast tumors, TAMs frequently localize near the vasculature. 
In this context, TAMs facilitate angiogenenic reprograming through secretion of VEGF 
and invasion by establishing chemotactic gradients of EGF (383-386). Gene expression 
signatures associated with poor patient outcome often include genes that are 
specifically expressed by macrophages (387). High levels of TAMs are associated with 
poor patient prognosis in breast and other tumor types (388-392). The expression of 
cytokines and chemokines, such as CCL2 and CSF-1, are essential to the recruit and 
activation of macrophages, correlated with poor patient prognosis (393-395). Depletion 
of macrophages in transgenic and xenograft models of breast tumorigenesis 
demonstrate reduced growth, invasion, angiogenesis, and metastasis (344, 396-399). 
Macrophages are differentiated in multiple phenotypes M1 macrophages 
activated by IFNγ and microbial components are pro-inflammatory, express major 
histocompatibility complex molecules and likely function in anti-tumor immunity. The 
majority of TAMs are believed to be of the M2-phenotype, alternatively activated by IL-
4, IL-10, and IL-13. M2-macrophages normally participate in the wound healing through 
the secretion of growth factors and angiogenic factors. In some models, tumor 
progression is dependent on a switch from the M1 to M2 phenotype (400). TAMs 
express high levels of pro-inflammatory cytokines reminiscent of the M1 phenotype 
suggesting that they do not fall into typical classifications. TGFβ is a critical factor in 
suppressing the role of TAMs in anti-tumor immunity and in the generation of a tumor 
promoting phenotype (401-403). Subsets of T-lymphocytes known to promote breast 
cancer in animal models and correlated with poor prognosis in breast cancer, 
progression enhance metastatic progression by stimulating the activity of TAMs through 
production of IL-4 and (404). TAMs stimulated by CSF-1 induces the expression of 
hypoxia-associated iNOS and arginase-1 which suppress the proliferation and 
activation of cytotoxic T-cells (405, 406). 
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Tumor-associated neutrophils (TAN) are also recruited by tumor cell-derived 
chemokines, especially IL-8 (368, 407). High levels of circulating neutrophils, induced 
by tumor-derived GM-CSF and other cytokines, are prognostic of poor survival in 
melanoma and renal carcinoma patients (408, 409). Relatively few studies have 
examined the prognostic significance of TAN. In renal cell carcinoma, TAN are 
prognostic of short recurrence-free survival (RFS). In the presence of TAN, patients 
demonstrated a five-year RFS of 53%, however in the absence of TAN patients had a 
five-year RFS of 87%. In multivariate analysis, TAN were shown to be an independent 
prognostic marker of disease-specific survival (DSS) and overall survival (OS) (410). In 
human gliomas, high numbers of TAN correlate with high tumor grade (411). High levels 
of neutrophils in the bronchoalveolar lavage fluid from patients with bronchioloalveolar 
carcinoma were associated with high levels of IL-8, NE, and poor DSS (407). Although 
not commonly observed in pancreatic tumors, TAN were shown to be associated with 
the relatively aggressive micropapillary and undifferentiated subtypes (412). 
Lymphocyte to neutrophil ratio is a prognostic factor in colorectal cancer and non-small 
cell lung cancer (413, 414).  
Depletion of neutrophils or disruption of neutrophil chemotaxis inhibits tumor 
growth, angiogenesis, and metastasis in mouse models of tumor progression (415-417) 
The majority of studies in humans and animal models show that TAN augment tumor 
progression through the secretion of growth factors, cytokines, ROS, and proteases 
(345, 418-421). TAN can be polarized by TGF-β blockade to assume an anti-tumor 
phenotype, however little evidence exists of a role for TAN in anti-tumor immunity in the 
absence of therapeutic manipulation (422, 423). 
Breast Cancer Subtypes 
Breast cancer is a collection of diseases sharing a common anatomical site but 
radical differences in incidence, morphology, genetics, therapeutic response, and 
outcome. Clinically, breast tumors are generally segregated into three groups, estrogen 
receptor (ER)-positive, HER2-amplified, and triple-negative breast cancer (TNBC: ER-, 
PR-, and HER2-negative); these distinctions are largely based on outcome and 
response to available targeted therapeutics. Gene expression profiling, using DNA 
microarray or RNA sequencing technologies, has the capacity to rapidly measure global 
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mRNA transcription. Comparative study of large cohorts of tumors by gene expression 
profiling has greatly enhanced our understanding of breast cancer biology and 
heterogeneity. These studies consistently highlight the importance of differences in 
hormone receptors, HER2, and proliferation in breast cancer classification (332, 333, 
424-426)  
Pioneering work by Perou and colleagues was among the first to use these high 
throughput technologies to classify breast tumors and remains the most influential. 
Their analysis first compared gene expression between breast tumors to define an 
intrinsic gene set, genes demonstrating the greatest differences in expression across 
the tumor spectrum. Using this intrinsic gene set the tumors were then subjected to 
hierarchical clustering, grouping tumors by similarities in gene expression. From this 
type of analysis five, reproducible intrinsic subtypes of breast cancer are widely 
considered: luminal A, luminal B, basal, HER2-enriched, and normal-like (291, 427). 
Recent publications also recognize a claudin-low subtype of breast cancer (428). 
Analysis of breast tumors using DNA copy number array, DNA sequencing 
technologies, global DNA methylation analysis, microRNA sequencing, and proteomic 
analysis can reproducibly group tumors into these subtypes (85). Each molecular 
subtype displays dramatic differences in incidence, patient outcome, and characteristic 
gene expression (Table 1) (425, 429-431). The intrinsic subtypes of breast cancer can 
be identified in DCIS evidencing distinct pathways of tumor progression (319).  
 44 
 
 
Table 2: The Intrinsic Subtypes of Breast Cancer. 
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Luminal Subtypes of Breast Cancer 
In general, the luminal subtypes are defined by expression of ER-complex 
components and target genes, including ESR1, GATA3, FOXA1, XBP1, and MYB. The 
luminal subtypes also highly express transcripts characteristics of the luminal lineage 
within the normal breast, such as cytokeratins 8/18. Luminal-subtype tumors are 
predominately ER-positive by immunohistochemistry (Lum A: 87% and Lum B 82%), 
however can contain TNBC (Lum A: 7% and Lum B 1%) and HER2-positive patients 
(Lum A: 2% and Lum B 15%). Segregation into luminal A and B is largely based on the 
differential expression of proliferation genes, which tend to be highly expressed in 
luminal B tumors relative to luminal A tumors. In ER-positive tumors, markers of 
proliferation (i.e. Ki67) can distinguish between Luminal A and Luminal B tumors (432, 
433). Luminal B tumors also tend to express lower relative levels of ER-target genes. A 
subset of luminal B tumors demonstrates HER2 amplification.  
The luminal A subtype is the largest tumor cohort (40-60% of the total) and 
demonstrates the greatest heterogeneity in gene expression. Luminal A tumors are 
characterized by low histological grade and have a relatively good prognosis. Luminal B 
subtype tumors are generally of higher histological grade and have an intermediate 
prognosis compared to all other subtypes. Luminal A patients have a 15-year relapse 
rate of 27.8% compared to 42.9% for luminal B patients. Following relapse, luminal A 
patients had a longer median survival of 2.2 years compared to 1.6 years for luminal B 
patients (425, 429-431).  
HER2-Enriched Subtype of Breast Cancer 
The HER2-enriched subtype generally demonstrates a high degree of 17q12 
amplification (71%) resulting in the overexpression of HER2 and adjacent genes. The 
majority of HER2-enriched subtype tumors, when evaluated by immunohistochemistry 
are HER2-positive and ER-negative (68%), but can contain ER-positive (20%) and 
TNBC tumors (9%). HER2 amplicon associated gene expression is an important 
component of the segregation of this subtype by transcriptomic analysis. Tumors in the 
HER-2 enriched subtype display overexpression of receptor tyrosine kinases, including 
FGFR4 and EGFR, and do not express luminal cluster genes (i.e. GATA3 and ESR1). 
The HER2-enriched subtype is largely defined by tumors of high histological grade, high 
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proliferation index, and is frequently metastatic. Historically, HER-2 enriched tumors 
have a poor prognosis (52.4% relapse, 0.7 year median survival following relapse), 
however HER-2 directed therapies have increased survivorship in both metastatic and 
non-metastatic tumors.  
Basal-like Subtype of Breast Cancer 
Basal-like tumors generally lack gene expression associated with the ER, PR, 
and HER2 (80%), however can contain ER-positive (10%) and HER2-positive tumors 
(1%). Basal-like tumors express markers of the basal/myoepithelial cell lineage in the 
normal breast, including cytokeratins 5/17, P-cadherin, caveolin 1, nestin, CD44, and 
EGFR. Evaluation of basal cytokeratins and EGFR can refine the ability to identify 
basal-like tumors by IHC (434).  Basal-like tumors are often large at diagnosis, have a 
high histological grade, high proliferation index, and a high frequency of lymph node 
involvement (425, 429-431). Basal-like tumors have a poor prognosis, 43.1% relapse 
with a 0.5 year median survival following relapse. A significant portion of hereditary 
BRCA1 and BRCA2 related tumors cluster within the basal subtype. Several studies 
have identified BRCA1 and BRCA2 downregulation, through either promoter 
methylation or transcriptional inactivation, in sporadic cases of basal-like breast cancer 
(61, 62). Conditional knockout of Brca1 and Trp53 in the mouse mammary gland 
generates tumors with distinctly basal-like features (63-65).   
Additional Subtypes of Breast Cancer 
Normal-like tumors cluster with normal breast tissue, have not been extensively 
characterized. The normal-like subtype may be an artifact of normal tissue 
contamination and is generally ignored (431).  
Since the original description of the intrinsic subtypes of breast cancer, several 
additional subtypes have been described, including the interferon subtype characterized 
by high levels of interferon gene expression and the molecular apocrine subtype 
characterized by androgen receptor signaling. Notable is the claudin-low subtype. 
These tumors cluster closely with the basal-like tumors, however they characteristically 
express very low levels of intracellular adhesion molecules including claudin-3,4,7, 
ocludin, and e-cadherin. These tumors are of high histological grade and low 
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proliferation index. Claudin-low tumors are enriched for mesenchymal and cancer stem 
cell properties and highly express genes characteristic of immune cell infiltration (428). 
Claudin low patients have a very poor prognosis.  
A recent study identified six-subtypes of TNBC through k-means and consensus 
clustering of gene expression profiles. Two basal-like tumor subtypes, basal-like 1, 
basal-like 2, were characterized by high expression of genes associated with cell 
proliferation and the DNA damage response making them extremely responsive to 
chemotherapy. An immunomodulatory subtype was identified by the presence of 
immune cell signaling. A mesenchymal and mesenchymal stem-like were defined by 
cell signaling characteristic of epithelial to mesenchymal transition and cancer stem 
cells. Finally a luminal androgen receptor (AR) subtype was identified expressing 
luminal cytokeratins, but lacking ER-signaling in favor of an AR gene signature (435).  
Although the intrinsic subtypes of breast cancer are prominently considered, a 
great deal of heterogeneity exists beyond the luminal A, luminal B, HER-2 enriched, and 
basal-like distinction. The ability to classify tumor heterogeneity through molecular 
profiling may allow cancer oncologists to identify effective therapeutic approaches to 
similar tumors. The analysis of breast tumors by multiple profiling platforms and using 
new bioinformatics techniques should continue to reveal sub-classifications of breast 
cancer, predict outcomes, and guide clinical management. 
Recurrent Genetic Abnormalities Associated with Breast Cancer Subtypes 
Breast tumors are genetically heterogeneous, however some recurrent 
abnormalities cluster within the intrinsic subtypes of breast cancer. Luminal A tumors 
(Figure 4) demonstrate the lowest overall mutation rate and generally have diploid 
genomes. Luminal B tumors (Figure 5) have an intermediate mutational rate and 
aneuploidy genomes. Recurrent mutations in the luminal subgroups include: PIK3CA 
(Lum A: 49%, Lum B: 32%), GATA3 (Lum A: 14%, Lum B: 15%), MAP3K1 (Lum A: 
13%, Lum B: 5%), and MAP2K4 (Lum A: 7%, Lum B: 2%). Mutations in p53 are more 
common in luminal B tumors (Lum A: 12%, Lum B:32%), overall the majority of luminal 
B tumors have some kind of inactivating events within the p53 pathway. Accordingly, 
luminal A tumors express higher levels of p53 target genes GADD45 and CDKN1A. The 
Rb-pathway inactivation is also higher in luminal B tumors. Common oncogenic events 
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in luminal B tumors include cyclin D1 (58%) and CDK4 (25%) amplification (compared 
to luminal A tumors cyclin D1 amp: 29% and CDK4 amp. 14%). Inactivating mutations 
in RB1 are also more common in luminal B tumors. Overall, differences in the clinical 
behavior of luminal A and B tumors can partially be explained by differences in Rb and 
p53 inactivation. 
HER2-enriched (Figure 6) and Basal-like (Figure 7) tumors demonstrate 
significantly higher mutational rates compared to luminal tumors and often have 
aneuploid genomes. Overall, TP53 mutations are highly enriched in basal-like and 
HER2 tumors (Basal:84%, HER2:75%). RB1 mutation/loss is a frequent event in basal-
like tumors (20%) as is cyclin E amplification (9%); interestingly cyclin D1 amplification 
is rare in the basal like subtype compared to luminal tumors and HER2 enriched tumors 
(cyclin D1 amp. 38%, CDK4 amp. 24%). PIK3CA mutations are less frequent in basal-
like tumors compared to luminal and HER2 enriched subtypes (Basal: 7%, HER2: 42%). 
However, basal like tumors display the highest Akt activity due in part to frequent 
PTEN/INPP4B loss and amplification of PIK3CA (49%). Basal-like tumors also display 
amplification of genes within the ERK signaling pathway, including KRAS, BRAF, and 
EGFR. 
The spectrum of genetic alterations plays an important role in breast cancer 
heterogeneity. However, alterations are often shared between subtypes. Unique 
mutational spectra does not account for the vast differences in gene expression that 
drive the segregation of tumors into the intrinsic subtypes. 
Cell of Origin and Breast Cancer Subtypes 
Differences in gene expression that segregate the distinct subtypes of breast 
cancer are believed to arise from different cells of origin. Analysis of histological and 
molecular profiles of breast tumors does not necessarily predict the normal cell of origin. 
BRCA1 mutation carriers are particularly susceptible to basal-like breast cancer; 
therefore the assumption was that BRCA1 mutation leads to the transformation of basal 
progenitor cells. Inactivation of BRCA1 and p53 in basal and luminal progenitor cells 
demonstrates that luminal progenitors are the target of BRCA1 loss and the genesis of 
basal like breast cancer (65). The cell of origin responsible for the genesis of the other 
breast cancer subtypes have not been convincingly demonstrated.  
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Figure 4: Common Genetic Alterations in Luminal A Breast Tumors. 
 
Amplifications, deletions, and mutations in recurrently altered genes within the luminal A 
subtype of breast cancer. Alterations were measure by exome sequencing and array 
comparative genomic hybridization (CGH) by TCGA. The data was visualized as 
presented here using the web-based cBioPortal for cancer genomics 
(www.cbioportal.org). 
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Figure 5: Common Genetic Alterations in Luminal B Breast Tumors. 
 
Amplifications, deletions, and mutations in recurrently altered genes within the luminal B 
subtype of breast cancer. Alterations were measure by exome sequencing and array 
comparative genomic hybridization (CGH) by TCGA. The data was visualized as 
presented here using the web-based cBioPortal for cancer genomics 
(www.cbioportal.org). 
. 
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Figure 6: Common Genetic Alterations in HER2-Enriched Breast Tumors. 
 
Amplifications, deletions, and mutations in recurrently altered genes within the HER2-
enriched subtype of breast cancer. Alterations were measure by exome sequencing and 
array comparative genomic hybridization (CGH) by TCGA. The data was visualized as 
presented here using the web-based cBioPortal for cancer genomics 
(www.cbioportal.org). 
. 
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Figure 7: Common Genetic Alterations in Basal-Like Breast Tumors . 
 
Amplifications, deletions, and mutations in recurrently altered genes within the basal-
like subtype of breast cancer. Alterations were measure by exome sequencing and 
array comparative genomic hybridization (CGH) by TCGA. The data was visualized as 
presented here using the web-based cBioPortal for cancer genomics 
(www.cbioportal.org). 
.  
 53 
Clinical Management of Breast Cancer 
Breast cancer remains a serious public health concern. In the United States, one in 
eight women will be diagnosed and treated for breast cancer within her lifetime.  
Declining mortality rates over the last several decades reflects progression in the 
clinical management of the disease (31). Prior to the mid-1970s breast cancer treatment 
had seen little change since the introduction of the radical mastectomy by William 
Halsted in 1882. Over the last several decades increased breast cancer survivorship 
has come from advances in screening/diagnostic imaging, surgical resection, evaluation 
of prognostic/predictive markers, radiotherapy, systemic chemotherapy, and targeted 
therapeutics.  
Mammography 
Mammographic screening has contributed to the decline in breast cancer 
mortality, however the effect is often overstated. Overall, the number of women who 
present with advance breast cancer has decreased only eight-percent due to screening 
mammography (436). The success of early detection is predicated on the linear 
progression of breast cancer from initiation to metastatic disease. However, metastatic 
proclivity may be pre-programed early during tumorigenesis, resulting in early 
dissemination of tumor cells. Mammography overwhelmingly detects slow-growing 
primary tumors, a significant proportion of which are unlikely to progress within the 
lifespan of an individual (437). The molecular mechanisms governing the tumor 
proliferation rate and metastasis are linked, therefore the tumors with the greatest 
proliferation rate may also be the most likely to metastasize and least likely to be 
detected by mammography (438, 439). Increased sensitivity and access to 
mammographic screening has contemporaneously led to the detection of a larger 
proportion of pre-invasive DCIS (440). DCIS currently accounts for 20% of all breast 
cancer diagnoses (440). Examined retrospectively, breast cancer screening results in 
over-diagnosis in 31% of patients. Prior to the widespread use of mammography DCIS 
was a very rare diagnosis (436). The development of complimentary screening 
methodologies is necessary to accurately define patient risk of disease progression and 
guide therapeutic intervention.  
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Breast Cancer Diagnosis and Assessment of Clinicopathological Parameters 
Diagnostic imaging and core needle biopsy are performed to determine the 
presence of malignancy. Following diagnosis, breast cancer treatment is based on 
stage and histopathological parameters. Tumor stage, the most important prognostic 
parameter, is based on evaluation of tumor size, the number/proximity of involved 
lymph nodes, and the presence or absence of distant metastasis. Guidelines for the 
evaluation of tumor stage are set by the American Joint Committee on Cancer (AJCC). 
Tumor stage is significantly associated with patient outcome and is a critical tool utilized 
by oncologists to make treatment decisions (Table 2). 
In the absence of metastasis pathological features of the tumor, including 
histological grade, hormone receptor (ER and PR), HER2 status, and the presence of 
lymphovascular invasion are heavily considered in making treatment decisions. 
Platforms including the PAM-50 Breast Cancer intrinsic classifier, the MammaPrint test, 
and the Oncotype DX are now being used to supplement traditional clinicopathological 
assessment. However, the adoption of these diagnostic platforms is limited by their 
substantial cost, lack of standardization, and incomplete clinical trials comparing 
outcomes of patients treated according to the established risk groups.  
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Stage Five-year Overall 
Survival (441) 
Description 
0 93% Carcinoma in situ 
I 88% 1A: The tumor is less than 20 mm in the greatest 
dimension with no evidence of axillary lymph node 
metastasis. 
1B: The tumor is greater than 20 mm with 
micrometastasis (<2mm) to a single axillary node. 
IIA 81% The tumor is either between 20 and 50 mm or less 
than 20 mm with 1-3 positive lymph nodes. 
IIB 74% The tumor is either greater than 50mm or between 20 
and 50mm with 1-3 positive node. 
IIIA 67% The tumor is either less than 50 mm and has 4-9 
positive nodes or a tumor is greater than 50 mm and 
has 1-3 positive nodes, 
IIIB 41% The tumor extends to the chest wall or the skin. 
IIIC 49% A tumor of any size with more than 10 positive 
nodes. 
IV 15% Stage IV infers distant metastasis. 
 
Table 3: Breast Cancer Staging and Survival. 
 
Tumor stage is the most important prognostic parameter available to clinicians. Tumor 
stage is based on the size of the tumor, the frequency of lymph node metastasis, and 
the presence of distant metastasis. 
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Surgery 
Breast conserving surgery (BCS), lumpectomy followed by radiation therapy is 
the gold standard. Large, randomized clinical trials have consistently failed to find a 
difference in local reoccurrence rates and overall survival between BCS and modified 
radical mastectomy (442-446). The morbidity associated with axillary lymph node 
dissection can also be avoided if biopsy of the sentinel lymph node, the node directly 
receiving drainage from the tumor, is negative for metastasis. Randomized clinical trials 
demonstrate no difference in the outcome of patients who undergo sentinel lymph node 
biopsy to determine if complete axillary lymph node dissection was necessary 
compared to complete dissection regardless of sentinel lymph node positivity (447, 
448). These studies have been practice changing such that complete node dissection 
will now be performed only in those patients with sentinel lymph node involvement.  
Radiotherapy 
Radiotherapy, a necessary component of breast conserving surgery, is 
administered to the entire breast to prevent local recurrence. Typically, external-beam 
radiation therapy is used to apply a total dose of 50 Gy to the breast over a five-week 
period in 2-Gy fractions. Radiation therapy reduces five-year local recurrence from 26% 
to 7% in the conserved breast and decreases 15-year breast cancer mortality to 30.9% 
compared to 35.9% for women who did not receive radiation therapy (442). An 
additional dose of 16 Gy directed at the tumor bed reduces the risk of recurrence even 
further from 7.3% to 4.3% at five years (449).  
Chemotherapy 
Systemic chemotherapy is frequently used to palliate the symptoms of patients 
with advanced breast cancer and to reduce the risk of recurrence in patients with 
operable breast cancer. The median survival of metastatic breast cancer patients is 18-
24 months. Treatment with systemic chemotherapy achieve complete responses in 
16.6% of patients of which only 3.1% will remain in remission after 5-years (450). 
Chemotherapeutics are generally administered in combination to increase therapeutic 
efficacy. In randomized clinical trials, many combinations have been tested for efficacy 
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and tolerability. In advance breast cancer patients, these studies generally observe 
greater response rates with combination therapy compared to mono-therapy, however 
with increase toxicity.   
For breast cancer patients the risk of recurrence spans decades following 
diagnosis and treatment. Following breast conserving surgery, 10-20% of patients will 
experience recurrence of those 9-25% are metastatic or locally advance (451-453). 
Adjuvant chemotherapy, administered after surgical resection, reduces the risk of 
developing distant metastasis by eliminating pockets of tumor cells within the body. 
However, the clinicopathological parameters used to determine risk are incomplete and 
fail to adequately stratify individual risk resulting in the indiscriminate application of 
adjuvant chemotherapy. As many as 80% of treated patients would never actually form 
metastases and needlessly suffer the morbidity associated with systemic chemotherapy 
(454).  
Neoadjuvant chemotherapy, administered prior to surgical resection, was 
originally used in patients with locally advanced disease to enhance operability, but is 
now more widely used in the treatment of operable breast tumors. A pathological 
complete response is achieved in 20-30% of patients treated with neoadjuvant 
chemotherapy. The response of breast tumors to chemotherapy is highly variable. A 
pathological complete response is achieved in 28-32% of TNBC and HER-2-enriched 
subtype patients, partially due to their high proliferation rate. In contrast, luminal tumors 
respond poorly to neoadjuvant chemotherapy, a pathological complete response is 
achieved in only 6.7% of luminal A patients and 11.2% of luminal B (HER2-negative) 
(455). Neoadjuvant therapy has the added advantage of allowing oncologists to 
evaluate the efficacy of the drugs being administered by diagnostic imaging, allowing 
them to modify the dose or the drugs being applied if ineffective. 
The earliest adjuvant chemotherapy trials utilized a combination of 
cyclophosphamide, methotrexate, and 5-flourouracil (CMF) to successfully increase 
disease specific and overall survival compared to surgery alone in a cohort of lymph 
node positive breast cancer patients (456). CMF was eventually supplanted by 
combination regimens containing anthracyclines, especially doxorubicin and epirubicin. 
In a randomized clinical trial, anthracycline regimens demonstrated an 11% reduction in 
the risk of recurrence compared to CMF, however others studies are inconclusive on 
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the benefits of anthracyclines in combination therapy (331, 457, 458).  Overall meta-
analysis of clinical trial using both the CMF and anthracycline based adjuvant 
chemotherapy regimes demonstrates a reduction in recurrence rate of 35% in women 
younger than 50 and 20% in women older that 50. Adjuvant chemotherapy increases 
10-year survival 7% (71% to 78%) in node negative patients and 11% (42% to 53%) in 
node positive patients (458). The addition of taxanes, docetaxel and paclitaxel, has 
further boosted the efficacy of anthracycline based adjuvant chemotherapy, increasing 
disease free survival 14% over five years (459).  
Large randomized trials testing adjuvant versus neoadjuvant chemotherapy fail 
to find a significant difference in disease-free or overall survival compared to adjuvant 
chemotherapy. However, neoadjuvant therapy does increase the percentage (7-12%) of 
patient eligible for breast conserving surgery without an increase in locoregional 
recurrence (460-462). Neoadjuvant therapy has had an important impact on 
translational research and clinical trial design, allowing novel therapies and therapeutic 
combinations to be tested on a smaller number of patients and with shorter follow-up 
compared to traditional adjuvant trails. Neoadjuvant trials are evaluated based on tumor 
response and permit collection of tumor tissue before/during treatment by serial biopsy 
and after surgical resection in patients not undergoing a pathological complete 
response. These trials are important to the development of predictive markers and 
optimization of therapy.  
Targeted Therapeutics 
Traditional chemotherapy is non-specific, targeting proliferating populations of 
tumor and normal cells, and is therefore associated with significant toxic side effects. 
Breast cancer was among the first tumor types to benefit from targeted therapeutics. 
The link between breast cancer and the endocrine system was established in 1896 
when it was observed that ovariectomy induced tumor regression in a subset of breast 
cancer patients. In 1952, adrenalectomy was found to produce a similar response in 
breast tumors. These early studies failed to identify the biological basis of these 
observations. Identification of the role of the estrogen in breast cancer and the 
introduction of therapeutics specifically inhibiting ER signaling has significantly 
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enhanced survivorship in the subsets of breast cancer patients expressing ER (331, 
437, 463-467).  
Selective estrogen receptor modulators (SERMs), such as tamoxifen, 
structurally resemble estrogen; however upon binding to the ER inhibit its ligand-
dependent functions. In metastatic breast cancer patients (pre-menopausal) the efficacy 
of tamoxifen is identical to bilateral ovariectomy (468). The tamoxifen response rate of 
ER-positive metastatic breast cancer is 30%, for both pre- and post-menopausal 
women (469). Long-term, administration of tamoxifen to ER-positive patients as 
adjuvant therapy cuts the recurrence rate in half and reduces mortality by a third over a 
15-year period (331). Treatment of DCIS patients with tamoxifen significantly reduces 
disease progression and prevents breast cancer in a cohort of high-risk patients (466, 
470). In some tissues tamoxifen acts as a partial agonist of ER, increasing the risk of 
developing endometrial cancer or a thromboembolic event (471, 472).  
Aromatase inhibitors, including anastrozole, letrozole, and exemestane, have 
been developed as alternatives to tamoxifen. Aromatase inhibitors interfere with the 
enzymatic conversion of androgens to estrogen and are therefore only effective in the 
treatment of post-menopausal women. In ER-positive metastatic breast cancer, 
aromatase inhibitors prolonged survival in women who fail to respond to tamoxifen 
(473-476). As first line therapy for metastatic breast cancer, aromatase inhibitors 
demonstrate greater clinical efficacy than tamoxifen alone (477, 478). In a large 
randomized, double-blinded study, anastrozole was compared to tamoxifen as adjuvant 
therapy in post-menopausal women. Anastrozole demonstrated greater clinical efficacy 
in the prevention of breast cancer recurrence (479-481). Fulvestrant, an antagonist that 
results in the downregulation of the ER and the PR, is another alternative to tamoxifen 
in the treatment of breast cancer. Fulvestrant demonstrates equivalent efficacy to 
anastrozole in patients resistant to tamoxifen (482) 
The receptor tyrosine receptor HER2 is amplified in approximately 30% of breast 
tumors. HER2 amplification is associated with aggressive disease and a poor survival. 
Introduction of the HER2-directed chimeric monoclonal antibody, trastuzumab, has 
dramatically improved the outcome of women with HER2-amplified breast tumors (both 
ER+ and ER-). Trastuzumab decreases the recurrence rate by 50% and reducing 
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mortality by a third (464). The dual (HER2/EGFR) kinase inhibitor, lapatinib, significantly 
extends survival in advanced, trastuzumab-resistant breast cancer patients (483).  
By age 70, 50-65% of women with deleterious mutations in BRCA1 and 40-57% 
of women with deleterious mutations in BRCA1 develop breast cancer (78). In sporadic 
cases of basal-like breast cancer, BRCA1 and BRCA2 are downregulated by either 
promoter methylation or transcriptional inactivation (61, 62). BRCA1 and BRCA2 are 
critical components of DNA double strand break repair. Poly(ADP-ribose) polymerase 1 
(PARP1) is an essential to DNA single strand break repair. Failure of DNA single strand 
break repair results in double strand breaks during DNA replication. Therefore, PARP1 
inhibitors result in the accumulation of double strand breaks. In tumors with complete 
BRCA1 and BRCA2 loss double stranded breaks cannot be efficiently repaired resulting 
in cell death. Cell death induced by the combination of two inactivating events is refered 
to as synthetic lethality(484-487).  
The success of treating breast cancer using targeted therapies is unprecedented 
among the major forms of cancer. Therapeutic resistance remains a problem in a 
subset of patients treated with targeted therapies therapy. The promise of targeted 
therapies is high efficacy coupled with relatively mild side affects. In order to be 
successful, targeted therapies must be tailored to the patient population that will receive 
the greatest benefit, using predictive markers. Future advances in the clinical 
application of DNA sequencing technologies promises to tightly couple the mutational 
spectrum with appropriate therapeutic modalities. Significant hurdles to the application 
of personalized medicine exist. Distinguishing causal/driving mutations in the cancer 
genes from random, passenger mutations can be challenging.  
Unmet Clinical Needs 
Currently, about one-third of women diagnosed with invasive breast cancer will 
die from the disease. Major areas of unmet clinical need include: 1) the identification of 
susceptible populations who could benefit from increased surveillance and the 
application of cancer prevention strategies, 2) highly sensitive and specific diagnostic 
technologies capable of discerning tumors with a high likelihood of progressing, 3) 
prognostic biomarkers capable of identifying early stage breast cancer patients at high 
risk of recurrence and metastasis, 4) predictive biomarkers of therapeutic response 
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especially capable of guiding the application of targeted therapeutics, 4) therapeutic 
modalities or biological technologies capable of targeting essential nodes in growth 
sustaining pathways, metastatic dissemination, and recurrence, and 5) overcome 
therapeutic resistance.  
Summary 
Breast cancer is the most frequently diagnosed malignancy and the leading 
cause of cancer mortality in women worldwide (28). Epidemiological studies 
demonstrate a major role for hereditary factors in breast cancer susceptibility (36-39). 
Environmental and physiological factors are also significantly associated with an 
individual’s risk of developing breast cancer, including age, lifetime estrogen exposure, 
reproductive history, and obesity (100, 103, 104, 121-123).  
The development and function of the mammary gland requires extensive 
remodeling throughout the reproductive lifespan of an individual. Dynamic tissues are 
inherently sensitive to tumorigenesis. Frequent proliferative episodes expose relatively 
long-lived mammary stem and progenitor cells to transformation and tumor initiation 
(261). Gene expression analysis reveals that breast cancer is a heterogeneous disease 
that can be separated into several subtypes, including luminal A, luminal B, HER2-
enriched and basal-like. The intrinsic subtypes of breast cancer demonstrate distinct 
etiology, progression, and clinical behaviors (291, 427, 429). Sources of breast cancer 
heterogeneity include cell of origin and the nature of the genetic and epigenetic 
alterations within the individual tumor (65). 
The stromal microenvironment is essential the normal development and function 
of the mammary gland. Extrinsic control of the cell proliferation and stem cell properties 
is an important barrier to breast tumorigenesis (6). Changes in the extracellular matrix 
and non-malignant cell types within the stromal microenvironment are essential to 
malignant progression (2-7). Until relatively recently, mainstream breast cancer 
research efforts have concentrated on the relationships between tumor genetics, cancer 
cell signaling pathways, and cellular properties of the tumor epithelium. From these 
efforts, therapeutic targeting pathways essential to tumor growth and progression have 
been developed. Therapeutic targeting of estrogen signaling and HER2 have 
dramatically increased the survivability of subsets of breast cancer patients (331, 464, 
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468, 469). Advances in breast cancer screen, diagnosis, surgery, and the administration 
of chemotherapy have also been critical to the declining mortality of breast cancer 
patients (30). 
Given the tumor suppressive effects of the normal mammary stroma (6) and the 
importance of an altered stromal microenvironment to breast tumor progression (2-7), 
essential microenvironmental factors may represent promising therapeutic anti-cancer 
targets. A critical advantage of targeting the tumor microenvironment are not 
susceptible is the lack of selective pressures driving therapeutic resistance in tumor 
cells. In this dissertation, disequilibrium between NE secreted by activated-neutrophils 
in the tumor microenvironment and its epithelial-secreted inhibitor elafin is explored. 
The data presented suggests that deregulated NE-activity is an important factor in 
tumor growth and a therapeutic target in breast cancer. 
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NEUTROPHIL ELASTASE 
Serine Proteases 
More than two-percent of the human genome encodes proteases and 18% of 
sequences deposited in the SwissProt database have been annotated as undergoing 
proteolysis. Overall, there are 611 proteases in the human genome and 388 non-
functional homologs that have lost residues critical to proteolytic activity (488).  The 
sheer abundance of proteases, attest to their importance in biology. Proteases have 
evolved to function under a variety of physiological conditions; variables include pH and 
oxidation state. Early biochemical work on proteases, concentrated on defining their 
catalytic mechanism. These studies identified five distinct proteases classes, aspartic, 
cysteine, metallo, serine, and threonine. Glutamic proteases have also been identified 
but are not found in mammals (489, 490). 
Serine proteases, characterized by a reactive serine residue at their catalytic 
core, are one of the largest and most divergent groups of mammalian proteases (489). 
Classically viewed as unrefined agents of protein catabolism, many serine proteases 
are now understood to be highly preferential in their choice of substrates. Pioneering 
work on the activation of trypsinogen and the mechanism of blood clotting revealed that 
limited proteolysis can result in altered activity and function (491-493). Proteolytic 
processing has the ability to rapidly and profoundly alter diverse cellular and 
physiological processes through irreversible post-translational modification of protein 
structure and consequently molecular function. Accordingly, serine protease activity is 
tightly regulated under normal physiological conditions by redundant mechanisms; 
including endogenous inhibitors, compartmentalization, and expression as zymogens. 
Inappropriate serine protease activity plays an important role in the etiology and/or 
pathogenesis of many disease states, including cancer. 
Neutrophil Elastase  
Neutrophil elastase (NE) belongs to the chymotrypsin superfamily of serine 
proteases. NE has two catalytically active homologs, proteinase 3 (PR3) and cathepsin 
G (CG), created by duplication of an ancestral protease gene. Azurocidin shares 
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significant sequence and structural homology with NE, PR3, and CG, but lacks protease 
activity (494). NE, PR3, and CG are collectively referred to as neutrophil serine 
proteases (NSPs), due to their predominate expression in the neutrophil lineage. NE 
and CG are also expressed in mast cells and monocytes, but at comparatively low 
levels (495). NE is transcribed from the ELA2 gene on chromosome 19p13.3, which is 
adjacent to the PR3 gene, PRTN3. CG is transcribed from the CTSG gene residing on 
chromosome 14q11.2. NSPs share a similar gene structure, consisting of five exons 
and four introns (494, 496).   
Neutrophil Elastase Synthesis 
NE is normally synthesized in the bone marrow during myeloid-differentiation 
and packaged into the azurophilic granules of neutrophils, along with PR3 and CG 
(497). Neutrophils contain four types of granules, azurophilic granules (primary), 
specific granules (secondary), gelatinase granules (tertiary), and secretory granules. 
Neutrophil granules are generated sequentially during differentiation. NSPs are 
abundantly expressed during the promyelocytic phase of neutrophil differentiation 
corresponding with the generation of azurophilic granules. Conserved PU.1, C/EBP, 
and c-Myb binding sites within the promoter sequence of NSPs drive their expression in 
promyelocytes (498). In addition to NSP, high concentrations of myeloperoxidase, 
azurocidin, bacterial permeability increasing protein, and defensin are contained within 
the azurophilic granules. The generation of azurophilic granules is limited to the 
promyelocyte. As promyelocytes differentiate into myelocytes, the NSP expression is 
downregulated. NSPs are not detected in specific granules, which are packaged in 
myelocytes (499). The intracellular concentration of NE in neutrophils is in excess 5 mM 
(500) 
Neutrophil Elastase Activation 
NSPs are synthesized in an inactive “pre-pro” form containing a signal sequence 
and a pro-dipeptide (Ser14-Glu15). Prior to being packaged into the azurophilic 
granules, pre-pro NE is rapidly processed into its active form first by a signal peptidase 
and then by a cysteine protease, dipeptidyl peptidase I (DPPI or cathepsin C). NE is 
also processed at the C-terminus by an unidentified protease. C-terminal processing of 
 65 
NE does not affect protease activity; instead it creates a docking site for adaptor protein 
3 (AP3), responsible for protein shuttling NE between the golgi and granule (501). 
Cleavage of the N-terminal pro-dipeptide of NE by DPPI is a crucial step in NE 
activation.  Following removal of the pro-dipeptide, the free amino group of isoluecine 
16 forms a salt bridge with the carboxylate side-chain of aspartate 194 opening the 
active site to substrates (502-504). Loss of function mutations in DPPI results in the loss 
of NSP activity, underlying the rare genetic disease Papillon-Lefevre syndrome (PLS). 
Patients with PLS suffer from periodontal disease, palmoplantar keratosis, and high 
susceptibility to systemic infection (505). 
Neutrophil Elastase Structure and Function 
Active NE prefers to cleave next to small, hydrophobic amino acids (P1 
according to the Schechter and Berger notation), especially valine, isoleucine, and 
alanine. The substrate specificity of NE overlaps with related NSPs (esp. PR3, 60%-
nucleotide similarity). However, the distribution of charged amino acids surrounding 
their active sites endows each NSP with specificity in substrate recognition (506). NE is 
a neutral serine protease, demonstrating the highest degree of activity at pH 7.0. 
As with all members of the chymotrypsin superfamily, NE cleaves peptide bonds 
using a charge relay system composed of three essential residues, histidine, aspartate, 
and serine, collectively referred to as the catalytic triad. The residues of the catalytic 
triad are similarly dispersed throughout the peptide sequence of chymotrypsin-like 
proteases (i.e. histidine 57, aspartate 102, and serine 195), however they are brought 
into close physical proximity by the three-dimensional structure of the protease.  
The three dimensional structure of NE consists of two highly similar β-barrels 
(six anti-parallel β-sheets) connected by a linker segment and a C-terminal α-helix. Four 
disulfide bonds play a critical role in stabilizing the three-dimensional structure of NE. 
The catalytic residues are located at the junction of the β-barrels. The active site of the 
NE runs along the β-barrels perpendicular to the catalytic amino acids (507). A 
substrate binds to the active site of NE with the sissle bond in close proximity to the 
reactive serine. The –OH group on the serine acts as a nucleophile, attacking the 
carbonyl carbon of the sissle bond and forming a covalent bond with the substrate. The 
nitrogen on the histidine residue accepts the -H from the serine –OH and electrons from 
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the oxygen of the carbonyl carbon, forming a tetrahedral intermediate. Electrons from 
the peptide bond between the carbonyl and amino groups of the substrate then attack 
the hydrogen of the histidine, the bond is broken and the N-terminal portion of the 
peptide is released. The electrons residing on the nitrogen of the histidine reconstitute 
the bond, forming an acyl-enzyme intermediate. A molecule of water is used to replace 
the N-terminus of the cleaved peptide, again through nucleophilic attack of the carbonyl 
carbon, resulting in the formation of another tetrahedral intermediate. Then the 
electrons from the bond between the serine and carbonyl carbon attacks the hydrogen 
on the histidine followed by double bonding of the carbonyl carbon to the oxygen, 
resolving the tetrahedral intermediate, releasing the C-terminal portion of the cleaved 
peptide, and resetting the active site of the protease (508).  
A list of biologically relevant NE substrates is presented in Table 3. 
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Neutrophil Elastase Substrates 
Extracellular Receptors 
NE Substrate Biological Significance 
IL-2Rα(509) Inhibition, Impairment of T-cells 
TNFRII (TNFRSF1B)(510) Reduced TNFα binding and inhibition of 
response 
CXCR1(511) Inhibition of IL-8 signal transduction, 
impaired activation of neutrophils 
CD2(512) Inhibition, Impairment of T-cell activation 
CD4(512) Inhibition, Impairment of T-cell activation 
CD8(512) Inhibition, Impairment of T-cell activation 
CD14(513) Inhibition of Toll-like Receptor 4 
responsiveness to bacterial LPS 
CD40(514) Inhibition, Impairment of Dendritic Cells 
CD43 (siaiophorin)(515) Enhanced T-cell adhesion 
CD80(514) Inhibition, Impairment of Dendritic Cells 
CD86(514) Inhibition, Impairment of Dendritic Cells 
Urokinase Receptor (CD87)(516) Inhibition, Inability to bind urokinase 
Complement Receptor 1(517) Inhibition, Insensitivity to complement 3b  
Granulocyte colony stimulating factor 
receptor (G-CSFR)(518) 
Inhibition, negatively impacts 
granulopoiesis 
Proteinase-activated receptor-1 
(PAR1)(519, 520) 
Inhibition, prevents thrombin induced 
activation 
Proteinase-activated receptor-2 (PAR2) 
(519, 521, 522) 
Activation of the ERK signaling pathway 
Proteinase-activated receptor-3 
(PAR3)(523) 
Inhibition, prevents thrombin induced 
activation 
 
Cytokines, Chemokines, Growth Factors, and Immune Modulators 
 
NE Substrate Biological Significance 
Chemokine (C-C motif) ligand 15 
(CCL15)(524) 
Activation/liberation of circulating CCL15, 
monocyte activation 
Complement 3(525, 526) Cleavage of C3bi into isoforms similar to 
C3c and C3d 
Complement 5(527) Cleavage of C5a into isoform similar to 
C5b 
Granulocyte colony stimulating factor (G-
CSF)(518) 
Inhibition, negatively impacts 
granulopoiesis 
Tumor Necrosis Factor alpha (TNFα)(528-
530) 
Conflicting results, may degrade or 
activate TNFα 
Vascular endothelial growth factor 
(VEGF)(531) 
Altered affinity for VEGF receptors, 
stimulates Akt activation and chemotaxis 
IL-1β(532) Activation of Pro- IL-1β 
IL-2(533) Inhibition, Impairment of T-cells migration 
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and adhesion 
IL-8(534) Inhibition, reduced activation of NF-κB 
IL-18(535) Inhibition of IFNγ expression 
Macrophage inflammatory protein-1α 
(CCL3)(536) 
Generation of isoforms with reduced 
chemotactic capabilities 
Stromal cell-derived factor-1 (SDF-1 or 
CXCL12) (537) 
Inhibition, reduced chemotactic 
capabilities 
Proepithelin/Progranulin (538, 539) Degraded, causing enhanced activation of 
pro-inflammatory signaling 
 
Transcription Factors and Modulators of Intracellular Signaling 
 
NE Substrate Biological Significance 
Cut-like homeobox 1 (CUX1)(540) Generation of a hyperactive p110 isoform  
Cyclin E(541) Generation of isoforms, hyperactive in 
their ability to activate CDK2 
Insulin Receptor Substrate 1 (IRS-1)(542) Degraded, enhanced PI3K-AKT activation 
PML-RARα(543) Cleavage required for initiation of acute 
promyelocytic leukemia in mouse model 
NF-κB p65(544) Diminished NF-κB activation 
Notch 2 N-terminal Like (NOTCH2NL or 
N2N)(545) 
Inhibition of Notch2 signaling 
STAT3 α-isoform(546) Generation of STAT3 γ-isoform 
 
Adhesion Molecules and ECM Components  
 
NE Substrate Biological Significance 
E-cadherin(547) Reduced intracellular adhesion 
Collagen(548) Degradation, alteration of ECM 
composition 
Cadherin-5 (Vascular-Endothelial 
Cadherin)(549) 
Reduced adhesion of endothelial cells, 
permissive of neutrophil transmigration 
Intercellular adhesion molecule 1 (ICAM-
1)(550) 
Reduced recruitment and transmigration of 
immune cells 
Laminins(551, 552) Generation of bio-active peptides with 
chemotactic properties 
Fibronectin(552, 553) Generation of bio-active peptides 
P-selectin glycoprotein ligand-1 (554) Reduced recruitment and transmigration of 
immune cells 
Aggrecan(555) Disruption of proteoglycan structures 
Elastin(556) Degradation, alteration of ECM 
composition 
 
Proteases and Protease Inhibitors 
 
NE Substrate Biological Significance 
Matrix metalloproteinase-2(557) Activation of protease activity 
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Matrix metalloproteinase-3(558) Activation of protease activity 
Matrix metalloproteinase-9 (559) Activation of protease activity 
Merpin α(560) Activation of protease activity 
Elafin(561) Inability to bind the ECM and loss of 
protease inhibitor capability 
C1-inactivator(562) Loss of protease inhibitor capability 
Tissue inhibitor of matrix 
metalloproteinase-1 (TIMP-1)(559, 563) 
Loss of protease inhibitor capability 
Cystatin C(564) Loss of protease inhibitor capability 
α2-plasmin inhibitor(562) Loss of protease inhibitor capability 
Secretory leukocyte peptidase inhibitor 
(SLPI)(565) 
Inability to bind the ECM and loss of 
protease inhibitor capability 
 
Blood Clotting 
 
NE Substrate Biological Significance 
Von Willebrand factor (vWf)(566) Release of vWf from endothelial cells 
Platelet integrin (αIIβ3, ITGA2B) (567) Enhanced integrin function, platelet 
aggregation 
Coagulation factor IX(568) Activation 
Coagulation factor V(569) Increased association with factor Xa 
Heparin cofactor II (570) Inability to inhibit thrombin 
Tissue factor pathway inhibitor(571) Reduced ability to inhibit factor VIIa/tissue 
factor 
Kininogens(572) Generation of bioactive kinins, enhanced 
vasodilatation and smooth muscle 
contraction  
Antithrombin-III(573) Inactivation, inability to inhibit thrombin 
 
Regulation of Blood Pressure 
 
NE Substrate Biological Significance 
Angiotensin-1(574) Local vasodilatation 
Angiotensin-2(574) Local vasodilatation 
Angiotensinogen(574) Local vasodilatation 
 
Lipid Metabolism 
 
NE Substrate Biological Significance 
Apolipoprotein A-II(575) ? 
Apolipoprotein(a)(576) ? 
 
Insulin Signaling 
 
NE Substrate Biological Significance 
Insulin β-chain(577) ? 
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Insulin-like growth factor binding protein 3 
(IGFBP3)(578) 
Alteration of IGF binding 
 
Other 
 
NE Substrate Biological Significance 
IgG heavy chain(579) Immune dysfunction 
Actin(580)  ? 
Pulmonary surfactant-associated protein 
D(581) 
Impaired anti-microbial and immune 
functions 
Ribonuclease L(582) ? 
 
Table 4: Experimentally Confirmed NE Substrates and the Biological Significance of their 
Modification. 
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Role of NE in Neutrophils in Inflammation and Immunity 
Circulating neutrophils normally have a half-life of only a few hours, however 
they are constantly renewed from stem cells in the bone marrow and are the most 
abundant leukocyte in the bloodstream (comprising 60% of circulating leukocytes in a 
healthy individual) at a concentration of 1.5 to 5 x109 cells/liter (506). Neutrophils are a 
critical component of the innate immune system. Neutropenia, an abnormally low 
number of neutrophils in the systemic circulation, dramatically increases susceptibility to 
bacterial infections and can lead to life threatening sepsis, evidencing the importance of 
neutrophils immunity. Neutropenia is a common side effect in patients undergoing 
cancer chemotherapy and can increase susceptibility to developing systemic infection. 
Rare genetic diseases, cyclic neutropenia and severe congenital neutropenia commonly 
harbor mutations to the ELA2 gene, and less frequently in genes involved in the normal 
trafficking of NE, or genes involved in the transcription of NE. The mutant forms of NE 
mislocalize and accumulate within neutrophils, however the mechanism by which 
mislocalized NE results in neutropenia has not yet been defined (501).  
In healthy individuals, neutrophils are the first inflammatory cell type to leave the 
vasculature following infection or wounding. Neutrophil chemotaxis requires the release 
of chemotactic cues, such as IL-8, complement 5a, leukotriene B4, and N-formyl-
methionyl-leucyl-phenylalanine (fMLP), from the inflammatory site. Neutrophils contain 
four types of granules, azurophilic granules (primary), specific granules (secondary), 
gelatinase granules (tertiary), and secretory granules. These granules contain a wide 
rande of antimicrobial factors, protease, and ROS. Also contained within neutrophil 
granules are number of membrane bound receptors including CD11b/CD18 and fMLP 
receptor, which are essential to neutrophil activation and chemotaxis. The intracellular 
mobilization of granules is essential to the activation and immune functionality of 
neutrophils.(583, 584).  
The major physiological function of NE is the intracellular destruction of 
pathogens, following phagocytosis at sites of infection. Once engulfed by a neutrophil, 
pathogens are sequestered in a membrane bound vesicle, know as the phagosome. 
Fusion of the phagosome with a lysosome creates the phagolysosome, triggering the 
exposure of the pathogen to massive quantities of reactive oxygen species (ROS) 
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generated by membrane-bound NADPH oxidase. The phagolysosome containing the 
pathogen then fuses with neutrophil granules releasing NSPs and antimicrobial 
compounds, which synergies with ROS in the intracellular destruction of pathogens. 
Consistent with its important role in innate immunity, NE knockout mice deficient in 
intracellular killing of gram-negative bacteria and are susceptible to infection (500).  
Role of Extracellular NE 
Non-resolving inflammation and the presence of inflammatory cells in the tumor 
microenvironment are regarded as essential components of tumor progression (9, 10). 
Activated neutrophils also secrete NE into the microenvironment through limited 
exocytosis of azurophilic granules (585). Neutrophils degranulate, releasing NE, in 
response to a variety of chemokines, cytokines, and bacterial derived chemotactic 
peptides, including IL-8, TNF-α, C5a, fMLP, and LPS (586) A portion of highly cationic 
NE associates with the neutrophil cell surface through electrostatic interactions with 
negatively charged proteoglycans (587, 588). Neutrophils are the first responders of the 
immune system and secreted NE is an important component of the early anti-microbial 
and inflammatory responses. In this context, NE is essential to the formation of 
neutrophil extracellular traps NETs, complexes formed by the extracellular association 
of NSPs, antimicrobial peptides, chromatin DNA, and histones. The high concentration 
of NSPs associates with NETs allows for extracellular killing of microbes and digestion 
of virulence factors. NE also participates in extracellular ECM remodeling, cleaves cell 
adhesion molecules, and alters inflammatory/growth factor signaling networks, 
contributing to the immune response, resolution of infection, and wound healing (589).  
Extracellular NE and Cell Signaling 
NE promotes activation of toll-like receptor 4 (TLR4), inducing NF-κB 
activation mediated by MyD88/IRAK/TRAF-6, and ultimately the expression of 
inflammatory cytokines such as IL-8 (590). The epidermal growth factor receptor 
(EGFR) may also play a role in the NE-induced activation of pro-inflammatory signaling. 
Following cleavage by NE the MMP, meprin α, is activated leading to the activation of 
pro-TGFα, which in turn results in activation of EGFR (560). Immunoprecipitation 
studies found an association between TLR4 and EGFR following NE simulation and is 
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essential to NE-induced IL-8 expression (560). NE can also activate the EGFR through 
the liberation of latent growth factors trapped by the ECM or adhered to the cell 
membrane (506). Proteinase activated receptor 2 (PAR2) belongs to a family of G-
coupled protein receptors that are activated following cleavage of their N-terminal 
extracellular domains. Several proteases cleave PAR-2, including NE, which activates 
ERK signaling (521). NE also cleaves PAR-1, inhibiting its activation by thrombin (520) 
The chemokine stromal cell-derived factor1α (SDF-1α or CXCL12) and its receptor 
CXCR4 play a critical role in the trafficking of lymphocytes. Cleavage of SDF-1α and 
CXCR4 by NE inhibits their activation (591). Progranulin (or pro-epithelin), suppresses 
inflammation by modulating neutrophil activation and preventing the release of NSPs 
and reactive oxygen species (ROS). NE and PR3 were found to cleave progranulin in 
vitro. In mice deficient in both PR3 and NE, demonstrate a blunted inflammatory 
response and progranulin accumulation following inflammation induced by immune 
complexes (538). 
Imbalance between NE and its Inhibitors in Inflammatory Disease 
Following physiological inflammation, serine protease inhibitors rapidly quench 
NE activity, inflammation resolves, and tissue homeostasis is restored (506). However, 
in disease states characterized by chronic or excessive inflammation and neutrophil 
accumulation, such as emphysema, chronic obstructive pulmonary disease (COPD), 
(11) and inflammatory bowel disease (IBD) (15), an imbalance between NE and its 
inhibitors results in symptomatic tissue destruction, perpetuates inflammation, and is 
critical to disease pathogenesis (11).  Deregulated NE activity has been implicated in a 
variety of inflammatory disease states. NE dramatically alters the immune response by 
proteolytically altering or degrading a wide rand of cytokine, chemokines, angiogenic 
factors, growth factors, complemtent, and cell surface receptors. 
In animal models, pharmacological inhibition of NE reduced granulocyte 
accumulation and microvascular dysfunction following ischemia-reperfusion of skeletal 
muscle (592), prevents the progression of acute lung injury following endotoxin 
inhalation (593), and decreased the severity of collagen-induced arthritis (594). DPPI 
knockout mice, deficient in the activation of NSPs, are also protected from experimental 
arthritis, demonstrating a local decrease in inflammatory makers (595). NE knockout 
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mice are protected from development of the autoimmune disease, bullous pemphigoid 
characterized by subdermal blistering (596). Chronic inflammation and the recruitment 
of neutrophils to the adipose tissue and liver play an integral role in insulin resistance. 
NE knockout in obese mice fed a high fat diet reduced inflammation, improved glucose 
tolerance, and enhanced insulin sensitivity compared to wild-type littermates (597). 
Taken together these studies suggest a prominent role for NE in the pathogenesis of 
chronic inflammatory disease.  
COPD is characterized by limited airflow within the lungs and progressive loss of 
the lung epithelium. The airways of healthy individuals is sterile, however in patients 
suffering from COPD bacteria are able to colonize the lung and stimulate massive 
neutrophil infiltration. COPD is a significant and growing cause of morbidity and 
mortality within the population. NE is believed to be critical to the degradation of the 
ECM and destruction of the lung parenchyma. Treatment of COPD patients with NE-
inhibitors has been hypothesized to improve lung function. NE inhibitors, such as 
AZD9668, have been developed for the treatment of COPD. Limited phase one and two 
studies have shown that AZD9668 is well tolerated, however it did not significantly 
enhance lung function (598). 
Role of Neutrophil Elastase in Tumorigenesis 
In the tumor microenvironment the majority of NE is contributed by activated 
neutrophils. In breast cancer patients, high levels of NE are prognostic of poor overall, 
metastasis-free, and disease-specific survival, and are predictive of resistance to 
therapy, suggesting a possible role for neutrophils and NE in tumor progression (12, 
599-601). High levels of NE are also found in the tumors of patients with bladder 
cancer, lung cancer, and pancreatic cancer (12, 601-605).  A recent study 
demonstrates that NE knockout in the loxP-Stop-loxP K-rasG12D mouse model of lung 
cancer severely limits tumor growth and proliferation, providing direct in vivo evidence 
of a role for NE in tumorigenesis (542). Sivelestat, a pharmacological inhibitor of NE, 
was able to reduce the proliferation, motility, and chemotaxis of the pancreatic cancer 
cell line Capan-1 in vitro (603). In a mouse xenograft model of non-small cell lung 
cancer using the EBC-1 and PC-1 cell lines, sivelestat attenuates proliferation and 
metastasis (606). Sivelestat also inhibited spontaneous metastasis of EBC-1 xenograft 
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tumors (607). Beige mice are deficient in NE (608). A mutant strain of NE-deficient mice 
was created by crossing beige mice with SKH 1 hairless mice. Following ultraviolet 
irradiation, NE-proficient mice developed 10 tumors per mouse after 20-weeks, while 
NE-deficient mice developed only 0.4 tumors per mouse over the same period. In the 
same system, benzopyrene exposure resulted in the formation of 7 tumors per control 
mouse and only 0.2 tumors per NE-deficient mouse. Pharmacological inhibitors of NE, 
2,4,6-trinitrochlorobenzene and oxazolone were able to attenuate the development of 
skin tumors following ultraviolet irradiation (609). NE knockout in the loxP-Stop-loxP K-
rasG12D mouse model of lung cancer was able to severely limits tumor growth and 
progression compared to NE-proficient mice (542).  
Extracellular NE 
The conventionally understood role of NE in tumor progression is largely 
extrapolated from the contributions of extracellular NE to chronic inflammatory disease, 
particularly emphasizing the importance of NE in tumor cell invasion and metastasis 
through ECM degradation and the cleavage of adhesion proteins (610, 611). NE has 
the ability to cleave the majority of ECM element and is known to activate a number of 
other tissue degrading proteases including MMP-2, MMP-3, and MMP-9 (559) (612, 
613). NE also cleaves adhesion molecules including E-cadherin (550, 614, 615).  
Intracellular NE 
Several recent studies demonstrate a novel functional context for NE in 
directly altering intracellular signaling. In these studies, the ability of cancer cells to 
endocytose NE from the microenvironment (542, 585, 616) or inappropriately express 
intracellular NE (541, 617) promotes proliferation and tumor progression through 
specific intracellular proteolytic events. The intracellular cleavage of cyclin E by NE 
generates low-molecular weight cyclin E isoforms (LMW-E) known to hyper-activate 
cyclin-dependent kinase 2 (CDK2) (541, 618, 619). LMW-E is prognostic of poor overall, 
metastasis-free, and disease-specific survival in breast cancer patients (620), induces 
genomic instability and cellular transformation in vitro (621, 622), and can drive mouse 
mammary tumorigenesis in a CDK2-dependant fashion (623, 624).  
Intracellular NE also acts through degradation of Insulin Receptor Substrate-1 
(IRS-1). Reduced levels of IRS-1 increase phosphatidylinositol 3-kinase (PI3K) activity 
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through enhanced association with the platelet-derived growth factor receptor (PDGFR), 
ultimately promoting Akt activation. In human lung adenocarcinoma, NE and IRS-1 
expression are inversely correlated, suggesting that NE-mediated degradation of IRS-1 
is relevant to human lung cancer progression (542). Through the proteolysis of a 
repertoire of extracellular and intracellular substrates, NE plays a critical role in 
deregulation of many processes and pathways known to promote tumor progression. 
NE has been implicated in the pathogenesis of acute promyelocytic leukemia 
(APL). A significant portion of APL patients harbors a fusion protein consisting of the 
promyelocytic leukemia gene and the retinoic acid receptor alpha (PML-RARα). NE 
cleaves the fusion protein PML-RARα in both mouse and human APL and is required 
for disease progression in mouse models of the disease (543).  
In acute myeloid leukemia (AML), the p200 form of transcription factor CUX-1 
(CCAAT Displacement Protein) is cleaved by NE into a shorter p110 form, which is 
hyperactive in its ability to stimulate promoter activity. CUX-1 (p110) is known to 
increase gene transcription associated with proliferation, motility, and invasion. CUX-
1(p110) is overexpressed in breast cancer. Mammary specific overexpression of CUX 
(p110) drives tumor formation and lung metastasis; indicating that the cleavage of CUX-
1 by NE may be important in breast cancer (540, 625).  
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ELAFIN 
Discovery of Elafin 
Early reports describe a low-molecular weight inhibitor of elastase-like activity in 
the bronchial mucus of human subjects. Failure to detect this protease inhibitor in the 
serum of these subjects suggested to the authors that it was produced locally in the 
lung, a critical distinction from previously identified elastase inhibitors (626, 627). 
Subsequent studies identified a serine protease inhibitor, termed elafin, in skin lesions 
associated with the autoimmune disease psoriasis. These reports revealed that elafin is 
a highly specific and potent inhibitor of porcine pancreatic elastase (PPE), NE, and PR3 
activity (13, 628) with significant sequence similarity to previously identified secretory 
leukocyte protease inhibitor (SLPI) (629). Nearly concurrent identification by several 
groups and expression as multiple isoforms has resulted in multiple designations, 
including skin-derived antileukoprotease (SKALP) and elastase specific inhibitor (ESI), 
however elafin is the consensus nomenclature used in this dissertation (630).  
Elafin Structure 
Elafin is expressed from the gene PI3 located on the chromosomal region 20q13 
in close proximity to several structurally related genes (631). The PI3 gene is composed 
of three exons separated by two introns. Following translation elafin is 117 amino acids 
in length. The N-terminal signal peptide is cleaved in the endoplasmic reticulum 
reducing the length of elafin to 85 amino acids (approximately 9 kDa). Following 
cleavage of the signal peptide, elafin is secreted via the canonical secretion pathway.   
Elafin contains two critical domains: 1) a N-terminal transglutaminase linking 
domain, referred to as the cementonin, and 2) a C-terminal globular domain stabilized 
by four-disulfide bonds. This four disulfide bond structural motif first observed whey 
acidic protein (WAP) an abundant component of milk in rodent and is therefore refered 
to as a WAP domain (630). The cementonin domain consists of Gly-Gln-Asp-Pro-Val-
Lys repeats that serves as a substrate for the enzyme transglutaminase, which 
catalyzes the covalent cross-linking of elafin to ECM components. Some non-canonical 
functions of elafin, such as the ability to bind LPS, have been shown to be dependent 
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on the cementonin-domain (632). The N-terminal region of elafin could not be resolved 
by crystallography because of its disordered conformation. Circular dichroism and 
nuclear magnetic resonance (NMR) analyses reveal that in the presence of membrane 
lipids the disordered N-terminal region adopts a α-helical secondary structure (633). 
The C-terminal WAP-domain contains the protease inhibitory loop. The WAP-domain of 
elafin can be released from the cementonin domain by proteolytic cleavage, generating 
a 57-amino acid form of elafin (approximately 6 kDa). Removal of the cementonin 
domain does not effect the protease inhibitor activity of elafin, however in the absence 
of the cementonin domain elafin can no longer bind the ECM (561).  
Physical Interaction between Elastase and Elafin 
Elafin non-covalently binds to the catalytic cleft of the target protease blocking 
access of substrates. This mechanism of action differs from serpins, such as α1-
antitrypsin. Serpins bind to the target protease and form a covalent linkage, 
permanently disabling the active site. The crystal structure of the C-terminal globular 
domain of full-length elafin in complex with PPE has been resolved (634), as well as the 
NMR structure of elafin alone (635). The conformation of elafin consists of a central β-
sheet stabilized by three disulfide bonds. The protease inhibitory loop is connected to 
the central β-sheet by two external peptide chains and is stabilized by the fourth 
disulfide bond. The protease inhibitor region is located between amino acids Leu20(P5) 
and Leu26(P2’). The side chains of the residues making up the inhibitory loop of elafin 
forms four hydrogen bonds and with the PPE active site, Ser214(S5)-Arg217(S2’). 
Extensive van der Waals interactions are also formed between the protease inhibitor 
domain of elafin (P5-P2’) and the active site of PPE (S5-S5’). The sissle peptide bond is 
between Ala24(P1) and Met25(P1’). The Ala24 carbonyl group projects into the 
oxyanion hole created by nitrogen atoms of Gly193 and Ser195 of PPE, disfavoring 
catalysis.  A secondary site of interaction between elafin Ser48, Cys49, and Ala52 and 
PPE Asp97 and Val99, further stabilizes the interaction between protease and inhibitor 
through hydrogen bonding and van der Waals interaction (634, 635).  
Oxidation of Ala24(P1) or Met25(P1’) reduces the ability of  elafin to inhibit PPE, 
further evidencing the importance of these residues (634, 635). Replacing the 
Met25(P1’) with either a lysine or glycine residue attenuates the ability of elafin to inhibit 
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NE and PR3, the glycine substitution is completely ineffective at inhibiting NE (636). 
The WAP-domain of PI3 and the C-terminal WAP-domain of SLPI (two WAP domains) 
share significant sequence similarity and are believed to have share a common 
ancestor, however the protease inhibitory domain of SLPI has the ability to inhibit 
trypsin, chymotrypsin, NE, and cathepsin G, but not PR3. The P1 residue appears to 
govern specificity; the P1 residue of elafin, Ala24, is too small to interact with the S1 
pocket of chymotrypsin. Comparatively, the P1 residue of SLPI, Leu72, is large enough 
to inhibit chymotrypsin activity (634, 635). 
Evolution of WAP-Domain Containing Genes 
Fourteen human WAP-domain containing genes are spread over a 683 kb 
stretch of chromosome 20q13. The clustering of WAP-domain containing genes 
suggests repeated duplication during evolution. Several WAP-domain containing 
proteins are encode by genes outside of the 20q13 cluster including WFIKKN, 
WFIKKN2, and ps20. Some of the WAP-domain containing proteins are known to have 
protease inhibitory function, including elafin, SLPI, human epididymis gene product 4 
(HE4), and eppin, however the majority fail to display anti-protease activity or are 
uncharacterized (637). Aside from the cysteine residue required for disulfide bonding, 
very little sequence conservation is observed between WAP-domain containing 
proteins. Significant functional diversity may exists between WAP-domain containing 
proteins, for example the porcine sodium-potassium ATPase inhibitor-2 (SPAI-2) has 
the ability to inhibit an intestinal NA+/K+ ATPase (638).  
The spectrum of WAP containing proteins is extremely variable between 
species. Elafin is a relevant example; there is no rodent homolog of human elafin, 
however there are six-elafin homologs in the porcine genome (639). WAP-domain 
containing genes have been subject to dynamic change over a relatively short period of 
evolutionary time. Comparison of the human and chimpanzee genomes identifies the 
WAP-locus is one of sixteen regions dense in rapidly evolving genes. One reason for 
this may be that the genes encoding the semen proteins, semenogelin 1 (SEMG1) and 
semenogelin 2 (SEMG2), are found within the WAP-domain containing gene locus. In 
primates with polyandrous mating systems the SEMG proteins form a copulatory plug, 
however in primates with monoandrous mating systems the SEMG contributes to the 
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viscosity of the semen but does not form a plug. The high rate of SEMG evolution is 
correlated with differences post-copulatory sperm competition (due to the evolution of 
monoandrous and polyandrous mating systems)  and semen coagulation (640, 641).  
Exon shuffling between an ancestral WAP-domain containing gene and a 
SEMG-like gene is responsible for the chimeric structure (cementonin and globular 
domain) of trappin family members, such as elafin. The first and third exons of elafin 
share sequence homology with SEMG proteins, while the central exon containing a 
WAP domain. Trappins and SEMG proteins are collectively referred to as rapidly 
evolving substrates for transglutaminase (REST) (642). Elafin is the only trappin in 
humans, sequence similarity with SLPI is restricted to the WAP domain (630). 
The Role of Elafin in Immunity and Inflammation 
Elafin Expression 
Systemic serine protease inhibitors, such as α1-antitrypsin and α1-
antichymotrypsin, are expressed by the liver and distributed throughout the body by the 
circulatory system. A germline mutation in the SERPINA1 gene (α1-antitrypsin) results 
in the accumulation of α1-antitrypsin in the liver and deficiency within the circulation, 
resulting in severe COPD, emphysema, liver cirrhosis, and several other inflammatory 
diseases (643, 644). Systemic serine protease inhibitors provide baseline control of 
deregulated protease activity. Elafin and other “alarm-proteases” are expressed at high 
concentration by epithelial cells, providing local anti-protease coverage where systemic 
inhibitors may be inadequate (645, 646). Epithelial cells express elafin either 
constitutively or in response to inflammatory cytokines, such as IL-1β and TNF-α (13, 
647). The p38 MAPK, c-JUN, and NF-κB pathways drive elafin expression downstream 
of inflammatory cytokines (646, 648, 649). The inducible expression of elafin is 
especially evident in the epidermis. The normal epidermis does not express elafin, 
except for the keratinizing cells surrounding the sweat duct and hair follicles. However, 
under inflammatory conditions, associated with the hyperproliferative disease psoriasis 
or wounding, elafin is highly expressed in the epidermal layer. Elafin expression in the 
inflamed epidermis is correlated with the amplitude of neutrophil influx (650-653). 
Larynx, lung, kidney, liver, and urthera are all elafin negative under non-inflammatory 
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conditions (647). Compared to the related serine protease inhibitor SLPI, elafin 
demonstrates much greater cytokine-mediated induction, suggesting that elafin has an 
especially important anti-protease role following inflammatory stimulus (645). 
Constitutive elafin expression has also been observed in mucosal tissues, for 
example the tongue, tonsils, gingiva, epiglottis, esophagus, vagina, and pharynx all 
express elafin. In addition to a protease inhibitory role, elafin also boast anti-microbial 
and immune functions, which likely underlie its constitutive expression at mucosal 
surfaces (647). Interestingly, the fetal tissues including the epidermis express high 
levels of elafin, which are downregulated at birth (647). Elafin expression by 
macrophages and γδ T-cells has also been reported in response to bacterial ligands 
(654). An inflammatory-like reaction is characteristic of tissue remodeling and other 
normal homeostatic processes. In the human endometrium, elafin is highly upregulated 
during menstruation correlating with the influx of inflammatory leukocytes and 
upregulation of inflammatory signaling, suggesting a role for elafin in tissue remodeling 
and homeostasis (655). 
Protease Independent Functions (Non-Canonical) 
Elafin plays a significant role in the immune and inflammatory responses. The 
bactericidal effect of elafin is largely due to its highly cationic charge, which allows elafin 
to disrupt bacterial membranes. Elafin also possess the ability to bind LPS and 
modulate the activity of the toll like receptor (TLR) pathway. Adenoviral overexpression 
of elafin reduces neutrophil infiltration and cytokine/chemokine levels in mice treated 
with lipopolysaccharide (LPS) (656, 657). Elafin also mediates anti-microbial immunity 
through interactions with the innate and adaptive immune response. Elafin can 
opsonize bacteria, activate antigen-presenting cells, and act as a neutrophil chemo-
attractant (632, 633). The antibacterial capacity of elafin against both gram-positive and 
gram-negative strains has been demonstrated in vitro and in vivo (20, 632, 658) Elafin 
has anti-fungal activity that could be disrupted by high salt and heparin implicating its 
cationic charge (659, 660). Elafin is an important component of the mucosal barrier to 
retroviral infection. Elafin blocks viral attachment, entry, and replication in experimental 
models (661-664). Commercial sex workers expressing high levels of vaginal elafin are 
resistant to HIV infection (662, 665). Although not directly tested, the available 
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mechanistic data suggests that immune functions discussed here are largely 
independent of the protease inhibitor domain and require the cementonin domain of full-
length elafin. 
Imbalance between NE and Elafin 
Elafin is a critical component of the epithelial barrier to NE-activity. Imbalance 
between NE and its inhibitors is implicated in the pathogenesis of a wide range of 
diseases characterized by excessive or chronic inflammation (15). Low levels of elafin 
and corresponding high levels of NE are observed in the serum of patients suffering 
from acute respiratory distress syndrome (ARDS) (14). A polymorphism in the elafin 
gene (Thr34Pro) correlates with a significant reduction in the serum elafin levels and 
increases susceptibility to ARDS (666). Compared to healthy individuals, the colon 
mucosa of patients with inflammatory bowel disease (both Crohn’s disease and 
ulcerative colitis) demonstrates reduced elafin expression and high levels of NE activity 
(15, 667). Analysis of bronchoalveolar lavage fluid from patients with acute lung injury 
found that elafin levels increased within 48 hours of onset compared to healthy adults. 
However, elafin levels decrease over time due to degradation by the 20S proteasome 
cooresponding to increased NE activity (16). Elafin levels are also decreased in cases 
of bacterial vaginosis and periodontitis (668, 669). Local decrease in elafin expression 
within the epidermis enhances pustule formation associated with psoriasis and impetigo 
herpetiformis (670-672). In the subset of inflammatory diseases examined, elafin levels 
are generally decreased favoring NE.  
Consequences of Elafin Overexpression in Mouse Models of Inflammation 
Given the important role of NE in regulating inflammation and symptomatic 
tissue destruction, the possibility exists that the loss of elafin is a critical factor in the 
pathogenesis of inflammatory disease. This hypothesis has been examined in mouse 
models of inflammatory disease. Transgenic overexpression or administration of food-
grade bacteria engineered to express elafin protects the colon mucosa from tissue 
destruction associated with dextran sodium sulfate induced experimental colitis (667). 
Adenoviral deliver of elafin to the lungs of mice significantly reduced acute lung injury 
induced by pseudomonas aeruginosa infection (20). Transgenic mice overexpressing 
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elafin in the cardiovascular system demonstrate reduced NE-activity, lower levels of 
MMPs, and reduced pulmonary hypertension following chronic hypoxia (19). These 
mice demonstrate reduced mortality, decreased inflammation, and improved heart 
function after viral myocarditis (18) or myocardial infarction (17). Mice pre-treated with 
wild-type elafin were resistant to NE-induced tissue destruction and neutrophil aveolisis 
in an experimental model of emphysema. However, mice pretreated with mutant elafin 
lacking protease inhibitory function was unable to attenuate the pathogenesis of 
experimental emphesyma (636). These results indicate that elafin is a critical 
counterbalance against NE-activity. Permutations in epithelial elafin expression affect 
the integrity of the anti-protease shield and dramatically alter the pathogenesis of 
inflammatory disease.  
The anti-inflammatory capacity of elafin may extend beyond its anti-protease 
activity. Elafin directly reduces NF-κB activation in monocytes exposed to LPS through 
a protease-independent, but otherwise undefined effect on the ubiquitantion of IκB 
(673). The contributions of these protease independent properties to the anti-
inflammatory role of elafin have not been sufficiently examined. Elafin is currently being 
tested in clinical trials aimed at determining the ability of elafin to modulate post-
operative inflammation (674)  
Deregulated NE activity drives vascular cell proliferation and intimal thickening 
following vascular injury. Transgenic overexpression of elafin in the cardiovascular 
system of mice prevents the proliferation of smooth muscle cells and the accumulation 
of inflammatory cells following vascular injury (675). Deregulated NE activity may also 
play a role in proliferation skin lesions associated with the inflammatory disease 
psoriasis. Treatment of the mouse epidermis with NE results in epidermal thickening, 
whereas application of elafin can prevent epidermal proliferation(676).  
Deregulation of Elafin in Tumorigenesis 
Several studies suggest that elafin is downregulated in poorly differentiated 
squamous cell carcinomas of the skin, head/neck, and esophagus compared to well-
differentiated tumors, suggesting a role for elafin downregulation in the development of 
a poorly differentiated and aggressive tumor phenotype (21, 22, 677). Elafin expression 
is absent from the majority of breast tumor derived cell lines when compared to normal 
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HMECs (23). The bZIP transcription factor, C/EBP β, is required for elafin expression in 
normal HMECs. C/EBP β is expressed as full-length transcriptional activators, termed 
liver-enriched activating protein 1 and 2 (LAP1 and LAP2), and a truncated repressor, 
termed liver-enriched inhibitory protein (LIP). C/EBP β, a transcription factor required for 
mammary gland development and differentiation In the majority of breast cancer cell 
lines, elafin is transcriptionally downregulated due to overexpression of a C/EBP β 
dominant negative isoform. Dominant negative C/EBP β is predominately expressed (as 
a ratio to full-length, activating isoforms) in a large proportion of breast tumors (24). 
Recent studies indicate that elafin induces growth arrest and/or apoptosis upon re-
expression in cancer cell lines; suggesting that elafin possesses tumor suppressive 
activity (678, 679). In breast cancer xenograft models the introduction of elafin, by 
intratumoral injection of elafin expressing adenovirus, greatly decreases tumor growth 
and progression (25). 
In HMECs, the expression of elafin is regulated by C/EBP β transcriptional 
elements. C/EBP β is frequently deregulated in breast cancer patients due to 
accumulation of the truncated, inhibitory isoform of C/EBP β (24).  
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Chapter 2: Imbalance between Neutrophil Elastase and Elafin Promotes Breast 
Cancer Progression 
 
INTRODUCTION 
NE, a potent serine protease, is normally synthesized in the bone marrow during 
myeloid-differentiation and sequestered within the azurophilic granules of neutrophils 
(504). NE has broad substrate specificity, preferentially cleaving peptide bonds adjacent 
to small hydrophobic amino acids (506). The major physiological function of NE is the 
intracellular destruction of pathogens following phagocytosis at sites of infection (500). 
Activated neutrophils also secrete NE into the extracellular environment through 
exocytosis of azurophilic granules. In this context NE has important roles in the anti-
microbial, inflammatory, and wound healing responses. Following normal inflammation, 
serine protease inhibitors rapidly quench NE activity and inflammation resolves (506). 
Imbalance between NE and its inhibitors is implicated in the pathogenesis of a wide 
range of diseases characterized by excessive or chronic inflammation (680). 
Pharmacological inhibitors of NE are under development for the treatment of 
symptomatic tissue destruction in chronic inflammatory lung diseases (11). 
The conventionally understood role of NE in tumor progression is promotion of 
cell invasion and metastasis through extracellular matrix degradation and the cleavage 
of adhesion molecules (610). However, several recent reports demonstrate a role of NE 
in the activation of intracellular signaling pathways during early tumorigenesis. NE was 
shown to enhance phosphoinositide 3-kinase (PI3K) activity following the degradation of 
insulin receptor substrate-1. In the loxP-Stop-loxP K-rasG12D mouse model of lung 
cancer, NE knockout reduces PI3K activity and severely limits tumor growth (542). NE 
has also been implicated in cleavage of cyclin E into low-molecular weight isoforms 
capable of hyperactivating cyclin-dependent kinase 2 and inducing tumor formation in 
mouse models (541, 624). NE activates intracellular signaling through cell surface 
receptors, including toll-like receptor 4 (TLR4) (590), proteinase-activated receptor 2 
(PAR2) (521), and epidermal growth factor receptor (EGFR) (681), either directly 
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through proteolysis of the extracellular domain or indirectly through the 
liberation/activation of latent ligands (506). 
Elafin is an endogenous inhibitor of NE and the highly related serine protease 
proteinase 3. Epithelial cells express elafin either constitutively or in response to 
inflammatory cytokines (13, 647). Imbalance between NE and elafin has been observed 
in many diseases, including acute respiratory distress syndrome (14), inflammatory 
bowel disease (15), and acute lung injury (16). In mouse models, overexpression of 
elafin diminishes tissue destruction associated with experimental colitis (15), protects 
against acute lung injury (20), reduces pulmonary hypertension following chronic 
hypoxia (19), and improves heart function after viral myocarditis (18) or myocardial 
infarction (17). Permutations in epithelial elafin expression affect the integrity of the 
antiprotease shield and dramatically alter the pathogenesis of inflammatory disease. 
Compelling evidence suggests that disequilibrium between NE and its inhibitors 
is a critical component in the pathogenesis inflammatory diseases. Inflammation and 
the presence of leukocytes in the tumor microenvironment are regarded as essential 
components of malignant progression (9). Tumor-associated neutrophils (TAN) are the 
major source of NE in the tumor microenvironment. In breast cancer patients, high 
levels of NE are prognostic of poor overall (OS), metastasis-free, and disease-specific 
survival (12).  
Several studies suggest that loss of elafin-mediated control of NE activity may 
also be a feature of malignant growth. Elafin is downregulated in poorly differentiated 
squamous cell carcinomas of the skin, head/neck, and esophagus compared to well-
differentiated tumors (21, 22). Subtractive cDNA hybridization identified elafin 
downregulation in breast cancer cell lines compared to HMECs (23). The transcription 
factor, C/EBP β, is required for elafin expression in normal HMECs. C/EBP β has critical 
roles in the regulation of cell proliferation and mammary gland development (24, 682-
684). In the majority of breast cancer cell lines, elafin is transcriptionally downregulated 
due to overexpression of a C/EBP β dominant negative isoform. Dominant negative 
C/EBP β is predominately expressed (as a ratio to full-length, activating isoforms) in a 
large proportion of breast tumors, suggesting that elafin is downregulated in these 
breast tumors (24). However, no published study has comprehensively investigated the 
expression of elafin during breast tumor progression.  
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HMECs as an In Vitro Model System 
No direct homolog of elafin exists within the mouse genome. Therefore, we 
utilized primary and immortalized HMECs as a model system to interrogate the role of 
elafin in the mammary epithelium (685, 686). HMECs are derived from freshly 
disassociated reduction mammoplasty or mastectomy tissue specimens. In some 
cases, HMEC cell lines have been generated from epithelial cells shed into human 
breast milk. Primary HMEC cultures contain a heterogeneous population of cells; 
including luminal epithelial cells, myoepithelial cells, stem/progenitor cells, and 
fibroblasts (687, 688). In culture, purified HMECs stop proliferating and become 
senescent after several passages. Early experiments found that HMECs could be 
immortalized by exposure to mutagenic insult, such as benzo(a)-pyrene and γ-radiation, 
however the frequency of immortalization was extremely low and the permissive genetic 
alterations were unknown (689). 
A refined model of HMEC growth and arrest in culture, following their derivation 
from human tissue explants, has lead to the creation of systems for the evaluation of 
normal breast epithelial cell behavior and carcinogenesis. The study of HMECs has 
enhanced understanding of the barriers to oncogenesis and the mechanisms by which 
these barriers are circumvented during tumorigenesis. Primary HMEC cultures exhibit 
an initial exponential growth phase of between fifteen and twenty population doublings 
before transiently growth arresting. This stress associated proliferative arrest, termed 
M0, can be overcome by genetic/epigenetic downregulation of p16 expression. The 
expression of the viral oncoproteins human papillomavirus (HPV) E7 and SV40-large T-
Antigen (SV40-Tag) result in Rb degradation and allow cells to circumvent M0-arrest 
(689-692).   
HMECs bypassing M0 cells are not immortalized and are eventually subject to 
irreversible replicative senescence (M1), characterized by cell enlargement, cell 
flattening, increased vacuolization, senescence-associated β-galactosidase activity, low 
proliferation index, and low apoptotic index (693-695). Telomere attrition causes 
HMECs to undergo senescence at M1. The finite replicative limit of normal cells is 
termed the Hayflick limit (694, 696). Inactivation of the p53 pathway can overcome 
replicative senescence in HMECs, this can be experimentally induced by expression of 
HPV-E6 or SV40 large T antigen oncoprotein (697, 698). Populations of HMECs 
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emerging from M1 undergo another 30-60 population doublings eventually reach a state 
of cell crisis, termed M2. HMECs at M2 are characterized by critically short to non-
existing telomeres, have a high proliferation index, an equally high apoptotic index, 
display polyploidy, and chromosomal abnormalities (695). Somatic cells lack the 
telomerase enzyme (TERT), which is required for the telomere maintenance (696). The 
expression of TERT in HMECs that have bypassed M0, allows bypass of both M1and 
M2 (694, 696, 699) 
The immortalization of HMECs requires disruption of the Rb pathway (M0), 
downregulation of p53 activity (M1), and activation of TERT (M1 and M2). Immortalized 
HMECs have the capacity for infinite cell division, a hallmark of cancer (10), however 
they are not capable of transformed, anchorage-independent growth and cannot form 
tumors in immunocompromised mice. Fully immortalized HMECs can be transformed by 
the introduction of a single oncogene, such as oncogenic H-Ras (315, 700). 
HMECs express high levels of elafin in comparison to breast tumor cells. In cell 
cycle synchronization experiments, elafin mRNA expression is downregulated in S-
phase-enriched cell fractions, indicating a potential role in the regulation of cell 
proliferation (23). HMECs provide an ideal system to explore the role of endogenous 
elafin expression in normal epithelial cells. 
Hypothesis and Central Findings 
The hypothesis tested in this chapter is that imbalance between NE and elafin 
promotes loss of growth control and is a feature of breast tumorigenesis. In support of 
this hypothesis, immunohistochemical analysis revealed progressive loss of elafin 
expression during breast and ovarian tumorigenesis. In HMECs, we showed that elafin 
was required to maintain quiescence (G0) by opposing the mitogenic effect of NE. 
Mechanistically, NE-induces activation of the ERK signaling pathway in a TLR4-
dependent manner. Our results suggest that imbalance between NE and its 
endogenous inhibitor, elafin, promotes tumor growth through the mitogenic activation of 
TLR4. A therapeutic approach designed to correct the imbalance between NE and its 
endogenous inhibitor, elafin, could limit tumor growth and progression. 
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MATERIALS AND METHODS 
Antibodies 
Antibodies Primary antibodies used for immunohistochemistry (IHC), western 
blot (WB), immunofluorescence (IF), and ELISA were:  
 
Antibody Species Clone Company Application Notes 
Elafin Mouse monoclonal TRAB/2F Hycult 
IHC, WB, IF, 
ELISA 
Epitope: 57 C-
terminal amino acids 
Elafin Mouse monoclonal TRAB/2O Hycult IHC, WB 
Epitope: 
Transglutaminase 
linking domain at the 
N-terminus 
Elafin Rabbit polyclonal  Hycult ELISA  
Phospho-Rb 
site Ser780 
Rabbit 
polyclonal  
Cell Signaling 
Technology WB  
Total-Rb Mouse monoclonal G3-245 
BD 
Biosciences WB  
p53 Mouse monoclonal DO-1 Calbiochem WB  
phospho-
p44/42 MAPK 
(Erk1/2) site 
Thr202/Tyr204 
Rabbit 
monoclonal D13.14.4E 
Cell Signaling 
Technology WB Used at 1:2000 (WB) 
p44/42 MAPK 
(ERK1/2) 
Mouse 
monoclonal L34F12 
Cell Signaling 
Technology WB  
KI-67 Mouse monoclonal MIB-1 Dako IF  
TLR4 Rabbit Polyclonal  
Santa Cruz 
Biotechnology WB H-80 
Actin Mouse monoclonal 
C4, 
MAB1501 Chemicon WB Used at 1:5000 (WB) 
Immunohistochemistry 
Breast cancer samples were obtained from 793 patients diagnosed with 
pathologic stage I or II breast cancer (American Joint Committee on Cancer) between 
1985 and 2000 and treated by surgical resection at The University of Texas M.D. 
Anderson Cancer Center (UT MDACC) (701). Samples of normal breast tissue were 
obtained from reduction mammoplasty and samples of DCIS were also obtained from 
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surgical resections both performed at UT MDACC. Normal breast and DCIS cases were 
also obtained from the NIH Cancer Diagnosis Program (progression TMA case sets 3, 
5, and 7).  Ovarian carcinoma samples were obtained from 213 patients diagnosed with 
ovarian carcinoma between 1990 and 2007 and treated by surgical resection at UT 
MDACC. Samples of ovarian cystadenoma, borderline tumors, and normal fallopian 
tube tissue were also obtained from surgical treatment at UT MDACC. Complete clinical 
and follow-up data on patients whose tissue samples were utilized in this study were 
obtained by retrospective review of the patients’ files. The Institutional Review Board at 
UT MDACC approved the use of patient-derived specimens and data and the authors of 
this study strictly followed ethical guidelines of informed consent and appropriate use of 
patient data.  
The sections were deparaffinized and rehydrated by submerging slides 3 x 5 
minutes in Histoclear (National Diagnostics), 1 x 5 minutes in 100% ethanol, 1 x 5 
minutes in 90% ethanol, 1 x 5 minutes in 70% ethanol, 1 x 5 minutes in PBS, and 1 x 5 
minutes in ddH20. Antigen retrieval was performed for elafin IHC by submerging slides 
in Antigen Unmasking Solution (Vector Laboratories) at sub-boiling temperature (95oC) 
for 20 minutes, the slides were then cooled to room temperature (20 minutes) in the 
solution. The slides were washed 3 x 5 minutes in ddH2O and then submerged in 3% 
H2O2 diluted in methanol for 15 minutes at room temperatures to block endogenous 
peroxidases. The slides were washed 3 x 5 minutes with 1X PBS and incubated in 
normal blocking serum from VECTASTAIN Elite ABC Kit (mouse IgG) diluted in PBS for 
one hour, at room temperature, in a humidified chamber. The slides were washed 3 x 5 
minutes with PBS and incubated in the primary antibody diluted in VECTASTAIN 
blocking serum (antibody concentration = 1:200 for elafin) overnight at 4º in a humidified 
chamber. The slides were wash 3 x 5 minutes in PBS + 0.1% Tween-20 and then 
incubated with biotinylated anti-mouse IgG from VECTASTAIN Elite ABC kit for 30 
minutes at RT. The slides were washed 3 x 5 minutes in PBS + 0.1% Tween-20 and 
incubated for 30 minutes with ABC solution from VECTASTAIN Elite ABC kit. The slides 
were again washed 3 x 5 minutes in PBS and 2 x 5 minutes in ddH20 and developed 
using DAB substrate (Vector Laboratories, following manufactures instructions) for 
approximately three minutes until maximum color developed under the microscope 
(elafin TMAs contained sections of spleen as positive controls, once maximum color 
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developed in these the reaction was stopped by submerging in ddH2O). The slides were 
washed in ddH2O and counterstained using Mayer’s hematoxylin (Lillie’s modification) 
(DAKO) diluted 1:5 in ddH20 for 10 seconds.  The slides were rinsed in tap-water and 
dehydrated by submerging 1 x 5 minutes in 70%, 90%, and 100% ethanol followed by 2 
x 5 minutes in Histoclear. The slides were coversliped using permount (Fisher 
Scientific). Evaluation was performed with a Leica DM LM light microscopy using the 
40x optical lens. Image acquisition was performed using SPOT Imaging Solutions 
camera and SPOT Advanced software. Image processing was performed using Adobe 
Photoshop software (Version 11.0.2). 
Cell lines and Culture Conditions 
Mortal human mammary epithelial cells (HMECs) 70N, 76N, and 81N were 
generated from reduction mammoplasty samples (685). Immortalized derivatives 
76NE6, 76NF2V, 76NE7, 81NE6, and 81NE7 were obtained from Dr. V. Band (686). 
These cell lines were generated by transfection of mortal 76N and 81N cells, with DNA 
from the human papillomavirus (HPV). The 76NE6/81NE6 cell lines were transfected 
with the E6 gene of HPV-16 and lack p53 due to E6 directed proteasomal degradation 
(702). The 76NF2V cell line were transfected with a mutant E6 gene (F2V) incapable of 
degrading p53, but still capable of immortalization (703).  The 76NE7/81NE7 cell lines 
were generated by transfection of the HPV-16 E7 and are devoid of Rb and related 
pocket proteins due to E7 directed proteasomal degradation (704). 
HMEC cell lines were cultured in DFCI-1 media, which consists of α-MEM and 
Ham's F-12 media (1:1 v/v) (HyClone) supplemented with 1% fetal bovine serum 
(Atlanta Biological), 0.01 M HEPES buffer, 2 mM L-glutamine, 12.5 ng/mL of epidermal 
growth factor (EGF), 10 nM triiodothyronine, 0.01 mM ascorbic acid, 2 nM estradiol, 1 
µg/mL of insulin, 1 mg/mL hydrocortisone, 0.1 mM ethanolamine, 0.1 mM 
phosphoethanolamine, 0.01 mg/ml transferrin, 2.5 ng/ml sodium selenite, 0.035 mg/ml 
of bovine pituitary extract and 0.01 mg/ml ciprofloxacin. DFCI-3 (growth factor 
deprivation) media omits from DFCI-1: bovine pituitary extract, EGF, triiodothyronine, 
estradiol, insulin, hydrocortisone and substitutes 1% BSA for fetal bovine serum (685, 
686). 293T cells for lentiviral packaging, were cultured in DMEM supplemented with 
10% fetal bovine serum (Atlanta Biological), 0.01 M HEPES buffer, 2 mM L-glutamine, 
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and 0.01 mg/ml ciprofloxacin. Tumor cell lines were cultured in α-MEM (HyClone) 
(HyClone) supplemented with 10% fetal bovine serum (Atlanta Biological), 0.01M 
HEPES, 2 mM L-glutamine, 0.1 mM non-essential amino acids,1 mM sodium pyruvate 
and 0.1 mg/mL of ciprofloxacin. Prior to stimulation with NE, the tumor cells were 
washed three times with PBS and cultured in identically supplemented α-MEM, except 
1% BSA was substituted for fetal bovine serum 
Cell Synchronization Conditions 
Lovastatin (Sigma) was used at a concentration of 10 µM to arrest HMECs in the 
G1 phase. Aphidicolin (Sigma) was used at a concentration of 10 µM to arrest HMECs 
in early S phase. Nocodazole (Sigma) was used at a concentration of 5 µM to arrest 
cells in M-phase. 
Lentiviral shRNA Infection 
Target specific shRNA was obtained in the GIPZ lentiviral vector system 
(OpenBiosystems) from the MD Anderson shRNA and ORFeome Core Facility. To 
generate lentivirus, 70-90% confluent 293T cells in 100 mm3 culture dishes were co-
transfected with 3ug of pCMV deltaR8.2, 3 ug of pMD2.G, and 4.5ug of the pGIPZ 
shRNA vector, using LipoD293 (SignaGen) transfection reagent (according to 
manufactures instructions). pCMV deltaR8.2 and pMD2.G were produced by the Didier 
Trono Lab and made available through the Addgene Repository. Twelve hours after 
transfection the media was changed to fresh DMEM. The virus containing media was 
collected 24 and 48 hours later and filtered through a 0.45 µM PVDF membrane. Target 
cells were infected with the virus containing media in the presence of 8 µg/mL 
polybrene. The cells were selected in 1ug/ml Puromycin for four to seven days until the 
population was 100% GFP positive (indicating integration of the shRNA). The shRNA 
sequences used were:  
 
Rb shRNA1 (V3LHS_340829)- TTGCTATCCGTGCACTCCT;  
Rb shRNA 2 (V3LHS_340827)- TTATTTCAGTAGATATCGA;  
C/EBPβ shRNA1 (V2LHS_48323)- TTATCATTCATCTGTACAC;  
C/EBPβ shRNA2  (V3LHS_371448)- TGAACAAGTTCCGCAGGGT;  
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Elafin shRNA1 (V2LHS_221931)-TTATCTTGACCTTTAACTG;  
Elafin shRNA2 (V3LHS_313908)- TGACCTTTAACTGAAACTT;  
TLR shRNA1 (V3LHS_374709)- TACTTTGAATCTTGTTGCT;  
TLR4 shRNA2 ( V3LHS_374707)- TCTTTACTAGCTCATTCCT;  
EGFR shRNA1 (V3LHS_361964)-TTCAGAATATCCAGTTCCT;  
EGFR shRNA2 (V2LHS_200678)- TTCCGTTACACACTTTGCG. 
Complementation of Elafin Knockdown Cells 
Elafin cDNA was obtained (Incyte PI3 cDNA, LIFESEQ1453048, OpenBiosystems) and 
cloned into the gateway pDONR201 via the gateway BP clonase (Invitrogen) using the 
following primers:  
 
attB1- Elafin-F: 
5'GGGGACAAGTTTGTACAAAAAAGCAGGCTTCatgagggccagcagcttcttgatcgtg-3'  
attB2-Elafin-R:  
5'-GGGGACCACTTTGTACAAGAAAGCTGGGTCCTActggggaacgaaacaggccatccc-3'  
 
(the gateway recombination sequences are in CAPS and the sequences 
complementary to the elafin cDNA are in lower case. The resulting elafin pENTR vector 
was verified by DNA sequencing. To create shRNA resistant elafin expression 
plasmids, three consecutive codons along the shRNA targeting region were mutated at 
the wobble position using the quikchange lightning site-directed mutagenesis kit 
(Stratagene) and the following primers:  
 
shRNA1mut- 5'-ggacaagtttcagttaaagtaaagggcaaagtcaaagcgc-3'  
shRNA2mut- 5'-cccgttaaaggacaggtctcggttaaaggtcaagataaa-3'.  
 
The M25G mutation to the protease inhibitor domain of elafin was introduced into the 
shRNA resistant elafin pENTR vectors again using the quikchange lightning site-
directed mutagenesis kit (Stratagene) and the following primer: 
 
elafinM25G-5’-tagggggattcaaccctgcgcaccggat-3’ (636).  
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The shRNA resistant elafin pENTR vectors were then cloned into the plenti CMV Blast 
DEST vector (obtained from the addgene repository) (705) using the LR clonase 
(invitrogen). The lentiviral particles were packaged using the same method as the 
pGIPZ lentivirus, see above. Elafin shRNA cells were infected with elafin containing 
plenti CMV vectors and selected in 20 ug/ml Blastacidin and 1 ug/ml Puromycin until 
100% cell kill was achieved in elafin shRNA cells uninfected by plenti CMV vectors, 4-7 
days. 
DNA Content Analysis  
Propidium iodide (PI) staining was performed to examine cell cycle distribution. 
Following indicated treatments, the cells were harvested by trypsination and washed in 
PBS. 2x106 cells were fixed by resuspension in ice-cold 70% ethanol and maintained at 
4°C for at least 24 hours. The fixed cells were than washed with PBS, and stained 
overnight at 4°C in 0.5 mL of PI staining solution: 10 µg/mL PI (Molecular Probes), 20 
µg/mL ribonuclease A (Sigma) in PBS containing 0.5% Tween-20 (Sigma) and 0.5% 
BSA (Sigma). The cells were incubated for 30 minutes at 37 °C and filtered through 
35µM nylon mesh capped tubes (BD Falcon). PI fluorescence was measured using a 
BD FACScalibur flow cytometer and analyzed based on DNA content using FloJo 
software (Version 8). 
Preparation of Protein Lysates and Western Blot Analysis 
 Cells were harvested using trypsin, (for measurement of phosphor-ERK using 
timepoints less than one hour we harvested cells by scraping them into PBS). The cells 
were washed in PBS (tissues were not) and resuspended in protease/phosphatase 
inhibition buffer (PPI); 25 g/ml leupeptin, 25 g/ml aprotinin, 10 g/ml pepstatin, 1 mm 
benzamidine, 10 g/ml soybean trypsin inhibitor, 0.5 mm PMSF (Phenyl methyl sulfonyl 
fluoride), 50 mm sodium fluoride, 0.5 mm sodium orthovanadate. Cells were lysed via 
sonication (Sonicator XL; Misonix Inc.) and the lysates were cleared by centrifugation at 
125 000 g for 45 min at 4 °C. Protein concentration was determined by Bradford assay 
(reagents from Biorad). Protein concentration was normalized by addition of PBS and 
mixed with 2x lammeli buffer (4% SDS, 20% glycerol, 120mM Tris-HCL pH 6.8, and 
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0.02% bromophenol blue) to a final concentration of 2.5 µg/µl for western blot. 
50 µg of protein from each condition being tested was loading into the lanes of a 
sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) gels (15% gels to resolve 
elafin, 13% gels for ERK and pERK, 10% gels for all other antibodies) and submitted to 
electrophoresis for 300 volt hours. These gels were then transferred to Immobilon P 
membrane (Millipore) by electrophoresis for 400 volt hours, at 4°C. The membranes 
were blocked for 1 hour in BLOTTO (5% nonfat dry milk in TBST; 20 mM Tris, 137 mM 
NaCl, 0.25% Tween, pH 7.6). Following blocking, the membranes were incubated in 
primary antibodies typically at a concentration of 0.1 µg/ml in BLOTTO for two hours at 
room temperature. Following incubation with primary antibody the membranes were 
washed 3 x 20 minutes in TBS-T and then incubated with goat anti-mouse or anti-rabbit 
IgG–horseradish peroxidase conjugated secondary antibodies (Pierce) at a dilution of 
1:3,000 in BLOTTO for one hour. The membrane was washed 3 x 20 minutes in TBS-T, 
and developed with the Renaissance chemiluminescence system (Perkin-Elmer Life 
Sciences, Inc.). The membranes were placed in an autoradiography cassette, exposed 
to film, and scanned.  
Three-Dimensional Culture 
The bottom of a six well plate was covered with 500µL of growth factor reduced 
matrigel (BD Biosciences). HMECs were plated at a concentration of 5000 cells per well 
in DFCI-1 media supplemented with 2% growth factor reduced matrigel (BD). The 
media was replaced every three days. The acini were washed once with cold PBS, 
scraped, and collected in a 15 mL conical tube.  Cell recovery solution (BD Biosciences) 
was added to the Matrigel/acini mixture (1:1 v/v) to digest the matrigel. The acini were 
washed twice with cold PBS and either embedded in histogel (Thermo) or lysed for 
western blot. The acini embedded in histogel were fixed in 10% buffered formalin, 
embedded in paraffin, and sectioned for immunoflourescence (IF) analysis. IF was 
performed identically to IHC described until after incubation with the primary antibody.  
The secondary antibody utilized was Alexa fluor 594-conjugated goat anti-mouse 
(Molecular Probes) and the sections were counterstained with 4,6-diamidino-2-
phenylindole (DAPI) (Sigma) for 15 min at room temperature, mounted with antifade 
solution (Molecular Probes), and sealed with clear nail polish (Sally Hansen). An 
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Olympus FV300 laser scanning confocal microscope (Olympus America) was used to 
obtain 40x magnification images.  
Immunofluorescence 
To evaluate the intracellular localization of elafin in HMECs; 5,000 cells were 
plated on an eight well chamber slide (BD Falcon). Following treatment, slides were 
fixed with 2.5% paraformaldehyde in PBS (pH 7.5) for 20 minutes at RT, permeabilized 
in PBS + 0.5 Triton X-100 for 10 minutes at RT, and rinsed three times for 15 minutes 
each in glycine rinse buffer (130 mM NaCl, 7 mM Na2HPO4, 3.5 mM NaH2PO4, 100mM 
glycine). Slides were then blocked in blocking buffer (130 mM NaCl, 7 mM Na2HPO4, 
3.5 mM NaH2PO4, 7.7 mM NaN3, 0.1% BSA, 0.2% Triton X-100, 0.05% Tween-20, 10% 
goat serum) for one hour. The slides were incubated in the primary antibody, mouse 
monoclonal elafin (TRAB/2F; HyCult Biotechnology) and Ki67 antigen (Dako), at a 
dilution of 1:200 in blocking buffer, overnight at 4oC. The slides were rinsed three times 
for 20 minutes in wash buffer (blocking buffer without the goat serum) and incubated in 
secondary anti-body Alexa-Flour 594 conjugated donkey-anti-mouse (Invitrogen). Slides 
were again rinsed, nuclei were counterstained with 0.5 µg/mL DAPI in PBS, and slides 
were mounted using Prolong Antifade Reagent (Invitrogen). Imaging was performed 
using a FV1000 laser confocal microscope (Olympus).  
Quantitative PCR Analysis 
RNA was extracted from 2 x106 cells using the RNAeasy kit (Qiagen) and subjected to 
on column DNase I (NEB) digestion. The RNA was reverse transcribed (1 µg of mRNA 
per sample) using the First Strand cDNA Synthesis Kit (Roche). Quantitative PCR was 
performed using SYBR Green PCR Master Mix (Applied Biosystems). 
 
Elafin-F-5′-TGGCTCCTGCCCCATTATC-3′  
Elafin-R-5′-CAGTATCTTTCAAGCAGCGGTTAG-3’ 
cFOS-F-5′- TGACTGATACACTCCAAGCGGA -3’ 
cFOS-R-5′- CAGGTCATCAGGGATCTTGCA-3′ 
EGR1-F-5′- AGCCCTACGAGCACCTGAC-3′  
EGR1-R-5′- GGTTTGGCTGGGGTAACTG -3′ 
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TLR4-F-5’-AGACCTGTCCCTGAACCCTAT-3’  
TLR4-R-5’-CGATGGACTTCTAAACCAGCCA-3’ 
EGFR-F-5’-GCGTCTCTTGCCGGAATGT-3’ and 
EGFR-R-5’-CTTGGCTCACCCTCCAGAAG-3’ 
C/EBPβ-F-5’-ACCGGGTTTCGGGACTTGA-3’ 
C/EBPβ-R-5’-GTTTCGATATCACTGGAG-3’ 
GAPDH-F-5′-TGTACCGTCTAGCATATCTCCGAC-3′  
GAPDH-R- 5′-ATGATGTGCTCTAGCTCTGGGTG-3′.  
Sandwich ELISA 
Immuno MaxiSorp U96 plate (Nunc) were coated with elafin polyclonal antibody 
at a concentration of 10 µg/mL diluted in 0.1 M sodium bicarbonate, overnight at 4°C. 
The plate was washed two times with PBS containing 0.1% Tween-20 and once with 
PBS between each step. The plate was blocked in 1µg/mL BSA (Sigma) in PBS for four 
hours at room temperature. 200 µL of conditioned media was added to each well and 
incubated for 1 hour at room temperature; serially diluted recombinant elafin 
(calbiochem) was used as a control and to derive a formula for concentration 
determination. The plate was incubated in mouse monoclonal antibody (TRAF/2O) 
diluted to a concentration of 50 ng/mL in 0.1µg/mL BSA in PBS for 30 minutes at room 
temperature. The TRAF/2O elafin antibody detects an epitope on the unfolded N-
terminus of elafin and provides greater sensitivity in this assay. The plate was incubated 
in 50 ng/mL goat anti–mouse IgG HRP conjugated (Thermo) in 0.1µg/mL BSA in PBS 
for 30 minutes at room temperature. The ELISA was developed using 1-Step Ultra TMB 
(Thermo) until maximum yellow color developed in the controls with maintenance of 
linearity, the reaction was quenched with 2M phosphoric acid and absorbance was 
measured at 450nM.  
Luciferase Assay 
HMECs were transiently transfected with firefly-luciferase promoter constructs 
containing the 440 bp proximal elafin promoter (pSPL440), the 440 bp proximal elafin 
promoter with mutations to the critical C/EBPβ binding sites 4 and 5 (pSPL440m4/5), or 
the minimal elafin promoter (pSPL94) (all constructs described in Yokota et. al, 2007) 
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using LipoD293 (SignaGen) transfection reagent (according to manufactures 
instructions). Cells were co-transfected with CMV-Renilla to control for transfection 
efficiency. Firefly and renilla luciferase activity were quantified sequentially according to 
manufactures instructions, using the dual-luciferase reporter assay kit (Promega) and 
the BD moonlight 3010 luminometer. Firefly luciferase values were normalized to renilla, 
Growth Curves 
HMECs were plated at a concentration of 2000 cells per well in a 24 well plate. 
After 24 hours the cells were washed three-times in sterile PBS and cultured in DFCI-3 
growth factor depleted media. At each timepoint examined, the cells were harvested via 
trypsinization and cell number was determined using the trypan blue (Fluka) exclusion 
test and a standard hemocytometer.  
MTT Assay  
Cell growth was also measured using the MTT assay in a 96-well plate. HMECs 
were plated at a concentration of 1000 cells per well. After 24 hours the cells were 
washed three-times in sterile PBS, cultured in DFCI-3 growth factor depleted media, 
and treated with NE (Elastin Products) as indicated in the figures. Following treatment, 
50 µl of 2.5 mg/mL MTT was added to each well for 4 hours. Following this incubation, 
all media was aspirated and 100 µl of solubilization solution (20mL 1N HCL, 50 mL 10% 
SDS, 430 mL isopropyl alcohol) was added to the cells. The plates were placed on a 
horizontal shaker for one hour and absorbance was quantified using a 
spectrophotometer (Victor3, Perkin-Elmer) at a wavelength of 590 nm.  
Microarray 
Total RNA was extracted from 2 x106 cells using the RNAeasy kit (Qiagen) and 
subjected to on column DNase I (NEB) digestion (all performed according to 
manufactures instructions). RNA integrity was confirmed using an Agilent Technologies 
Bioanalyzer 2100. The Genomics Core Facility at MD Anderson Cancer Center 
performed the cDNA labeling, hybridization to the Illumina HT-12 v4 BeadChip, and 
image acquisition. Raw signal intensities were obtained using the Beadstudio analysis 
software from Illumina and imported into the lumi Bioconductor package (R version 2.15 
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and Bioconductor version 2.11). The lumi package was used to perform quality control, 
background correction by RMA method (implemented in affy package), variance 
stabilizing transformation, and quantile normalization. To identify differentially 
expressed mRNAs between the comparative groups, we applied modified two-sample t-
tests using limma Bioconductor package. The beta-uniform mixture (BUM) model was 
used to control false discovery rate (FDR) (706). Differentially expressed genes were 
identified using fold change greater than 1.5 and a p-value yielding a FDR of 0.10 as cut 
offs. 
Statistics 
All experiments were performed in triplicates. The results of each experiment 
are reported as the mean of experiment replicates. Error-bars represent the standard 
deviation from the mean. All pair-wise comparisons were analyzed using the unpaired, 
two-sided, t-test assuming a normal distribution of experimental values. A two-tailed 
Fisher’s exact test was used for contingency table analysis. For all statistical test, a 
p<0.05 was considered significant.  
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RESULTS 
Elafin is Downregulated During Breast Cancer Progression.  
 
Several published studies demonstrate that elafin is expressed at the mRNA 
level in normal human mammary epithelial cells (HMECs), but not in the majority of 
breast cancer cell lines (23, 24). Based on these studies, we utilized patient-derived 
tissue specimens to test the hypothesis that elafin is downregulated during breast 
cancer progression. Tissue microarrays (TMAs) containing normal breast tissue from 
reduction mammoplasty specimens (n=24), ductal carcinoma in situ (DCIS) (n=54), and 
invasive breast carcinoma (n=793) were subjected to immunohistochemical analysis 
using a monoclonal antibody against elafin (Figure 8, A and B) (707). Despite a 
secretion signal near the N-terminus of the elafin peptide sequence (708), 
immunohistochemical analysis showed that elafin expression was intracellularly 
localized (Figure 8A). In order to quantify the expression of elafin in patient samples, we 
employed a scoring system adapted from Allred et al. that considers both the 
percentage of positive cells and staining intensity (Figure 9, A and B) (709). Scoring of 
elafin immunohistochemistry was performed in collaboration with Dr. Cansu Karakas 
M.D., Dr. Jing Zhang M.D. Ph.D., and Dr. Opoku Adjapong M.D. 
Representative photomicrographs of elafin expression in normal breast tissue, 
DCIS, and invasive breast tissue are presented in Figure 10A. Quantification of elafin 
expression reveals that elafin is highly expressed in the epithelium of the normal 
mammary gland in comparison to DCIS and invasive breast tumors. Because all 
samples of normal breast tissue had an elafin score of 6 (Figure 10B), we defined elafin 
downregulation as an elafin score of 0-5. Elafin expression was at or above the level in 
normal breast tissue (i.e., the elafin score was 6-8) in 76% of DCIS lesions but only 
17% of invasive breast tumors (Figure 10C). Among the invasive breast tumors, tumors 
with elafin expression at or above the level in normal breast tissue were more likely than 
tumors with elafin downregulation to be estrogen receptor and progesterone receptor 
negative and have higher tumor grade (Table 5). Elafin expression was not associated 
with trends in recurrence-free survival (Figure 11A) or overall survival (Figure 11B). 
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We also examined elafin expression by immunohistochemistry during ovarian 
cancer progression (Figure 12A). Elafin was highly expressed in the epithelium of the 
normal fallopian tube (n=20), the site of origin for more than half of ovarian carcinomas 
(710), but elafin expression in normal fallopian tube demonstrated greater variability 
than was observed for elafin expression in normal breast tissue (compare Figure 9B 
and Figure 12B). Because most cases of normal fallopian tube had an elafin score of 4 
or higher, we defined elafin downregulation as an elafin score of 0-3 (Figure 12B). Elafin 
expression was comparable to that in the normal fallopian tube in 67% of preinvasive 
ovarian cystadenomas (n=9), 57% of borderline ovarian tumors (low malignant 
potential) (n=21), but only 14% of invasive ovarian carcinomas (n=216) (Figure 12C). 
The distribution of histological subtypes differed significantly by elafin expression: 
ovarian cancer cases with elafin scores of 0-3 were less likely to be of the endometrioid 
subtype (Table 6). No association was observed between elafin expression and other 
clinicopathological parameters (Table 6), RFS (Figure 13A), or OS (Figure 13B). 
Overall, these results demonstrated that elafin expression is lost during both 
breast and ovarian cancer progression. 
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Figure 8: Antibodies for Elafin Immunohistochemistry  
 
(A) Serial sections of normal breast tissue from reduction mammoplasty specimens (i 
and ii are from the same patient, iii and iv are from another patient) were stained with 
monoclonal antibodies to the 57 C-terminal amino acids of fully-processed elafin 
(Hycult, Clone: TRAB/2F) (i and iii) and to the N-terminal transglutaminase linking 
domain of full length elafin (Hycult, Clone: TRAB/2O) (ii and iv). The intracellular 
staining pattern was similar for both antibodies. (B) HMECs (76NF2V) were cultured in 
either DFCI-1 growth factor containing media (+GFs) or DFCI-3 growth factor deficient 
media (-GFs) for 48 hours. Lysates were resolved on a 15% gel in duplicate and 
subjected to western blot analysis. One half of the membrane was probed with 
TRAB/2F and the other half was probed with TRAB/2O. TRAB/2F appears to be more 
specific to elafin than TRAB/2O, which detects several additional proteins of varying 
molecular weights presumably with transglutaminase-linking domains. 
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Figure 9: Elafin Immunohistochemistry Scoring System.   
 
(A) The scoring system from Allred et al.,1998 (for the quantification of estrogen 
receptor positivity in breast tumors)  was adapted  for elafin IHC scoring. This 
system consists of a final score (0-8) that is the sum of a frequency score (0-5) 
and an intensity score (0-3). (A) Representative photomicrographs from invasive 
breast cancer samples illustrating each frequency score; 0 = 0%, 1 = <1%, 2 = 
1-10%, 3 = 10-33%, 4 = 33-66%, and 5 = 66-100%. (B) Representative 
photomicrographs from invasive breast cancer samples illustrating each 
intensity score; 0 = Negative, 1 = Low, 2 = Medium, and 3 = High.  
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Figure 10: Elafin is 
Downregulated During Breast 
Cancer Progression.  
 
A) Representative 
photomicrographs of elafin 
immunohistochemical 
staining in normal breast 
tissue (i and ii), DCIS (iii 
and iv), and invasive breast 
cancer (v and vi). (B) 
Frequency distribution 
illustrating the percentage 
of cases falling into each 
categorical score over the 
range 0-8. (C) 
Quantification of elafin 
downregulation. An elafin 
score of 6-8 denotes cases 
at or above the elafin 
expression level observed 
in the normal breast 
epithelium, while an elafin 
score of 0-5 denotes 
downregulation.  
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Table 5: Comparison of Breast Cancer Patient and Tumor Characteristics as a Function of Elafin 
Expression 
 
The correlation between common clinicopathological characteristics of breast cancer 
patients (age, stage, ER, PR, HER2, and Grade) and elafin expression (positive: elafin 
score 6-8 and negative: elafin score 0-5) were examined using a fisher-exact test for 
correlation with elafin expression. 
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Figure 11: Survival Analysis of Breast Cancer Patients.  
 
(A) Kaplan-Meier analysis of recurrence-free survival in elafin positive and negative 
breast cancer cases. (C) Kaplan-Meier analysis of overall survival in elafin positive and 
negative breast cancer cases.
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Figure 12: Elafin is Downregulated During Ovarian Cancer Progression. 
 
(A) Representative photomicrographs of elafin immunohistochemical staining in normal 
fallopian tube (i and ii), nonmalignant ovarian cystadenoma (iii), ovarian borderline 
tumor (iv), and invasive ovarian carcinoma (v and vi). (E) Frequency distribution as 
described in B. (F) Quantification of elafin downregulation. An elafin score of 4-8 
denotes cases at or above the elafin expression level observed in the normal fallopian 
tube, while an elafin score of 0-3 denotes downregulation. 
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Table 6: Comparison of Ovarian Cancer Patient and Tumor Characteristics as a Function of Elafin 
Expression 
 
The correlation between common clinicopathological characteristics of ovarian cancer 
(age, histological type, FIGO stage, and Grade) and elafin expression (positive: elafin 
score 6-8 and negative: elafin score 0-5) were examined using a fisher-exact test for 
correlation with elafin expression.
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Figure 13: Survival Analysis for Ovarian Cancer Patients.  
 
(A) Kaplan-Meier analysis of recurrence-free survival in elafin positive and negative 
ovarian cancer cases. (B) Kaplan-Meier analysis of overall survival in elafin positive and 
negative ovarian cancer cases
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Elafin is Upregulated in Mortal HMECs Following Growth Factor Deprivation-
Induced Cell Cycle Exit. 
 
Elafin is highly expressed in HMECs and was previously shown to be cell cycle 
regulated at the mRNA level (23). Given the relevance of cell cycle alterations to early 
tumor progression, we hypothesized that elafin is required for normal cell cycle control. 
Growth factor-deprivation induced G0 arrest of immortalized HMECs results in the 
upregulation of elafin compared to the low levels observed in HMECs asynchronously 
proliferating in growth factor-containing medium or arrested in the G1, S, or G2/M phase 
of the cell cycle (Figure 14). 
To further explore the expression of elafin in G0-arrested cells, primary (i.e. 
mortal) 81N, 70N, and 76N HMECs were cultured under growth factor-deficient 
conditions and harvested at 6-hour intervals for 48 hours. DNA content analysis 
revealed that HMECs were progressively arrested in G0/G1 phase, and complete arrest 
was seen between 24 and 36 hours of continuous culture (Figure 15A). Western blot 
analysis showed upregulation of elafin over the growth factor deprivation time course 
(Figure 15B), corresponding to the accumulation of HMECs in G0/G1 phase. 
We next performed immunofluorescence analysis of Ki67, a marker of cells 
actively progressing through or arrested within the cell cycle, which is downregulated in 
G0 cells (Figure 16A). Quantitation of Ki67-positive cells revealed that in growth factor-
containing medium, 70-76% of HMECs expressed Ki67, whereas under growth factor 
deprivation, only 6-10% of total HMECs at 24 hours and fewer than 1% of total HMECs 
at 48 hours expressed Ki67. This downregulation of Ki67 confirmed that growth factor 
deprivation of HMECs induces arrest in G0 and not G1. Elafin expression, examined by 
immunofluorescence, dramatically increased in intensity following growth factor 
deprivation, and elafin acquired a strongly cytoplasmic localization (Figure 16B).  
Quantitative RT-PCR (qPCR) analysis revealed that elafin is highly induced at 
the mRNA level under growth factor deprivation conditions, increasing 12- to 178-fold 
by 24 hours and 165- to 240-fold by 48 hours compared to the level of elafin mRNA in 
HMECs cultured in growth factor-containing medium (Figure 16C). We also examined 
elafin levels in the conditioned media of 81N, 70N, and 76N HMECs by ELISA. Fresh 
growth factor-deficient medium was added halfway through the 48-hour time period, 
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such that all samples of conditioned medium measured in this assay were incubated 
with cells for 24 hours. The concentration of elafin in the conditioned media of 81N, 
70N, and 76N HMECs cultured in the presence of growth factors was 2.6-2.9 ng/mL, 
compared to significantly higher concentrations of elafin in HMECs cultured in growth 
factor-deprived medium: 4.0-6.3 ng/mL at 24 hours and 7.1-11.5 ng/mL at 48 hours 
(Figure 16D). 
Luciferase reporter analysis of the elafin promoter revealed that elafin 
upregulation in HMECs was dependent on C/EBPβ sites 4 and 5, as we previously 
described (24) (Figure 17A). In the immortalized HMECs 76NF2V, knockdown of 
C/EBPβ (Figure 17B) rendered cells incapable of elafin upregulation following growth 
factor deprivation (Figure 17C). 
These experiments demonstrated that primary HMECs induced to enter G0 by 
growth factor deprivation highly upregulate elafin at the mRNA level, resulting in the 
intracellular accumulation and secretion of elafin. 
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Figure 14: Elafin is Upregulated Following Growth Factor Deprivation 
 
(A) Western blot of phosphorylated Rb (S780) and elafin in 76NE6 and 76NF2V cells 
cultured in DFCI-1 medium (asynchronous), DFCI-3 medium (arrested in G0), 10 µM 
lovastatin (arrested in G1), 10 µM aphidicolin (arrested in early S phase), and 5 µM 
nocodazole (arrested in M phase).  
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Figure 15: Elafin is Upregulated in Mortal HMECs Following Growth Factor Deprivation-Induced 
Cell Cycle Exit.  
 
(A-B) 81N, 70N, and 76N HMECs were cultured in growth factor depleted DFCI-3 media 
and harvested every six hours for 48 hours following growth factor removal (n=3 for 
each timepoint). (A) Cell cycle distribution determined by DNA content analysis of 
propidium iodide stained cells, measured by flow cytometry. (B) Representative western 
blots of elafin expression, actin as a loading control. Elafin western blots were analyzed 
by densitometry; values normalized to actin and are represented as a percent of the 
maximum elafin expression  
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Figure 16: Elafin is Upregulated in Mortal HMECs Following Growth Factor Deprivation-Induced 
Cell Cycle Exit.  
 
(A,B) 81N, 70N, and 76N HMECs cultured in either DFCI-1 (+GFs for 24 hours) or 
DFCI-3 media (-GFs for 24 and 48 hours) were examined by immunofluorescence 
staining for Ki67 (A) and elafin (B) expression. (C) HMECs cultured as in D were 
examined by quantitative RT-PCR for elafin expression; values were normalized to 
GAPDH expression and are represented relative to control (+GFs condition). (D) 
Conditioned media from HMECs treated as in D was examined by sandwich ELISA for 
elafin levels, concentrations are reported as ng of elafin per mL of media.  
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Figure 17: Elafin Upregulation in Mortal HMECs Following Growth Factor Deprivation-Induced 
Cell Cycle Exit is Dependant on C/EBPβ. 
 
(A) 81N, 70N, and 76N cells were co-transfected with the indicated firefly luciferase 
elafin promoter construct and CMV-Renilla luciferase and cultured in either DFCI-1 
media (+GFs, for 24 hours) or DFCI-3 media (-GFs, for 24 hours). Elafin promoter 
activity was normalized to renilla and expressed relative to control (pSPL440 +GFs). (B) 
76NF2V cells stably infected with pGIPZ lentiviral vectors containing control or two 
unique, C/EBPβ-specific shRNAs were cultured in DFCI-1 (+GFs) or DFCI-3 (-GFs) 
media for 24 hours, knockdown was confirmed by qPCR analysis using C/EBPβ specific 
primers, values were normalized to GAPDH and represented as a ratio to the control 
shRNA level. (C) Lysates from C/EBPβ knockdown and control 76NF2V in B were 
subjected to western blot analysis for elafin. Actin, loading control.  
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Rb-Deficient HMECs are Incapable of Entering Quiescence and Fail to Upregulate 
Elafin Following Growth Factor Deprivation.  
 
In G0-arrested cells, Rb is required to prevent E2F-induced cell cycle re-entry 
(711). Immortalized 76NE6 HMECs, which lack p53, and 76NF2V, which express both 
p53 and Rb (686), progressively arrested in the G0/G1 phase when cultured in growth 
factor-deficient medium (Figure 18A). However, 76NE7 HMECs, which are deficient in 
Rb and related pocket proteins (686), accumulated in the G2 phase of the cell cycle 
when cultured in growth factor-deficient medium (Figure 18A). 76NE6, 76NF2V, and 
76NE7 HMECs cultured with growth factors were Ki67 positive (76.3-83.5% of cells). 
Following growth factor deprivation for 48 hours, only 8.4% of 76NE6 cells and 7.3% of 
76NF2V cells were Ki67 positive, while 63.9% of 76NE7 cells remained Ki67 positive 
(Figure 18B). Maintenance of Ki67 expression in growth factor-deprived 76NE7 cells 
suggests that loss of the Rb checkpoint eliminates the ability of HMECs to arrest in G0. 
Western blot analysis of elafin expression over 48 hours of growth factor 
deprivation demonstrated elafin upregulation in 76NE6 and 76NF2V cells (Figure 18C). 
In contrast, 76NE7 cells did not express Rb and did not demonstrate elafin upregulation 
following 48 hours of growth factor deprivation (Figure 18D). This elafin expression 
pattern was confirmed by immunofluorescence analysis (Figure 18E). Culture of 
HMECs on reconstituted basement membrane (matrigel) generates three-dimensional 
structures resembling mammary acini (316, 712, 713). Immunofluorescence analysis 
finds the upregulation of elafin in the matrix-deprived, growth-arrested interior of 
mammary acini formed from 76NE6 and 76NF2V, but not 76NE7 cells (Figure 19) 
Following 48 hours of growth factor deprivation, Rb-deficient 81NE7 HMECs 
failed to upregulate elafin compared to Rb-expressing 81NE6 and parental 81N cells 
(Figure 20A). 81NE7 could not arrest in G0/G1 phase as indicated by DNA content 
analysis (Figure 20B). 76NF2V and 76NE6 cells with Rb knockdown were also unable 
to arrest in G0/G1 phase (Figure 20C) and were incapable of elafin upregulation (Figure 
20D) following growth factor deprivation. 
Taken together, these results showed that Rb is required for G0 arrest and 
concomitant elafin upregulation.  
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Figure 18: Rb-Deficient HMECs are Incapable of Entering Quiescence and Fail to Upregulate elafin 
Following Growth Factor Deprivation.  
 
(A-D) 76NE6, 76NF2V, and 76NE7 immortalized HMECs were growth factor deprived 
as in figure 10A. (A) Cell cycle distribution determined by DNA content analysis of 
propidium iodide stained cells, measured by flow cytometry. (B) Immunofluorescence 
staining for Ki67 at the 0 and 48 hour timepoints. (C) Representative western blots of 
elafin expression (only 76NE6 and 76NF2V shown), actin as a loading control. (D) 
Densitometry analysis of elafin western blots; values normalized to actin and are 
represented as a percent of the maximum elafin expression (E) Western blot of 
phosphorylated Rb (S780), total Rb, p53, and elafin in 76NE6, 76NF2V, and 76NE7 
cultured in DFCI-1 (+GFs for 24 hours) or DFCI-3 media (-GFs for 24 and hours), actin 
as a loading control. (E) 76NE6, 76NF2V, and 76NE7 cells cultured in either DFCI-1 
(+GFs for 24 hours) or DFCI-3 media (-GFs for 24 hours) were examined by 
immunofluorescence staining for elafin expression. 
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Figure 19: Elafin Expression in Mammary Acini. 
 
(A) 76NE6, 76NF2V, and 76NE7 cells were grown on reconstituted basement 
membrane (matrigel), acini formed and were harvested at 3, 9, and 15 days; at each 
timepoint acini were formalin-fixed, paraffin-embedded, and subjected to 
immunofluorescence staining for elafin expression.  
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Figure 20: Quiescence and Fail to Upregulate elafin Following Growth Factor Deprivation.  
 
(A,B) 81N, 81NE6, and 81NE7 cells were cultured in either DFCI-1 (+GFs) or DFCI-3 
media (-GFs) for 24 hours. 81N cells immortalized by HPV-E6 lack p53 and 81N cells 
immortalized by HPV- E7 lack Rb and related pocket proteins. (A) Lysates were 
subjected to western blot analysis for elafin. Actin, loading control. (B) Cell cycle 
distribution determined by DNA content analysis of propidium iodide stained cells. (C,D) 
76NF2V and 76NE6 cells stably infected with pGIPZ lentiviral vectors containing control 
and two unique, RB-specific shRNAs were cultured in DFCI-1 (+GFs) or DFCI-3 (-GFs) 
media for 24 hours. (C) Western blot of phosphorylated Rb (S780), total Rb, and elafin. 
Actin, loading control. (D) Cell cycle distribution was determined DNA content analysis 
of propidium iodide stained cells.  
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Elafin Knockdown HMECs Circumvent Quiescence and Proliferate in a Growth 
Factors Independent Manner.  
 
To examine the role of elafin in maintenance of G0 arrest, we generated 76NE6 
(Figure 21A) and 81NE6 HMEC lines with elafin knockdown. Elafin-knockdown and 
control cells were cultured in growth factor-deprived medium, and cell number was 
assessed at the indicated time points (Figure 21B). Both 76NE6 and 81NE6 elafin-
knockdown cell lines exhibited modest but significant growth factor-independent 
proliferation, with doubling times between 66 and 81 hours, while control cells exhibited 
complete growth cessation after only 24 hours in growth factor-depleted medium 
(Figure 21C). 
To verify the specificity of elafin knockdown and examine the importance of 
elafin-mediated protease inhibition in this system, we complemented 76NE6 elafin-
knockdown cells with wild-type elafin (sensitive to shRNA downregulation), shRNA-
resistant-elafin, and shRNA-resistant-M25G-elafin (the M25G mutation inactivates the 
protease inhibitor domain) (636) (Figures 21D). Elafin-knockdown 76NE6 cells 
demonstrated an approximate doubling in cell number compared to controls following 
144 hours of growth factor deprivation (Figure 21E). Complementation of elafin-
knockdown 76NE6 cells with wild-type elafin, but not M25G-elafin, reduced cell number 
to the level of controls (Figure 21E). 
These experiments revealed a critical role of elafin-mediated protease inhibition 
in the maintenance of G0 arrest in long-term growth factor-deprived HMECs. 
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Figure 21: Elafin Knockdown HMECs Circumvent Quiescence and Proliferate in a Growth Factors 
Independent Manner.  
 
A) Western blot of elafin expression in parental, empty vector, non-targeting shRNA 
control, and elafin knockdown (shElafin 1 and shElafin 2) 76NE6 cells cultured with GF 
(0 hours) and without GFs for 48 and 96 hours. Actin, loading control. (B) Schematic of 
experimental design. 76NE6 cell lines from A were plated at an initial density of 2000 
cells/well in 24-well plates and counted at the indicated times after growth factor 
removal. (C) Cell counts over time as described in B. Asterisks denote significant 
differences (p<0.05) between control and elafin-knockdown groups. (D) 76NE6 cells 
expressing elafin shRNA (shRNA1 [S1] and shRNA2 [S2]) were stably transduced with 
wild-type elafin (wt), shRNA-resistant elafin (R1, shRNA1-resistant elafin; R2, shRNA2-
resistant elafin), or shRNA-resistant elafin with a M25G mutation (results for shRNA1 
shown). Cell lysates were subjected to western blot analysis for elafin. Actin, loading 
control. (E) 76NE6 cells as described in D were cultured in the absence of GFs for 144 
hours and counted. 
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Elafin Knockdown 76NE6 are Sensitive to the Growth Promoting Effect of NE. 
 
Activated TAN contribute the majority of NE in the tumor microenvironment 
(542). Therefore, we assessed the ability of exogenous NE to induce the proliferation of 
HMECs. Elafin-knockdown and control 76NE6 cells were growth factor deprived for 24 
hours followed by the addition of NE purified from human sputum directly to the media. 
Cell density was measured using the MTT assay 48 hours after addition of NE (72 
hours after the removal of growth factors) (Figure 22A). Compared to controls, elafin-
knockdown 76NE6 cells stimulated with NE at concentrations of 1-8 nM demonstrate a 
statistically significant increase in cell number (Figure 22B). 
The ability of NE to induce proliferation was dose dependent. Elafin-deficient 
76NE6 cells were sensitive to the growth-promoting effect of 2 nM NE, whereas elafin-
expressing controls were not (Figure 22C). Complementation of elafin-knockdown 
76NE6 cells with shRNA-resistant-elafin, but not shRNA-resistant-M25G-elafin, 
attenuated proliferation induced by 2 nM NE (Figure 22C). No differences were 
observed in this experiment between groups not treated with NE because cell number 
was assessed following only 72 hours of growth factor deprivation. [Significant 
differences in cell number were not seen in elafin-knockdown HMECs until 120 hours of 
growth factor deprivations (Figure 22C).] Pharmacological inhibitors of NE activity 
sivelestat and GW311616 inhibited NE-induced proliferation under all tested conditions 
(Figure 23, A and B); further evidencing that the mitogenic-effect of NE is dependent on 
NE-activity and not contaminates in the NE preparation. 
These findings provided evidence that the growth-promoting effect of NE is 
dependent on its protease activity. 
.  
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Figure 22: Elafin Knockdown 76NE6 are Sensitive to the Growth Promoting Effect of Exogenous 
NE.  
 
(A) Schematic of experimental design; elafin knockdown and complemented 76NE6 
cells described in figure 21 were growth factor deprived in DFCI-3 media for 24 hours, 
followed by addition of exogenous NE (purified from human sputum) in DFCI-3 media. 
Cell number was determined 48 hours after the addition of NE by either MTT assay or 
counting cells using a hemocytometer. (B) Elafin knockdown and control 76NE6 cells, 
percent change in cell density in response to 0, 2, 4, 6, and 8 nM NE, measured by 
MTT as described in A. (C) Control, elafin knockdown, and elafin complemented 76NE6 
cells, cell number following stimulation with 2nM NE as described in A.  
 
 
 
 
 
 
 
 
 
 
 127 
 
 
 
 
Figure 23: The Growth Promoting Effect 
of Exogenous NE is Dependant on its 
Proteolytic Activity  
 
(A) Schematic of experimental 
design; elafin knockdown and 
control 76NE6 cells were growth 
factor deprived for 24 hours, 
followed by addition of 0, 0.5, 1, 2, 
4, 6, and 8 nM NE for 48 hours. NE 
inhibitors GW311616 (20µM) and 
Sivelestat (100µM) were added two-
hours prior and 24 hours post NE 
addition. (B) 76NE6 control and 
shRNA cell lines were treated with 
NE in the presence of PBS, DMSO, 
GW311616, or Sivelestat as 
described in A.   
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NE Induces the Deregulated Proliferation of Growth Factor Deprived HMECs 
Through TLR4-Dependent activation of ERK Signaling. 
 
 We performed microarray analysis to identify the molecular alterations 
underlying deregulated proliferation in growth factor-deprived elafin-knockdown 
HMECs. Genes differentially expressed between elafin-knockdown and control 76NE6 
cells were identified following 0, 48, and 168 hours of growth factor deprivation (Table 
6). Upregulation of the immediate early response gene, EGR1, at the 48-hour time point 
was of particular interest given the previously identified role of EGR1 in cell cycle re-
entry of G0-arrested HMECs (714, 715). We validated the upregulation of EGR1 in 
76NE6 elafin-knockdown cells by qPCR (Figure 24A). Complementation with shRNA-
resistant elafin diminished EGR1 mRNA levels (Figure 24A). The ERK signaling 
pathway is known to control EGR1 transcription (715). In elafin-knockdown 76NE6 cells, 
the MEK inhibitor U0126 (10 µM) abrogated EGR1 upregulation (Figure S24, B and C) 
and inhibited proliferation (Figure S19D) following prolonged growth factor deprivation. 
We chose to further explore the role of ERK signaling in NE-induced 
proliferation. 76NE6 cells were growth factor-deprived for 24 hours and then stimulated 
with 10 nM NE. The addition of NE resulted in activation of ERK phosphorylation that 
peaked within 15 to 30 minutes (Figure 25A). Upregulation of ERK target genes EGR1 
and FOS was observed 3 hours after the addition of NE to growth-arrested 76NE6 cells 
(Figure 25B). Addition of U0126 (Figure 25C) to growth factor-deprived elafin-
knockdown 76NE6 cells prevented proliferation induction by 2 nM NE (Figure 25D). 
Sivelestat, a specific NE inhibitor, also prevented proliferation induction by NE (Figure 
25D). Given the rapidity of ERK activation following the addition of NE, we hypothesized 
that an extracellular receptor mediates the mitogenic effect of NE on HMECs. TLR4 
(590), PAR2 (521), and EGFR (681) have all been implicated in NE-induced ERK 
activation. Knockdown of TLR4 reproducibly abrogated ERK activation in growth factor-
deprived 76NE6 and 81NE6 cells (Figure 25E) following the addition of 10 nM NE and 
attenuated NE-induced proliferation (Figure 25F).  
Both U0126 and MEK1 siRNA effectively inhibited ERK phosphorylation 
following the addition of NE to growth-arrested 76NE6 cells (Figure 26A) and 
consistently attenuated NE-induced proliferation (Figure 26, B and C). We transduced 
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76NE6 HMECs with shRNA specific to PAR2 and EGFR (shown is comparison to TLR4 
knockdown). PAR2 was not detected in HMECs (data not shown) and was omitted from 
this analysis (Figure 27A). EGFR-knockdown HMECs demonstrated reduced ERK 
phosphorylation upon stimulation with 10 nM NE suggesting a role for EGFR in NE-
induced ERK activation (Figure 27B). A role for EGR-1 was previously shown in EGF-
induced cell cycle re-entry (716). However, knockdown of EGR-1 in 76NE6 cells (Figure 
28A) was insufficient to block proliferation induced by NE, EGF, or serum-containing 
media (Figure 28B). 
These findings suggested that the mitogenic activity of NE in quiescent HMECs 
is dependent on TLR4-induced ERK activation. 
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Table 7: Microarray Analysis Identifies EGR1 Upregulation in Growth Factor Deprived Elafin 
Knockdown 76NE6 HMECs 
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Figure 24: The Growth Promoting Effect of Exogenous NE is Dependant on its Proteolytic Activity 
and Requires ERK Signaling  
 
(A) Elafin knockdown and complemented 76NE6 cells described in figure 4D were 
cultured in growth factor depleted media for 48 hours and analyzed for elafin and EGR1 
mRNA expression and normalized to control. (B) Schematic of experimental design; 
76NE6 control, shElafin1, and shElafin2 were continuously cultured with 10 µM of the 
MEK inhibitor U0196 following growth factor removal. (C) Quantitative RT-PCR of 
EGR1 expression in U0196/DMSO treated elafin knockdown 76NE6 48 hours post 
growth factor removal, normalized as in B. (D) Cell number of U0196/DMSO treated 
elafin knockdown 76NE6 cells 144 hours post growth factor removal. 
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Figure 25: NE Induces the Deregulated Proliferation of Growth Factor Deprived HMECs Through 
the TLR4/EGFR-Dependant Activation of ERK Signaling  
 
(A) Western blot analysis of pERK and total ERK in parental 76NE6 cells growth factor 
(GF) deprived for 24 hours and then stimulated with 10 nM NE. (B) qPCR analysis of 
EGR1 and FOS 3 and 6 hours after addition of NE. Values are represented relative to 
control (-GFs 24 hr). (C) Schematic of experimental design. Elafin-knockdown 76NE6 
cells were GF deprived for 24 hours, and stimulated with 2 nM NE for an additional 48 
hours. Two hours before and 24 hours after the addition of NE, DMSO, sivelestat (100 
µM), or U0126 (10 µM) was added. (D) Control and elafin-knockdown 76NE6 cells 
described in C were counted. (E) Western blot analysis of TLR4, pERK, and total ERK 
expression in 76NE6 and 81NE6 TLR4-knockdown cells GF deprived for 24 hours 
followed by stimulation with 10 nM NE. Actin, loading control. Par., parental. Cont., 
control. (F) 76NE6 and 81NE6 TLR4-knockdown cells were counted 48 hours after the 
addition of 10 nM NE 
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Figure 26: The Growth Promoting Effect of Exogenous NE is Dependent on its Proteolytic Activity 
and Requires ERK Signaling  
 
(A) 76NE6 cells were transfected with MEK1 or control siRNA, growth factor deprived 
for 24 hours, and stimulated with NE (10 nM). Alternatively, 76NE6 cells were growth 
factor deprived for 24 hours and treated with DMSO or the MEK inhibitor, U0126 (10 
µM), two-hours prior to NE addition. Cells were harvested 15, 30, and 45 minutes after 
NE addition and subjected to western blot analysis for phosphorylated (Thr202/Tyr204)- 
and total-ERK expression. (B) Elafin knockdown and control 76NE6 cells were prepared 
as above with MEK/control siRNA and stimulated with 0, 0.5, 1, 2, 4, and 8 nM NE for 
48 hours, the percent change in cell number was calculated by MTT assay. (C) 76NE6 
cells were examined as in B except for the use of U0126/DMSO/PBS (administered 2 
hours prior and 24 hours post NE addition) instead of siRNA.  
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Figure 27: Knockdown of EGFR and TLR4 
 
(A-D) 76NE6 cells were stably infected with pGIPZ lentiviral vectors containing control 
or two unique shRNAs targeting EGFR or TLR4. Knockdown of EGFR (A) and TLR4 (B) 
was confirmed by qPCR analysis. Values were normalized to GAPDH and represented 
as a ratio to the control shRNA level.  PAR2 shRNA was also included; however, we 
were unable to detect PAR2 expression in these cells by qPCR. (C) Western blot 
analysis of phosphorylated (Thr202/Tyr204) and total ERK expression in 24-hour 
growth factor-deprived 76NE6 cells stably transduced with control shRNA or shRNA 
targeting PAR2, TLR4, and EGFR following stimulation with 10 nM NE or vehicle alone.  
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Figure 28: Knockdown of EGR-1 Fails to Prevent Cell Cycle Reentry Following Addition with NE, 
EGF, or Serum Containing Media 
 
(A,B) 76NE6 cells were stably infected with pGIPZ lentiviral vectors containing control 
or three unique shRNAs targeting EGR1. The cells were growth factor deprived and 
then stimulated with 10 nM NE, 1 nM EGF, 10% serum containing media, or not-treated 
(NT). (A) Three hours after treatment the cells were harvested and lysates were 
subjected to western blot analysis. Both EGF and NE increased EGR1 levels compared 
to NT. EGR1 shRNA1 and shRNA3 abolished EGR1 upregulation. (B) Cells were 
counted 48 hours after treatment. NE, EGF, and serum containing media significantly 
increased cell number regardless of EGR1 levels. 
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DISCUSSION 
Immunohistochemical analysis reveals that elafin is highly expressed in the normal 
epithelium of the breast and fallopian tube, but is switched off as breast and ovarian 
tumors achieve an invasive phenotype. HMECs served as a model system to 
understand the role of elafin in the normal mammary epithelium and to discover the 
rationale behind elafin downregulation during tumorigenesis. 
A model based on the in vitro analysis performed in chapter two is presented in 
Figure 29. In this model, elafin is expressed by the normal quiescent epithelium under 
the transcriptional control of C/EBPβ, as a shield against neutrophil secreted NE activity 
(Figure 29A). During tumorigenesis elafin is downregulated due to deregulation of 
C/EBPβ, eliminating a critical counterbalance against the mitogenic effect of NE. We 
found that deregulated NE induces proliferation through TLR4-dependant activation of 
the ERK signaling pathway (Figure 29B). These results suggest a role for deregulated 
NE in promoting ERK-signaling and tumor growth. 
Several published studies have observed elafin downregulation in invasive 
tumors and tumor-derived cell lines (21, 23, 24, 26). However, contradictory studies 
examining elafin expression in ovarian cancer and glioblastoma conclude that elafin 
overexpression is a marker of poor prognosis (717, 718). In an experimental 
glioblastoma model of anti-angiogenesis therapy, elafin upregulation was observed by 
microarray analysis along with CHI3L1, CHI3L2, and IL-1β in avascular when compared 
to vascularized tumors. In glioblastoma patient samples, elafin mRNA expression was 
associated with higher tumor grade and poor overall patieint survival. IHC examination 
of elafin is a small cohort of glioblastoma cases found elafin expression in cells adjacent 
to necrotic regions of the tumor (718). 
The authors of the ovarian cancer study used a previously unpublished 
polyclonal antibody for immunohistochemical detection of elafin and were unable to 
detect elafin expression in normal ovarian epithelial cells (717). Aside from 
methodological discrepancies, the critical advantage of the immunohistochemical 
analysis presented here is the use of a scoring system based on elafin expression in 
normal tissue. Using this system, elafin overexpression can be defined as expression 
greater than that in the normal epithelium. Elafin overexpression, based on this criteria, 
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was observed in only 8% of breast tumors and <2% of ovarian tumors and had no 
prognostic significance. The Clauss et al. study scored elafin expression by the 
percentage of cells positive only. Tumors demonstrating elafin positivity in less than six-
percent of cells were grouped into the low elafin group (77 of 134 tumor samples) and 
tumors demonstrating elafin positivity in greater than six-percent of cells were grouped 
into the high elafin group (57 of 134 tumor samples), suggesting that the anti-protease 
shield is still diminished in these tumors.  
Alternative avenues of elafin transcription may differentiate the outcome of 
studies identifying elafin overexpression (717, 718) and downregulation (21-24, 26). 
Inducible elafin expression has been described in response to pro-inflammatory 
cytokines, especially IL-1β and TNF-α (646, 647), and is dependent NF-κB (717). 
C/EBP β sites (24) in the elafin promoter drive the expression of elafin in G0 HMECs 
(Figure 17). C/EBP β is essential to the constitutive expression of elafin in the normal 
epithelium. 
In ovarian tumor cells, elafin expression was NF-κB-dependent (717). In 
glioblastoma, focal elafin expression was associated with necrotic tumor areas. 
Necrosis is associated with inflammatory cytokine production and NF-κB activation 
(718). Elafin immunohistochemical scoring based solely on invasive tumors therefore 
reveals an association with inflammation and necrosis, which is known to be associated 
with poor prognosis. Consistent with this observation, the relatively small cohort of 
breast tumors expressing elafin, at or above the level observed in the normal breast 
epithelium, correlates with histopathological markers of aggressive tumor behavior 
(Table 5). We hypothesize that inflammation and NF-κB activation results in elafin 
reactivation in this subset. Ranking the expression of genes that covariate with elafin in 
the TCGA breast cancer (85), Yau et al. 2010 (719), TCGA ovarian (720), and TCGA 
glioblastoma (721) cancer datasets finds that elafin expression is highly correlated with 
the expression of inflammatory genes, especially secreted factors, cytokines, 
chemokines, and proteases (Table 8). The role of elafin in tumors is unclear. Elafin has 
never been shown to have oncogenic functions in experimental models. Excessive 
inflammation and high levels of NE activity can lead to tissue destruction and apoptotic 
cell death (722-724). Elafin expression in aggressive tumors may be meaningless, 
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however elafin in these tumors may also function to maintain NE activity within a range 
that induces proliferation, but not cell death. 
Elafin expression in G0 HMECs requires C/EBP β sites (24) in the elafin 
promoter (Figure 17). Alternative splicing results in the expression of C/EBP β as 
multiple isoforms, including a truncated transcriptional repressor. The accumulation of 
this dominant-negative C/EBP β isoform results in elafin downregulation in HMECs and 
tumor cells (24). We also found that Rb is required for elafin expression in HMECs 
(Figure 18). Physical interaction with Rb was previously shown to be critical for C/EBP β 
DNA-binding (725). In some cell types direct interaction between Rb and C/EBP β leads 
to enhanced transcriptional activity of C/EBP β target genes involved in quiescence and 
differentiation (726, 727). In fibroblasts, C/EBP β causes cell cycle exit in the presence 
of Rb, but accelerates proliferation in the absence of Rb (728). Deregulation of the Rb 
(85) and C/EBP β (24) pathways are a frequent event in human cancers and likely 
drives elafin downregulation during malignant progression.  
Another explanation for the finding that elafin is overexpressed in a subset of 
breast and ovarian tumors is amplification of the PI3-gene. Amplification of the 
chromosomal region 20q13.2, where elafin resides, is frequently observed in ovarian 
cancer, breast, and other tumor types. Several candidate oncogenes have been 
identified in the region including NABC1, ZNF217, TPD54, ADRM1, and BTAK, 
however no consensus exists on the gene or genes driving amplification. 20q13.2 
amplification is consistently associated with poor prognosis across a spectrum of tumor-
types including breast and ovarian cancer (729-733). Elafin overexpression may be a 
readout on this amplification event. 
The preponderate loss of elafin in invasive tumors compared to pre-invasive 
lesions suggests that elafin downregulation may play an important role in the transition 
to invasive carcinoma. Consistent with a tumor suppressive role for elafin in cancer, 
several published studies have observed cytotoxity following elafin re-expression in 
tumor cell lines and xenograft tumors (25, 26, 678). 
In this study, we concentrated on the stoichiometric relationship (1:1 molar ratio) 
between elafin and NE. Under normal culture conditions HMECs do not express NE 
(25), however NE expression by epithelial cells has been reported in response to 
reactive oxygen species (734). Metabolic stress is a byproduct of growth factor 
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deprivation and may be driving inappropriate NE expression in HMECs. However, the 
low levels of proliferation observed in elafin KD HMECs following prolonged growth 
factor deprivation (Figure 21) likely reflects a low concentration of relevant protease 
activity in this system. NE expression has previously been characterized in tumor cell 
lines (617, 735), however in the tumor microenvironment the majority of NE is 
contributed by activated neutrophils (542, 616). To model this, we added purified NE to 
the media of G0 HMECs. The level of cell growth achieved in elafin KD HMECs 48-
hours after addition of 2 nM NE (Figure 22) is comparable to the level observed 
following 144-hours of growth factor deprivation alone (Figure 21).  
Several published studies have demonstrated increased proliferation following 
addition of exogenous NE (542, 676, 736). The concentrations of NE resulting in a 
physiological response in vitro vary between studies; proliferation was induced in airway 
smooth muscle cell by addition of 0.35-1.7 nM NE (736), in keratinocytes by addition of 
0.1-33 nM NE (676), in lung fibroblasts by addition of 3.5-862 nM NE (681), and in lung 
cancer cells be addition of 20-80 nM NE (542). In the present study, the concentrations 
of NE utilized ranged from 1-10 nM to induce proliferation in HMECs, which is 
comparable to the concentrations used in most published studies. The specific activity 
of the purified NE, the intrinsic sensitivity of the cell lines, and the level of anti-proteases 
in the culture system are likely important factors in the concentration of NE required to 
generate a response. In vivo application of NE results in thickening of the epidermis and 
can be attenuated by addition of NE (676)  
NE-induced ERK signaling and resultant proliferation is dependent on the TLR4. 
Direct cleavage of TLR4 by NE has been reported to induce its activation (737). In both 
leukocytes and epithelial cells, NE-induced TLR4 activation has an established role in 
the activation of the NF-κB pathway and downstream cytokines expression, such as IL-
8, TNFα, and IL-6. TLR4 can also activate MAPK pathways including ERK signaling 
(590). We observed that knockdown of EGFR in HMECs partially inhibited NE-induced 
ERK activation (Figure 27). Stimulation of TLR4 by NE (560) or bacterial ligands (738) 
has previously been shown to result in activation of the EGFR, which is responsible for 
downstream ERK activation. In a non-small cell lung cancer (NSCLC) cell line, TLR4 
ligands promote proliferation in an EGFR-dependent manner (739).  
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Figure 29: Proposed Model for NE-Elafin Equilibrium 
 
(A) Elafin is expressed under the control of C/EBPβ and Rb in G0 HMECs. In this 
context, elafin blocks the mitogenic effects of secreted NE and maintains G0 arrest. (B) 
Loss of elafin expression and the accumulation of TAN-secreted NE in the tumor 
microenvironment lead to TLR4/EGFR-dependent activation of the ERK signaling 
pathway. The ERK pathway induces an immediate early gene response resulting in the 
transcription of growth factors, cell cycle regulatory factors and ultimately cell 
proliferation. 
 144 
 
 
Table 8: Inflammatory Gene Expression Covariates with the Expression of Elafin in Tumors. 
 
Tumor gene expression data from the TCGA breast, ovarian, and gliobastoma projects 
and the Yau et al. 2010 breast tumor dataset was examined for correlation with elafin. 
All genes were compared to elafin (PI3) and ranked by Pearson product-moment 
correlation coefficient (Corr.). P values were calculated based on the t-distribution. The 
TCGA breast tumor database was broken down further by intrinsic subtype. 
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Chapter 3: The Neutrophil Elastase Inhibitor, Elafin, Triggers Rb-Mediated Growth 
Arrest and Caspase-Dependent Apoptosis in Breast Cancer 
 
INTRODUCTION 
Endogenous Serine Protease Inhibitors in Tumorigenesis 
Maspin is a member of the serpin family of serine protease inhibitors. Similar to 
elafin, maspin expression was originally identified as highly expressed in HMECs, but 
downregulated in breast tumor derived cells (740, 741). Maspin downregulation has 
been observed in several tumor types including melanoma, breast, prostate, and gastric 
cancers (742-745). In experimental models, maspin demonstrates tumor suppressor 
properties, including reduction of tumor growth, angiogenesis, invasion, and metastasis 
(741, 746, 747). Intracellular maspin (esp. nuclear) is a marker of good prognosis in 
breast cancer (748, 749). Recent studies suggest that nuclear localization of maspin is 
essential to its tumor suppressive activity (750). Intracellular maspin induces apoptosis 
in breast cancer cells by associating with the mitochondrial membrane and facilitating 
the release of cytochrome c. Maspin also modulates the expression of anti-apoptotic 
BCL-2 family members and promotes caspase activation (747, 751-753).  
An essential feature of serpin protease inhibition is the exposed reactive center 
loop (RCL). The RCL makes contact with the active site of the protease target. Upon 
formation of an acyl-enzyme intermediate the serpin undergoes a rapid stressed to 
relaxed conformational change, distorting the active site of the target protease, and 
disfavoring hydrolysis. Following this reaction the RCL of the serpin remain covalently 
bound to the target protease, irreversibly inhibiting protease activity. The RCL of maspin 
is short and contains several hydrophobic residues that make it incapable of interacting 
with and inhibiting serine proteases (754). Therefore, the tumor suppressive properties 
of maspin are not dependent on an ability to inhibit protease activity. 
Plasminogen activator inhibitor 1 (PAI-1) is another serpin with a role in 
tumorigenesis. PAI-1 is an active inhibitor of urokinase-type plasminogen activator 
(uPA), which has an established role in tumor progression. PAI-1 was originally 
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hypothesized to have a tumor suppressive role in cancer by opposing the 
tumor/metastasis enhancing activities of uPA. Several early studies supported a tumor 
suppressive role for PAI-1, however in breast cancer patients the expression of both 
uPA and PAI-1 are prognosis of poor prognosis (755-758). Protease independent roles 
have since been described for PAI-1 in enhancing tumor growth, angiogenesis, and 
metastasis (759).  
WAP-domain containing, secretory leukocyte protease inhibitor (SLPI) has also 
been shown to have context dependent roles in tumor growth and progression (760, 
761). Overexpression of both wild-type or protease inhibitor-dead SLPI enhanced 
proliferation, colony formation, survival, and xenograft tumor formation following 
overexpression in the HEY-A8 ovarian cancer cell line (760). Overexpression of SLPI 
enhances the tumorigenicity and metastatic capacity in the 3LL-S (Lewis Lung 
Carcinoma) cell line in a subcutaneous xenograft model. Contrarty to the results 
reported in the ovarian cancer cell line HEY-A8, ithe pro-tumorigenic capacity of SLPI n 
the 3LL-S cell line was dependnat on its protease inhibitory domain. (762, 763). Tumor 
suppressive effects of SLPI overexpression have also been reported. In the F3II BALB/c 
murine mammary carcinoma cell line, SLPI overexpression severely limited the ability of 
these cells to form tumors in mice (764). Overexpression of SLPI in the metastatic cell 
line H-59 reduces the ability of these cells to elicit a pro-inflammatory response in the 
liver and to form metastases (765). In a particularly interesting study, SLPI 
overexpression was shown to enhance the proliferation and growth of colon xenograft 
tumors, but inhibit the growth of mammary xenograft tumors. In vitro SLPI induces 
apoptosis in breast tumor cells, but not colon tumor cells (761). 
Endogenous serine protease inhibitors play important roles in tumor 
progression. Interestingly, many studies have identified protease-independent role for 
protease inhibitors in tumorigenesis and progression. Protease-independent function 
(673) have also been identified for elafin. There is no known role for elafin in 
tumorigenesis. 
Hypothesis and Central Findings 
Several published studies suggest that elafin expression is downregulated 
during tumorigenesis including in squamous cell carcinomas of the skin, head/neck, and 
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esophagus (21, 22, 677, 766). Data presented in chapter 2 of this dissertation clearly 
demonstrates that elafin is downregulated in breast and ovarian cancer patients. The 
downregulation of elafin during tumorigenesis suggests that elafin possesses tumor 
suppressive properties. The majority of breast tumor derived cell lines demonstrate 
transcriptional downregulation of elafin, when compared HMECs (23). 
The central hypothesis of this chapter states that elafin has tumor suppressive 
activity in breast cancer. The observations presented here suggest that the Rb pathway 
governs the anti-tumor properties of elafin. In breast cancer cells with functional Rb, the 
expression of elafin triggered Rb-dependent cell cycle arrest. Elafin also exhibited 
suppressive activity in breast cancer cell lines lacking Rb, but this was associated with 
an induction of caspase-3 dependent. Normal mammary epithelial cells were not 
affected by elafin. Collectively, these results argue that elafin mediates tumor 
suppressive effects that are cytostatic or cytotoxic depending on Rb status. These 
findings suggest that elafin could be engineered as a therapeutic modality to treat 
breast cancer without toxicity to normal proliferating cells. 
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MATERIALS AND METHODS 
The methodology for DNA content analysis, preparation of protein lysates, 
western blot analysis, growth curves, and MTT assay are detailed in chapter two, 
additional reagents and protocols are described here.  
Antibodies 
Primary antibodies used for western blot (WB) or immunoprecipitation (IP):  
 
Antibody Species Clone Company Application Notes 
Rb Mouse monoclonal 4H1 
Cell Signaling 
Technology WB 
Detects only 
phosphorylated 
Rb 
Phospho-Rb 
site 
Ser807/811 
Rabbit 
Polyclonal  
Cell Signaling 
Technology WB  
PARP Rabbit Polyclonal  
Cell Signaling 
Technology WB  
Caspase 3 Rabbit Polyclonal  
Cell Signaling 
Technology WB  
Cleaved 
Caspase 3 
Asp 175 
Rabbit 
Polyclonal  
Cell Signaling 
Technology WB  
CDK4 Rabbit Polyclonal  
Santa Cruz 
Biotechnology IP  
Cell Lines and Culture Conditions 
All cell lines were maintained in a humidified tissue culture incubator at 37ºC and 
6.5% CO2.  All tumor derived cell lines (MDA-MB-157, MDA-MB-231, MDA-MB-468, 
MCF-7, ZR75.1, and T47D) were obtained from ATCC. Between 18 and 36% of 
established cell lines are cross contaminated or incorrectly identified (767), therefore all 
cell lines utilized were authenticated by the short tandem repeat method. All cell lines 
were also tested for mycoplasma contamination using the MycoAlert kit (Lonza). MDA-
MB-468 cells were maintained in DMEM (HyClone) supplemented with 10% fetal calf 
serum (Atlanta Biological), 0.01M HEPES, 2 mM L-glutamine, and 0.1 mg/mL of 
ciprofloxacin. The remaining tumor cell lines were maintained in α-MEM (HyClone) 
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supplemented in the same manner as DMEM with the addition of 0.1 mM non-essential 
amino acids and 1 mM sodium pyruvate.  
The pan-caspase inhibitor zVad-fmk (calbiochem) was solubilized in DMSO at 
50 mM and diluted in media at a concentration of 50µM. Cyclohexamide was dissolved 
in PBS at a concentration of 1 mg/mL, filtered, and diluted in media to a final 
concentration of 100 µg/mL. 
Knockdown/Overexpression in Breast Cancer Cell Lines 
MDA-MB-231 and MCF-7 cells stably expressing shRNA directed against Rb 
were a gift from Dr. E. Knudsen; these cells were maintained in α-MEM supplemented 
with 2 ug/mL puromycin (Sigma). MCF-7 cells with reconstituted caspase 3 were a gift 
from Dr. B. Fang; these cells were maintained in α-MEM supplemented with 0.1 mg/mL 
G418 (Mediatech). MCF-7 RBKD and MCF-7 shRNA control cell lines expressing 
caspase 3 or pcDNA3.1 empty vector were generated by transfection of the MCF-7 
RBKD and MCF-7 shRNA control cell lines with 6 µg of pcDNA3.1/Casp3 (also from Dr. 
B. Fang) or 6 µg of pcDNA3.1 empty vector using Genejuice reagent (Novagen), 
according to manufactures instructions. Cells expressing these vectors were selected in 
α-MEM containing 0.5 mg/ml G418 (Mediatech) and 2 ug/mL puromycin (Sigma) for four 
weeks. Single-cell clones were selected and expanded in culture media supplemented 
with 0.1 mg/ml G418 and 2 ug/mL puromycin (Sigma) and screened by western blot 
analysis for the expression for Rb and caspase 3.  
Production of Adenovirus and Infection of Target Cells 
  Elafin and Firefly Luciferase transgenes were expressed downstream of a 
cytomegalovirus (CMV) promoter in replication incompetent adenovirus type 5. Viruses 
were amplified in the packaging cell line AD-293 (Stratagene) and purified in a CsCl 
gradient by centrifugation at 176 000 g (Beckman ultracentrifuge) at 4oC for 18 hours. 
Multiplicity of Infection (MOI) was calculated based on the number of plaque forming 
units (pfu) in AD-293 cells. For infections 2 x 106 cells were plated on a 100mm plate, 
after 24 hours cells were washed with sterile PBS and treated with AD-elafin, AD-
luciferase, or PBS in four mL of media. After two hours of infection the media was 
removed and replaced with fresh culture media. All tumor cell lines were optimally 
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infected at 1 MOI except for MDA-MB-231, which along with HMEC cell lines were 
infected at 2 MOIs. Transgene expression was determined by western blot analysis. 
Infection efficiency was monitored using an identically tittered adenovirus expressing 
cDNA corresponding to GFP, all cell lines were infected at greater than 90% efficiency. 
BrdU incorporation 
Cells were plated in a 100 mm3 plate and treated 24 hours later with Ad-Elafin, 
Ad-Luc, or PBS. 48 hours post-treatment, cells were pulsed for 1 hour with 10 µM BrdU 
(Invitrogen), harvested, washed in PBS, and fixed in ice cold 70% ethanol for at least 24 
hours. Following fixation, 2 x 106 cells were aliquoted from each condition and washed 
in wash buffer (PBS + 1% BSA). The DNA was slightly denatured in 2M HCL, the cells 
were rinsed in wash buffer, residual acid was quenched by addition of 0.1 M sodium 
borate, and the rinsed again in wash buffer. Cells were then incubated in the dark for 1 
hour on a rocker in 50 uL of dilution buffer (PBS + 0.5% tween-20 + 1%BSA) containing 
a 1:10 dilution of FITC-conjugated anti-BrdU monoclonal antibody (BD Bioscience). 
Cells were washed in buffer to remove background and resuspended in 0.5 mL of 
propidium iodide (PI) (Molecular Probes) staining solution (10 ug/mL PI + 20ug/mL 
Ribonuclease A (Sigma) in wash buffer) for 30 minutes at RT. PI and FITC fluorescence 
was measured using a BD FACScalibur flow cytometer and analyzed using FloJo 
software. 
TUNEL Assay 
 To assess the percentage of cells that had undergone apoptosis, cells were 
treated as indicated and harvested 72 hours post treatment. Both the floating and 
adherent cells (by trypsin) were collected and 2 x 106 cells were aliquoted per condition 
and washed in PBS. Cells were fixed on ice for 20 minutes in 2.5% (w/v) 
paraformaldhyde (Sigma) in PBS (pH 7.4) and post-fixed in ice cold 70% ethanol for at 
least 24 hours. The TUNEL reaction was performed using the APO-BrdU TUNEL Assay 
Kit (Invitrogen) according to manufactures instructions. The included Alexa-Fluor 488 
conjugated anti-BrdU antibody was used in all cases except where GFP expression 
from stably transfected plasmids (RBKD and control cell line) interfered with detection of 
the Alexa-Fluor 488 dye; in this case Alexa-Fluor 647 conjugated Anti-BrdU antibody 
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(BD) was substituted. 
Immunoprecipitation-Kinase Assay  
For determination of CDK4 kinase activity, 1 µl/sample of polyclonal rabbit CDK4 
antibody was added to 30 µl/sample of protein A sepharose beads (GE HealthCare) at 
a concentration of 0.1 g/mL in lysis buffer (0.5M tris, pH 7.5, 2.5M sodium chloride, 1% 
NP-40 (Igepal)) and 36 µl/sample of 10 mM DTT/lysis buffer/PPI and incubated 
overnight, at 4oC on a rocker.  The following day, 200 µg of protein samples were added 
to the mixture and incubated for one hour, at 4oC with rotation.  The beads are then 
washed in 500 µl of the lysis buffer three times and then washed an additional three 
times in 500 µl of kinase wash buffer (10mM MgCl2, 1mM DTT, 0.1 mg/ml BSA, 25mM 
Tris HCL pH 7.5, 125mM NaCl). All liquid is then removed from the reaction and the 
beads are resuspended in the kinase reaction buffer: 10mM MgCl2, 1 mM DTT, 0.1 
mg/ml BSA, 25 mM Tris HCL pH 7.5, 125mM NaCl plus 60mM ATP, 5µ Ci of γ-32P ATP 
and 1µg of GST-Rb 769 substrate (Santa Cruz).  The reaction was allowed to proceed 
for 30 minutes at 37ºC and inactivated by addition of 15µl of sample buffer.  The 
samples were resolved on a 10% SDS-PAGE gel, stained in Brilliant Blue (Sigma) for 
one hour and de-stained overnight. The gel is then dried onto filter paper, exposed to a 
phosphorimager screen, and analysis by a Typhoon scanner (Molecular Dynamics).  
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RESULTS 
Exogenously Expressed Elafin Induces Apoptosis in HMECs Lacking Functional 
Rb. 
 
In Chapter two, we demonstrate that actively proliferating HMECs in growth 
factor containing media do not express elafin. However, elafin is highly upregulated in 
growth factor deprived, G0-arrest HMECs (Figure 15). In the HMECs, elafin is required 
for maintenance of G0-arrest during long-term growth factor deprivation conditions 
(Figure 21). To determine if exogenously expressed elafin can affect growth of actively 
proliferating HMECs, elafin was overexpressed using an adenoviral vector. Adenoviral 
expression of luciferase was used as a control for viral infection. Mock transduced cells 
were treated with an equivalent volume of PBS. 
Sub-confluent 76NE6, 76NF2V, and 76NE7 cells were treated with adenoviral 
elafin, adenoviral luciferase, or PBS. Lysates were subjected to western blot analysis to 
demonstrate expression of the elafin transgene in comparison to endogenous elafin 
expression in growth factor deprived 76NE6 cells (Figure 30A-compare lane C [control: 
76NE6 –GFs 48 hr], to lane E for each cell line). Adenoviral expression of elafin in 
proliferating HMECs produces expression levels comparable to growth factor deprived 
76NE6 cells (Figure 30A). The overexpression of elafin causes no statistically 
significant change in the doubling times of Rb-proficient cell lines 76NE6 (PBS: 16±1.1 
hours, luciferase: 15±0.5 hours, and elafin 15±0.3 hours) and 76NF2V (PBS: 18±0.6 
hours, luciferase: 18±0.6 hours, and elafin 20.3±0.5 hours), suggesting that elafin 
expression alone is insufficient to induce growth arrest. However, overexpression of 
elafin in 76NE7 cells, which are devoid of Rb, resulted in a significant decrease in cell 
number by 96 hours post-treatment (Figure 30B).  
To determine if the decrease in cell number seen in 76NE7 cells (Figure 30B) is 
due to adenoviral elafin-induced cell cycle arrest or induction of apoptosis we analyzed 
BrdU incorporation (Figure 30C) and TUNEL staining (Figure 30D). There was no 
statistically significant change in BrdU incorporation following ectopic expression of 
elafin in any of the cell lines tested (76NE6, 76NF2V, or 76NE7) (Figure 30C). There 
was a significant increase in TUNEL positive cells in adenoviral elafin treated 76NE7 
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cells compared to adenoviral luciferase treated 76NE7 or adenoviral elafin treated 
76NE6 or 76NF2V cells (Figure 30D). The TUNEL assay measures DNA fragmentation, 
a result of apoptotic cell death. 
These results suggest that elafin induces apoptosis preferentially in Rb deficient 
HMECs (76NE7) compared to Rb-expressing HMECs (76NE6 and 76NF2V). 
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Figure 30: Exogenously Expressed Elafin Induces Apoptosis in HMECs Lacking Functional Rb.  
 
(A-D) 76NE6, 76NF2V, and 76NE7 cells were treated with PBS, adenoviral luciferase 
(Ad-L), or adenoviral elafin (Ad-E). (A) Cells were harvested 48 hours post-treatment 
and subjected to western blot analysis for elafin expression. Actin, loading control. (B) 
Growth was monitored by trypan blue exclusion test every 24 hours for 96 hours. 
Asterisk indicates statistical significant. (C) Proliferation was assessed 48 hours post-
treatment by measuring BrdU incorporation. (D) Apoptosis was assessed 72 hours 
post-treatment by TUNEL assay.  
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Expression of Elafin in Rb Negative Breast Cancer Cells Results in Apoptosis.  
 
Based on the finding that elafin induces apoptosis in Rb deficient HMECs, we 
hypothesized that Rb deficient breast cancer cell lines are susceptibility to elafin-
induced apoptosis. We examined elafin re-expression in three breast cancer cell lines 
with functional/wild-type Rb (MCF-7, ZR75.1, and T47D) and three cell lines deficient in 
Rb (MDA-MB-157, MDA-MB-468 and MDA-MB-436).  All six cell lines were treated with 
adenoviral elafin, adenoviral luciferase, or PBS and were examined for growth kinetics, 
BrdU incorporation, and TUNEL positivity (Figure 31). Western blot analysis of 
adenoviral transduced cells reveals restoration of elafin expression in breast cancer cell 
lines comparable to control (76NE6 cells growth factor deprived for 48 hours), 
suggesting that elafin is being expressed at physiologically relevant levels (Figure 31A). 
Treatment of Rb positive breast cancer cell lines with adenoviral elafin resulted in a 
modest growth inhibition, whereas treatment of Rb negative cell lines with adenoviral 
elafin resulted in a precipitous decline in cell number (Figure 31B).  
All three of the Rb expressing cell lines demonstrated a significant reduction in 
BrdU incorporation, while the Rb deficient cell lines demonstrated no significant change 
in BrdU incorporation (Figure 32A). Examination of TUNEL positivity fails to identify an 
increase in apoptotic cell death in Rb positive cell lines in response to adenoviral elafin. 
However, all three Rb negative cell lines underwent significant levels of apoptosis in 
response to elafin expression (Figure 32B).  The percent TUNEL positivity ranged 
between 22-30% of all Rb negative cells treated with adenoviral elafin, compared to 1-
5% of cells treated with adenoviral luciferase (p<0.01).  
These results suggest that elafin overexpression results in growth inhibition in 
Rb positive cells and apoptosis in Rb negative breast cancer cells. 
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Figure 31: Expression of Elafin in Rb Negative Breast Cancer Cells Results in Apoptosis.  
 
(A,B) MCF-7, ZR75.1, T47D, MDA-MB-157, MDA-MB-436, and MDA-MB-468 cells 
were treated with PBS, adenoviral luciferase, or adenoviral elafin. (A) Cells were 
harvested 48 hours post-treatment and subjected to western blot analysis for elafin 
expression. Actin, loading control. (B) Growth was monitored by trypan blue exclusion 
test every 24 hours for 96 hours. Asterisks indicate a statistically significant change in 
cell number, elafin treated compared to controls.  
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Figure 32: Expression of Elafin in Rb Negative Breast Cancer Cells Results in Apoptosis. 
 
(A,B) MCF-7, ZR75.1, T47D, MDA-MB-157, MDA-MB-436, and MDA-MB-468 cells 
were treated with PBS, adenoviral luciferase, or adenoviral elafin. (A) Proliferation was 
assessed 48 hours post-treatment by measuring BrdU incorporation. (B) Apoptosis was 
assessed 72 hours post-treatment by TUNEL assay.  
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Inhibition of Caspase Activity Leads to Attenuation of Elafin-Mediated Apoptosis.   
 
Caspase activation is essential to apoptotic cell death. Caspase 3 is a 
component of both the intrinsic and extrinsic (death receptor) apoptotic pathways.  
Cleavage of caspase 3 and caspase 3 target PARP are specific indicators of apoptotic 
cell death (Figure 33). To determine if caspase activity is increased by adenoviral elafin 
expression in the Rb negative cells we examined caspase 3 and PARP cleavage by 
western blot analysis. Treatment of the Rb deficient cell line MDA-MB-468 with 
adenoviral elafin dramatically increased cleavage of PARP and caspase 3, suggesting 
activation of caspase-dependent apoptosis (Figure 33A). To determine if adenoviral 
elafin-induced cell death is caspase-dependent, MDA-MB-468 and MDA-MB-157 cells 
were treated with adenoviral elafin in the presence of the pan-caspase inhibitor zVad-
fmk. Treatment with zVad-fmk significantly reduced elafin-mediated cell death, 
indicating a requirement for caspase activation in elafin-induced cell death (Figure 33B). 
These results suggest that elafin induces caspase-dependent, apoptosis in Rb deficient 
breast cancer cells and not another form of cell death.  
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Figure 33: Inhibition of Caspase Activity Leads to Attenuation of Elafin-Mediated Apoptosis. 
 
(A) MDA-MB-468 cells were treated with PBS, adenoviral luciferase, or adenoviral elafin 
for 48, 72, and 96 hours. Cells were harvested and lysates were subjected to western 
blot analysis for full length caspase 3, cleaved caspase 3 (Asp175), PARP, and elafin. 
Actin, loading control. (B) MDA-MB-468 and MDA-MB-157 cells were treated with PBS, 
adenoviral luciferase, or adenoviral elafin in the presence of 50 µM zVad-fmk, DMSO, 
or PBS. Viability was measure by MTT assay every 24 hours for 120 hours. Eight 
replicates from two independent experiments were combined and expressed as a 
percentage of the PBS control. Statistical significance was calculated by the t-test for no 
treatment vs. elafin-alone (1), luciferase alone vs. elafin alone (2), and elafin + DMSO 
vs. elafin + zVad-fmk (3): displayed as a table. 
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MDA-MB-231 Rb Knockdown Cells are Sensitive to Elafin-Induced Apoptosis.  
 
We next examined if Rb directly mediates the sensitivity of breast cancer cell 
lines to elafin-induced cytotoxicity. MDA-MB-231 cells expressing Rb shRNA (RBKD) 
cells were evaluated by western blot analysis. In these cells Rb is efficiently 
downregulated (Figure 34A; left panel). Adenoviral expression of the elafin transgene 
was approximately equivalent in the MDA-MB-231 RBKD and controls cell lines and 
similar to the level expressed by 76NE6 cells growth factor deprived for 48 hours 
(control) (Figure 34A; right panel). MDA-MB-231 RBKD cells demonstrate enhanced 
growth kinetics compared to control and parental cells (Figure 34B). MDA-MB-231 
RBKD cells also demonstrate enhanced sensitivity to the adenoviral elafin-induced 
cytotoxicity (Figure 34B). Treatment of the MDA-MB-231 RBKD cells with adenoviral 
elafin resulted in a significant reduction in cell number 72 and 96 hours post-treatment 
when compared to MDA-MB-231 parental or shRNA control cells (Figure 34C).  To 
validate that the decrease in cell number was due to adenoviral elafin induced 
apoptosis, TUNEL staining was performed. A significant increase in TUNEL positivity 
was detected in MDA-MB-231 RBKD cells compared to control cell lines (Figure 34D). 
These results illustrate a direct role for Rb deficiency in sensitizing breast cancer cells 
to elafin-induced apoptosis.  
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Figure 34: Knockdown of Rb in MDA-MB-231 Cells Increases Sensitivity to Elafin-Induced 
Apoptosis.  
 
(A-D) MDA-MB-231 parental, shRNA control, and RBKD cell lines were treated with 
PBS, adenoviral luciferase, or adenoviral elafin (A)  Lysates were collected at 48 hours 
and subjected to western blot analysis. PBS treated lysates were examined by western 
for Rb expression, left panel. All lysates were examined for elafin expression, right 
panel. Actin, loading control. (B) Growth was monitored by trypan blue exclusion test 
every 24 hours for 96 hours.  Asterisks indicate a statistically significant difference in 
cell number comparing elafin treated to luciferase and PBS treated cells. (C) Cell 
number at 96 hours was compared between MDA-MB-231 parental, control, and RBKD 
cells; cell viability was calculated as a percentage of the PBS control. (D) Apoptosis was 
assessed 72 hours post-treatment by TUNEL assay.  
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Rb is Required for Elafin Induced G0/G1 Arrest in MCF-7 Cells.   
Treatment of Rb positive breast cancer cell lines with adenoviral elafin causes 
them to undergo proliferative arrest not apoptosis (Figure 32). To further characterize 
cell cycle arrest in Rb positive breast cancer cells we performed DNA content analysis. 
Treatment of MCF-7 (Rb positive) cells with adenoviral elafin results in the accumulation 
of cells in the in the G1 phase of the cell cycle (Figure 35A). Rb is a critical component 
of the G1 checkpoint control, therefore we examined if elafin overexpression modulates 
CDK4 kinase activity and Rb phosphorylation in MCF-7 breast cancer cells.  For these 
experiments MCF-7 cells were treated with PBS, adenoviral luciferase, or adenoviral 
elafin for the 24, 48, and 72 hours. Lysates were subjected to western blot analysis and 
a CDK4 immunoprecipitation kinase assays (Figure 35). Elafin treatment resulted in a 
decrease in the phosphorylation of Rb using phospho-specific antibodies, directed 
against serine 807/811, serine 780, and total phosphorylated Rb (Figure 35B). The 
CDK4 kinase activity was measured using GST-Rb as a substrate. CDK4 kinase activity 
was profoundly decreased following overexpression of elafin (Figure 35C). These 
results suggest that the expression of elafin in MCF-7 cells causes a G1 arrest 
characterized by a decreased in Rb phosphorylation, in part due to attenuation of CDK-
4 kinase activity.  
Next, we set out to examine if Rb downregulation in MCF-7 cells is sufficient to 
convert cell fate from growth arrest to apoptosis following elafin expression (as was the 
case in the RBKD MDA-MB-231 cells [Figure 34]). To accomplish this we treated MCF-
7 cells stably expressing an shRNA vector targeting Rb with PBS, adenoviral luciferase, 
or adenoviral elafin and examined cell viability (Figure 36). Efficient downregulation of 
Rb was observed by western blot analysis in MCF-7 RBKD cells compared to control 
and parental MCF-7 cells (Figure 36A; left panel). Consistent expression of the elafin 
transgene was confirmed by western blot analysis for MCF-7 RBKD and control cells 
(Figure 36A; right panel). Elafin expression achieved in MCF-7 RBKD and controls was 
equivalent to levels observed in 76NE6 cells growth factor deprived for 48 hours (Figure 
36A; right panel). MCF-7 shRNA control cells treated with adenoviral elafin 
demonstrated a moderate reduction in cell number at 96 hours when compared to 
luciferase control (Figure 36B), similar to the pattern seen in the MCF-7 parental cell 
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line (Figure 31A). MCF-7 RBKD cells showed no significant change in growth kinetics 
following treatment with adenoviral elafin or adenoviral luciferase (Figure 36C). MCF-7 
RBKD cells demonstrate enhanced growth kinetics compared to controls (Figure 36C) 
Direct comparison of the parental, shRNA control, and RBKD cell lines (normalized to 
PBS control) illustrates failure of RBKD cells to arrest following administration of 
adenoviral elafin, compared to control and parental cells. MCF-7 RBKD cells 
demonstrate significantly less sensitivity to elafin-induced cell cycle arrest, as measured 
by BrdU incorporation (Figure 36D). This indicates that knockdown of Rb in MCF-7 cells 
does not sensitize cells to apoptosis, but is sufficient to attenuate cell cycle arrest.  
Collectively, these results show that elafin induced growth arrest in breast 
cancer cells is Rb-dependent.  
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Figure 35: Expression of Elafin in MCF-7 Cells Causes a G0/G1 arrest.  
 
(A) MCF-7 cells were infected with adenoviral luciferase or adenoviral elafin. Cells were 
collected every six-hours for 72-hours and subjected to DNA content analysis. (B-C) 
MCF-7 cells were treated with PBS, adenoviral luciferase, or adenoviral elafin. (B) 
Lysates were subjected to western blot analysis and probed for pRb S807/811, pRb 
S780, total pRb, and elafin. (C) CDK-4 was immunoprecipitated from 250 µg of protein 
lysates, the immunocomplex was then subjected to in vitro kinase assay using GST-Rb 
as a substrate. 
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Figure 36: Rb is Required for Eafin-Induced G0/G1 Arrest in MCF-7 Cells.   
 
(A-D) MCF-7 parental, shRNA control, and RBKD cell lines were treated with PBS, 
adenoviral luciferase, or adenoviral elafin (A) Lysates were collected at 48 hours and 
subjected to western blot analysis. PBS treated samples were examined for Rb 
expression, left panel. All lysates were examined for elafin expression, right panel. 
Actin, loading control. (B) Growth was monitored by the trypan blue exclusion test every 
24 hours for 96 hours. Asterisk denotes statistical significance. (C) Cell number was 
compared 96 hours post-treatment between MCF-7 parental, shRNA control, and RBKD 
cell lines as a percentage of the PBS controls. (D) Proliferation was assessed 48 hours 
post-treatment by measuring BrdU incorporation. Values are expressed as percent 
inhibition of BrdU incorporation; values normalized to PBS and then subtracted from 
100. 
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Overexpression of Elafin Causes Apoptosis in MCF-7 Cells Only After 
Knockdown of Rb and Restoration of Caspase 3.  
 
Downregulation of Rb was shown to sensitize MDA-MB-231 cells to elafin 
induced apoptosis; however downregulation of Rb in MCF-7 cells failed to replicate 
these results. MCF-7 cells lack endogenously expressed caspase 3. Therefore we 
hypothesized that loss of Rb and presence of caspase 3 are both required for elafin-
induced apoptosis. To address this hypothesis, we first confirmed that elafin expression 
fails to induce apoptosis following reconstitution of caspase 3 alone. Western blot 
confirmed the expression of caspase 3 in stably transfected MCF-7 cells (Figure 37A, 
left panel). MCF-7 caspase 3 reconstituted cells were treated with PBS, adenoviral 
luciferase, or adenoviral elafin. Western blot analysis confirms equivalent expression of 
elafin (Figure 37A). No significant increase in apoptotic cell death, measured by TUNEL 
assay, was seen in MCF-7 caspase 3 or MCF-7 RBKD cells in response to adenoviral 
elafin (Figure 37B). 
To directly examine if Rb downregulation and presence of caspase 3 are co-
requirements for apoptosis in MCF-7 cells following elafin expression, we established 
clones of MCF-7 RBKD and MCF-7 shRNA control cell lines expressing either 
pcDNA3.1-empty vector or pcDNA3.1-caspase 3. Knockdown of Rb, stable expression 
of caspase 3, and expression of the elafin transgene were verified by western blot 
analysis (Figure 37C,D).  Treatment of MCF-7 RBKD cells expressing caspase 3 with 
adenoviral elafin caused a severe reduction in cell viability (Figure 38A). The same 
experiment was performed in MCF-7 shRNA control cells line, however in these cells 
reconstitution of caspase 3 did not lead to a significant decrease in viability compared to 
controls. Comparison of cell viability at 120 hours post treatment demonstrates that 
elafin mediated loss of cell viability in MCF-7 RBKD clones expressing caspase 3 is 
significantly different from all other MCF-7 cell lines examined (Figure 38B). TUNEL 
assay reveals a significant increase in the percentage of cells undergoing apoptosis in 
MCF-7 RBKD expressing caspase 3 versus controls (PCDNA + Ad-luc, PCDNA+Ad-
Elafin or CASP 3 + Ad-Luc) (Figure 38C).  
These results indicate that loss of Rb and the reconstitution of caspase 3 are 
both required for elafin-induced apoptosis in the MCF-7 cell line. 
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Figure 37: Adenoviral Elafin does not Induce Apoptosis in MCF-7 Rb Knockdown Cells.  
 
(A) Lysates from MCF-7 pcDNA3.1 empty vector and pcDNA3.1-caspase 3 stable 
clones were subjected to western blot analysis for caspase 3. Actin, loading control (left 
panel). Lysates from MCF-7 pcDNA3.1 empty vector and pcDNA3.1-caspase 3 were 
subjected to western blot analysis for elafin 48 hours after treatment with PBS, 
adenovirus luciferase, or adenovirus elafin. Actin, loading control (right panels). (B) 
MCF-7 pcDNA3.1 empty vector, pcDNA3.1-caspase 3, RbKD, and shRNA control cells 
were treated with PBS, adenovirus luciferase, or adenovirus elafin. Apoptosis was 
assessed by TUNEL assay. (B) MCF-7 RBKD cells were transected with either 
pcDNA3.1 empty vector or pcDNA3.1-caspase 3 and selected in puromycin. Cells were 
treated with adenoviral elafin. Lysates were subjected to western blot analysis. 
Untreated cells were used to assess the levels of Rb and caspase 3, reproducibility of 
transgene expression was assessed by western blot for elafin. 
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Figure 38: Overexpression of Elafin Causes Apoptosis in MCF-7 Cells Only After Knockdown of Rb 
and Restoration of Caspase 3.   
 
(A) Cell viability was measured by MTT assay every 24 hours for 120 hours and 
calculated at each time point by normalizing values from luciferase and elafin treated 
cells to PBS control then plotting the difference between the viability of elafin and 
luciferase (i.e. elafin effect – viral effect). (B,C)  MCF-7 control shRNA background cells 
expressing either pcDNA3.1 empty vector or pcDNA3.1-caspase 3. These cells were 
assayed in the same manner as panels B and C. (C) The viabilities measured at 120 
hours in the cell lines generated from the MCF-7 RBKD and MCF-7 control shRNA as 
well as the parental cell lines were pooled and statistically compared. (C) Apoptosis was 
measured by TUNEL assay.
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DISCUSSION 
Elafin is expressed in HMECs, but it is transcriptionally downregulated in tumor 
derived cell lines (24). In chapter 2, the data presented demonstrated that elafin was 
highly upregulated in growth factor deprived, G0-HMECs (Figure 15) and is required for 
maintenance of G0-arrest (Figure 21). In the absence of Rb, growth factor deprived 
HMECs failed to arrest in G0 and did not express elafin at levels comparable to Rb-
expressing HMECs (Figure 18). In this chapter, adenoviral-mediated expression of 
elafin was used to determine if elafin expression alone is sufficient to induce growth 
arrest in normally proliferating Rb-expressing HMECs (76NE6 and 76NF2V) and Rb-
deficient (76NE7) HMECs. In this experiment, adenoviral-elafin failed to induce growth 
arrest in Rb-expressing HMECs. However, in HMECs lacking Rb, adenoviral-elafin 
surprisingly caused apoptotic cell death (Figure 30). This Rb-dependent apoptotic effect 
led to the hypothesis that tumor cells with a deregulated Rb pathway could also be 
forced to undergo apoptosis following elafin expression. Indeed, we observed that the 
expression of elafin could induce apoptosis in Rb-negative cells (Figure 32). We also 
found that Rb-positive breast cancer cells are growth inhibited in response to elafin 
expression (Figure 32). In these cells, elafin expression led to the downregulation of 
CDK4 activity and a reduction in Rb phosphorylation (Figure 35). Critically, Rb-positive 
MDA-MB-231 cells, which are insensitive to adenoviral elafin-induced apoptosis, could 
be converted to a sensitive phenotype by downregulation of Rb alone (Figure 34). 
Of note, the Rb-negative cell lines used in this work were all of the basal-like 
subtype and the Rb-positive cell lines were all of the luminal subtype. Rb-loss is rare in 
the luminal subtypes of breast cancer (Figures 4 and 5), however it occurs with greater 
frequency in the basal-like subtype of breast cancer (Figure 7). To exclude the 
possibility that adenoviral elafin-induced cytotoxicity is exclusive to the basal-like 
subtype, MCF-7 (luminal subtype) cells were converted to an elafin-sensitive phenotype 
(Figure 38). MCF-7 cells were not sensitized to the apoptotic effect of adenoviral elafin 
following Rb knockdown alone (Figure 37), as was the case with MDA-MB-231 cells 
(Figure 34). Caspase activity is required for adenoviral elafin induced apoptosis (Figure 
33). MCF-7 cells lack caspase 3 (Figure 37). Restoration of caspase 3 in MCF-7 Rb 
knockdown cells was sufficient to sensitize these cells to adenoviral elafin induced 
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apoptotic cell death, suggesting that the activity of elafin in breast cancer cell lines is not 
dictated by breast cancer subtype. Rb-status and an intact caspase-dependent 
apoptotic cascade are major determinate of sensitivity to elafin-induced apoptosis 
versus growth arrest. Taken together, the results presented here clearly indicate that 
elafin has tumor suppressive properties in breast cancer cell lines similar to results 
reported for the serine protease inhibitors SLPI and maspin (747, 751-753, 761).  
Following publication of the work presented here (678), adenoviral elafin was 
shown to have therapeutic efficacy following intratumoral injection of MDA-MB-468 
xenograft tumors (25). Adenoviral elafin treated MDA-MB-468 xenograft tumors 
demonstrate a significant growth delay compared to adenoviral luciferase or PBS 
treated tumors. The survival of adenoviral elafin treated, tumor-bearing mice was 
significantly extended. Approximately 20% of the tumors were completely eradicated by 
adenoviral elafin treatment (25). 
Elafin downregulation has also been observed in melanoma. Elafin re-
expression using a tet-inducible system resulted in apoptotic cell death in melanoma 
cells, but not normal melanocytes. In this system p53 was required for the elafin-
induced cell death (27). In the work presented here, apoptotic cell death is p53 
independent since all of the breast tumor cell lines (MDA-MB-468, MDA-MB-157, MDA-
MB-436) sensitive to elafin-induced apoptosis express mutant p53. Induction of elafin 
expression in melanoma xenograft tumors significantly reduced tumor size (27).  
The majority of breast tumors demonstrate elafin downregulation (Figure 10). 
Approximately one-quarter of all breast tumors exhibit homologous loss or mutation of 
Rb (768, 769). Rb loss is associated with aggressive breast cancer subtypes, especially 
basal-like tumors (Figure 7) (770, 771). The basal-like subtype of breast cancer are 
resistant to currently available targeted therapies (i.e. anti-estrogens and anti-HER2) 
(427, 772). A therapy capable of specifically targeting breast tumors with Rb loss may 
have significant clinical utility in highly aggressive breast tumors. Elafin represents a 
candidate therapeutic capable of specifically targeting tumor cells with disruption of the 
G1 checkpoint with no toxicity in normally dividing cells.  
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Chapter 4: Neutrophil Elastase in Basal-like Breast Cancer Progression 
 
INTRODUCTION 
TAN and Tumorigenesis  
Inflammatory signaling and the presence of leukocytes within the tumor 
microenvironment are critical components of tumor progression (9, 10). Early tumor 
microenvironment studies largely ignored the neutrophil component of the inflammatory 
infiltrate due to doubts that such a short-lived cell type could dramatically impact 
tumorigenesis (423).Tumor-derived chemokines drive the constant replenishment of 
neutrophils in the tumor microenvironment. Chemokines are produced directly by tumor 
cells as a consequence of oncogene-induced (e.g. K-Ras and Myc) NF-κB pathway 
activation (368, 407) and by activated fibroblasts subjected to hypoxia, 
chemotherapeutics, and other cellular stresses (373, 375).  
Relatively few studies have examined tumor-associated neutrophils (TAN) in 
human cancer. In renal cell carcinoma, TAN (CD66b-positive) were prognostic of short 
recurrence-free survival (RFS). In the presence of TAN, patients demonstrated a five-
year RFS of 53%, however in the absence of TAN patients had a five-year RFS of 87%. 
In multivariate analysis, TAN were an independent prognostic marker of disease-
specific survival (DSS) and overall survival (OS) (410). In human gliomas, the 
concentration of TAN (CD15-positive and myeloperoxidase-positive) correlate with high 
tumor grade (411). High levels of neutrophils (scored based on H&E) in the 
bronchoalveolar lavage fluid from patients with bronchioloalveolar carcinoma were 
associated with high levels of IL-8, NE, and poor DSS (407). Although not commonly 
observed in pancreatic tumors, TAN (scored based on H&E staining) were associated 
with the aggressive micropapillary and undifferentiated subtypes (412). High neutrophil 
levels in the peripheral blood were associated with poor outcome in metastatic 
melanoma and renal cell carcinoma patients (408, 409). 
TAN contribute growth factors (i.e. HGF), cytokines (i.e. Oncostatin M, TNFα, 
IL1-β, IL-6, and IL-12), reactive oxygen species (ROS), and proteases (i.e. NE, PR3, 
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CG, MMP-8, and MMP-9) to the tumor microenvironment (345, 418-421). In mouse 
models, neutrophil depletion using Gr-1 (LY-6G) antibodies or blockade of neutrophil 
recruitment using antibodies against Cxcr2, profoundly inhibited tumor growth, 
angiogenesis, and metastasis in mouse tumor models (415-417). These studies 
suggest a pro-tumorigenic role for TAN in human cancer. TGF-β blockade forced TAN 
to assume an anti-tumor phenotype, however little evidence exists of a role for TAN in 
anti-tumor immunity in the absence of therapeutic manipulation (422, 423). 
NE and Tumorigenesis 
 Several groups demonstrated that high levels of NE (measured by ELISA) were 
independently prognostic of OS, metastasis-free survival, DSS, and RFS in multivariate 
analysis of breast cancer patients (12, 599-601). High NE expression demonstrated a 
negative correlation with tumor ER and PR status. In ER-positive tumors the mean level 
of NE was 5.8 ng/mg of tissue compared to 14.9 ng/mg in ER-negative tumors. In PR-
positive tumors the mean level of NE was 6.0 ng/mg compared to 9.1 ng/mg in PR-
negative tumors (12). Triple-receptor negative breast cancer (TNBC) highly expresses 
chemokines critical to the recruitment and activation of TAN (773-776), indicating that 
the recruitment of neutrophils is highest in TNBC and that these are the tumors with the 
greatest concentration of NE. However, NE may also play a role in the outcome of 
patients with ER-positive tumors. High levels of NE are associated with a poor response 
rate to tamoxifen, shorter progression-free survival, and poor post-relapse free survival. 
In multivariate analysis, NE is an independent predictive marker of response to 
tamoxifen (599).  
Sivelestat, a pharmacological inhibitor of NE, was able to reduce the 
proliferation, motility, and chemotaxis of the pancreatic cancer cell line Capan-1 in vitro 
(603). In a mouse xenograft model of non-small cell lung cancer using the EBC-1 and 
PC-1 cell lines, sivelestat attenuates tumor proliferation (606). Sivelestat also inhibited 
spontaneous metastasis of EBC-1 xenograft tumors (607). Beige mice are deficient in 
NE (608). Cohorts of NE-deficient and control mice were created for the study of NE in 
tumorigenesis by crossing beige mice with SKH 1 hairless mice. Following ultraviolet 
irradiation, NE-expressing control mice developed an average of 10 tumors per mouse 
after 20-weeks, while NE-deficient mice developed an average of only 0.4 tumors per 
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mouse over the same period. In the same system, benzopyrene exposure resulted in 
the formation an average of 7 tumors per control mouse and an average of only 0.2 
tumors per NE-deficient mouse. Pharmacological inhibitors of NE, 2,4,6-
trinitrochlorobenzene and oxazolone were able to attenuate the development of skin 
tumors following ultraviolet irradiation of SKH 1 mice (609). NE knockout mice were 
developed to understand the normal role of NE in immunity and inflammation (500). NE 
knockout in the transgenic loxP-Stop-loxP K-rasG12D mouse model of lung cancer 
dramatically reduced tumor burden compared to control. NE knockout significantly 
extended survival in loxP-Stop-loxP K-rasG12D mice. Over a 30 weeks period following 
administration of adenoviral Cre all of the NE+/+ genotype mice had reached the limit of 
tumor burden, however none of the NE-/- mice has reached the same limit. NE 
knockout dramatically reduced tumor growth. NE-mediated degradation of IRS-1 
resulted in the activation of the PI3K-Akt pathway and may be responsible for enhanced 
tumor growth (542).  
Hypothesis and Central Findings 
The hypothesis tested in this chapter states that NE is essential to the growth 
and progression of breast cancer. Immunohistochemical analysis of NE in breast 
tumors revealed that high levels of NE-expressing, TAN are associated with TNBC and 
are prognostic of poor recurrence-free survival (RFS). ERK-catalyzed phosphorylation 
of p90RSK (T359/S363) and Rb phosphorylation (S807/811) were significantly enriched 
in NE-positive tumors. We generated C3(1)TAg  x NE-/- mice  to directly examine the 
role of NE in TNBC development. Compared to C3(1)TAg x NE+/+ littermates, the 
C3(1)TAg NE-/- mice showed decreased tumor growth and proliferation. Although NE is 
implicated in inflammation, no statistically significant difference in the expression of 
inflammatory cytokines, neutrophil, or macrophage infiltration was observed. 
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MATERIALS AND METHODS 
The methodology for preparation of protein lysates, western blot analysis, 
growth curves, and immunohistochemistry are detailed in chapter two, modifications, 
additional reagents, and additional protocols are described here.  
Antibodies 
Primary antibodies used for western blot (WB) and immunohistochemistry (IHC): 
 
Immunohistochemistry 
IHC analysis was performed as described in chapter two. The antigen retrieval 
was omitted for NE-IHC because it destroys the epitope recognized by the antibody. For 
IHC detection of BrdU, Ly6G, and F4/80 antibodies the biotin conjugated rabbit anti-rat 
Antibody Species Clone Company Application 
Neutrophil 
Elastase 
Mouse 
monoclonal NP57 DAKO IHC 
Egr-1 Rabbit polyclonal  
Santa Cruz 
Biotechnology WB 
Phospho-
p90RSK site 
Thr359/Ser363 
Rabbit 
polyclonal  
Cell Signaling 
Technology WB 
BrdU Rat monoclonal 
BU1/75 
(ICR1) AbD Serotec IHC 
Ly6G (Gr-1) Rat monoclonal clone 1A8 
BD 
Biosciences IHC 
F4/80 Rat monoclonal 6A545 
Santa Cruz 
Biotechnology IHC 
Irs-1 Mouse monoclonal 4.2.2 Millipore WB 
Phospho-Akt Rabbit monoclonal D9E 
Cell Signaling 
Technology WB 
IκB Rabbit monoclonal 44D4 
Cell Signaling 
Technology WB 
Phospho-
GSK3β site 
Ser9 
Rabbit 
polyclonal  
Cell Signaling 
Technology WB 
SV40 large T-
antigen 
Rabbit 
polyclonal  
Santa Cruz 
Biotechnology WB 
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secondary antibody (Abcam) was substituted for the secondary goat anti-mouse 
antibody included on the Vectastain kit (Vector).  
Patient Samples 
 For analysis of NE in breast tumors, 306 patients with stage I-III breast cancer 
were enrolled in a prospective study between January 2000 and June 2010 (MD 
Anderson lab protocol 00222). Fresh frozen tumor tissue and formalin-fixed, paraffin-
embedded tissue blocks were obtained from eligible participants. The median age of the 
patient population was 56 years (range: 26-92 years) and median follow up was 6.2 
years. Complete clinical and follow-up data was obtained by review of the patients’ files.  
The MD Anderson Institutional Review Board approved the use of all patient derived 
tissues. 
Reverse Phase Protein Array (RPPA) 
Tumor tissue was thawed and homogenized using a micromincer (BioSpec) and 
prepared using the same protocol as western blot analysis described in chapter two. 
RPPA analysis performed by the Functional Proteomics core facility at UT MDACC has 
been previously described (777). Patient tumors were homogenized, lysed via 
sonication, and cleared by ultracentrifugation; as previously described for western blot 
analysis (678). Protein concentration was determined by Bradford assay and the lysates 
were aliquoted in SDS containing sample buffer at a concentration of 1µg/µL. Protein 
samples were serially diluted and arrayed on nitrocellulose coated slides (Grace Biolab) 
using an Aushon 2470 Arrayer (Aushon BioSystems). The slides are probed with 
different primary antibodies, followed by the appropriate biotin-conjugated secondary 
antibody.  The signal was amplified using the Catalyzed Signal Amplification System 
(DAKO) and detected using DAB (DAKO). The slides were scanned with ImageQuant 
(Molecular Dynamics) and spot intensity was determined by MicroVigene software 
(VigeneTech Inc.). Protein abundance was defined by supercurve fitting, a logistic 
model developed by the Dept. of Bioinformatics and Computaional Biology UT MDACC 
for the relative quantification of each sample, and normalized for protein loading.  
 178 
RPPA Antibodies 
 
14-3-3 ζ 
14-3-3 β 
4EBP1 
4EBP1 pS65 
4EBP1 pT37 
A-Raf pS299 
αTubulin 
αβ-Crystallin 
ACC pS79 
ACC1 
AIB1 
AKT 
AKT pS473 
AKT pT308 
AMPK pT172 
AMPK  
Annexin  
ARV 
ATM  
ATM pS198 
ATR pS423  
ATRIP 
Beta-Catenin 
Beta-catenin 
pS33 
B-RAF  
BAD pS112 
BAK 
BAX 
BClX 
BClXL 
BCl2 
BCl2 
BCl2 pS70 
BID 
BIM 
BRCA1 
BRCA2  
cJun pS73  
cKIT 
cMyc 
cMyc pT58 
cRAF  
Caspase 7 
cleaved  
Caspase 3 
cleaved 
Caveolin 
CD20 
CD31 
CD86 
CHK1 
CHK1 pS345 
CHK2 
Collagenase VI 
Cyclin B1 
Cyclin D1 
Cyclin E1 
Cyclin E2 
ECadherin 
EGFR  
EGFR pY1173  
EGFR pY992 
eIF4E 
ELK1 pS383 
ER pS167 
ERα pS118 
ERK2 
ETV6 
FAKC 
FGFR1 
FGFR2 
Fibronectin 
Fortilin 
FOXM1 
FOXO3a 
FOXO3a pS318 
GATA3  
GSK pS9 
GSK3 αβ 
GSK3 αβ pS21 
GYS1 
GYS1 pS640 
HER2 
HLA-E  
HSP27 
HSP70 
IGFBP2 
IGFRb 
IRS1 
IRS1 p307  
JNK pT183 
KU80  
MAPK pT202V 
MEK1  
MEK1/2 pS217 
MGMTV 
MMECD10 
MRE11 
MSH2 
mTOR  
N-Cadherin 
NFκB p65 
pS536 
p21 
p27 
p38 
p38_pT180 
p53 
p70S6K 
p70S6K pS371 
p70S6K pT389 
p90RSK 
p90RSK T359 
PAI1  
PARP cleaved 
PAX2  
PCNA 
PDK1 
PDK1 pS241 
PI3K p110α 
PKCE pT40 
PKCα 
PKCα pS657 
PKCδ pS644 
PLCR2 pY759 
PLK1 
PR 
PTCH  
PTEN 
Rab25 
RAD51 
Rb 
Rb  pS807/811 
S6 
S6 pS235 
S6 pS240 
SHC pY317 
SMAD1 
SMAD3  
SMAD3 pS423 
SMAD4 
SMAD6 
SRC 
SRC pY527 
STAT3 
STAT3 pS727 
STAT3 pY705 
STAT5 
STAT5 pY694  
STAT6 pY641 
STAT6 pY641  
Stathmin 
SYK  
TAU 
TAZ  
TAZ pS89 
Telomerase 
TSC2 
TSC2 pT1462 
VASP 
VEGFR2 
XRCC1 
YAP 
YAP pY127 
YBI 
YBI pS112 
YKL40 
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Mice 
The generation of C3(1)Tag (778) and NE knockout (500) mice were previously 
described. Both were maintained in the FVB/N background. Experimental cohorts of 
C3(1)Tag x NE-/- and C3(1)Tag x NE+/+ virgin female mice were monitored for tumor 
development by biweekly palpation. Tumor growth rate was analyzed by bi-weekly 
measurement of two orthogonal tumor diameters with a Vernier caliper. Mice were 
sacrificed when tumor reached the 1.5 cm along greatest axis according to institutional 
guidelines. Several mice were sacrificed at two months of age to assess tumor 
progression. Two hours prior to sacrifice the mice were injected intraperitoneally with 
100 mg BrdU/kg body weight. The contralateral mammary gland was fixed in formalin 
and paraffin embedding for IHC analysis. The tumor was excised, half was fixed in 
formalin and paraffin embedding for IHC analysis and the other half was snap frozen in 
liquid nitrogen for protein and mRNA extraction.  
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RESULTS 
NE-Positive TAN Predict Recurrence in Breast Cancer Patients and Correlate with 
the Phosphorylation of Erk-Effector p90RSK and Rb.  
 
To understand the role of NE in patients with invasive breast cancer, the 
correlation between NE expression, patient outcome, clinicopathological parameters, 
and intracellular signaling pathways was examined in breast tumor samples. For this 
study, we performed immunohistochemical staining for NE and elafin on 305 breast 
tumors prospectively collected from patients at The University of Texas MD Anderson 
Cancer Center for the examination of predictive markers. This patient cohort had 
advantages compared to the TMA cohort presented in Chapter 2. First, full tumor blocks 
were available, allowing our pathologists to examine representative areas of tumor 
epithelium and include the peritumoral area, where TAN often localize. Second, fresh 
frozen tissue was available from the majority (276/305) of patients, allowing us to 
perform RPPA analysis. 
We first validated the finding presented in Chapter 2 that elafin is downregulated 
in invasive breast tumors. As in Chapter 2, elafin expression was classified as at or 
above the expression level in normal breast epithelium (elafin score 6-8) or 
downregulated compared to the expression level in normal breast epithelium (elafin 
score 0-5) (Figure 39A). This analysis revealed that the percentage of tumors with elafin 
downregulation in this patient cohort was almost identical to the percentage of tumors 
with elafin downregulation in the TMA cohort presented in Chapter 2 (Figure 39B). 
Immunohistochemical analysis of NE (Figure 40A) revealed the presence of 
TAN in 118 of 305 (39%) tumors examined. Positivity was defined as greater than 5 
TAN per high-power field; only NE-positive neutrophils within the tumor area were 
counted. Breast cancer patients with high levels of TAN, defined as greater than 15 
TAN per high-power field, were present in 45 of 305 tumors (15%) and correlated with a 
significantly poorer RFS than tumors with low levels of TAN or no TAN (Figure 40B). 
High levels of TAN were significantly associated with TNBC, high tumor grade, and 
recurrence on univariate analysis (Table 9). Cox proportional hazards analysis revealed 
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that high levels of TAN were independently prognostic of RFS and were associated with 
a hazard ratio of 2.4 (95% CI, 1.1-5.5) for RFS (Table 10). 
The correlation between the NE-positive infiltrate and cancer cell signaling 
pathways was examined by subjecting tumor lysates from the 276 patients who had 
fresh frozen tissue available for RPPA analysis (Figure 41). Comparison of breast 
tumors positive for TAN (107/276) and breast tumors negative for TAN (169/276) using 
the Mann-Whitney U-test revealed differences in the abundance of several signaling 
intermediates (Table 11). High levels of p90RSK phosphorylated at threonine 
359/serine 363 (phosphorylation catalyzed by ERK) and Rb phosphorylated at serine 
807/811 were strongly associated with the presence of NE-positive TAN (Figure 42A). 
To determine if NE can induce phosphorylation of p90RSK and Rb, 76NE6 cells 
and the breast cancer cell lines MDA-MB-231 and MDA-MB-157 were cultured in the 
absence of growth factors for 24 hours and stimulated with 10 nM NE. We observed 
dose-dependent increases in cell proliferation in both tumor cell lines and 76NE6 
HMECs 48 hours after addition of NE (Figure 42B). MDA-MB-231, MDA-MB-157, and 
76NE6 cells were also harvested 30 and 120 minutes after NE addition. Western blot 
analysis revealed increased phosphorylation of p90RSK T359/S363 and Rb S807/811, 
especially in MDA-MB-157 and 76NE6 cells (Figure 42C). NE stimulation also 
enhanced phosphorylation of ERK and resulted in EGR1 upregulation in these cell lines 
(Figure 36C). Both ERK and Rb phosphorylation were largely saturated in MDA-MB-231 
cells; however, addition of NE modestly enhanced phosphorylation of p90RSK and still 
resulted in upregulation of EGR1 (Figure 42C). 
NE-positive TAN were prognostic of poor RFS, associated with an aggressive 
tumor phenotype, and correlated with the phosphorylation of p90RSK and Rb. 
Exogenous NE activates the ERK signaling pathway in immortalized HMECs and breast 
cancer cell lines.  
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Figure 39: Comparison of Elafin Expression between Breast Cancer Patient Cohorts.   
 
(A,B) Elafin expression was examined by IHC in the TMA breast cancer patient cohort 
presented in chapter 2 (Cohort 1) and in the non-TMA breast cancer patient cohort 
described in this chapter (Cohort 2). (A) Frequency distribution illustrating the 
percentage of cases falling into each categorical score over the range 0-8 for breast 
cancer patient cohorts. (B) Quantification of elafin downregulation in the two breast 
cancer patient cohorts. An elafin score of 6-8 denotes cases at or above the elafin 
expression level observed in the normal breast epithelium, while an elafin score of 0-5 
denotes downregulation.  
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Figure 40: NE-Positive TAN Predict Recurrence in Breast Cancer Patients 
 
(A) Representative photomicrographs of NE immunohistochemical staining of invasive 
breast carcinoma with negative (i), low (ii), and high (iii and iv) levels of TAN. (B) 
Kaplan-Meier plot of RFS in breast cancer patients segregated by expression of TAN, 
low/negative versus high.  
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Table 9: Univariate Analysis of Patient and Tumor Characteristic in Breast Cancer Patients with 
and without Tumor Associated Neutrophils.  
 
Tumors with high TAN were compared to tumors with low/negative TAN for their 
relationship to clinicopathological factors in breast cancer. The p-value was calculated 
by Fisher’s exact test, unknowns were excluded from the analysis.  
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Table 10: Multivariate Cox Proportional Hazards Analysis of Clinicopathologic Variables’ 
Influence on Breast Cancer Recurrence-free Survival.  
 
Multivariate analysis was performed using the whole cohort (n=305) on all 
clinicopathological except for ER, PR and tumor grade since those variables were 
highly associated with TAN in univaritate analysis.  
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Figure 41: Hierarchical Clustering of RPPA data.  
 
RPPA analysis was performed on 276 breast tumor lysates. Hierarchical clustering was 
performed on the log2-median centered values by Pearson correlation (centered) using 
the Cluster 3.0 software (Eisen Lab) and visualized as a heatmap using treeview (Eisen 
Lab). Tumors were segregated into three clusters, however these clusters did not 
correlate with ER, PR, or HER status and did not segregate NE positive and negative 
tumors. A possible explanation is the neo-adjuvant treatment of these patients. 
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Table 11: Statistically Significant Events Correlating with TAN-Positivity in RPPA Analysis.  
 
Relative abundance of critical nodes in cell signaling pathways was examined using 
RPPA with 174 validated antibodies. Statistical comparison of TAN-positive and TAN-
negative cohorts was performed using the Mann-Whitney U-test. The mean of the 
normalized, linear RPPA values are reported for each group. 
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Figure 42: NE-Positive TAN Correlate with the Phosphorylation of ERK-Effector p90RSK and Rb 
in Breast Tumors.   
 
(A) Relative abundance of pp90RSK T359/S363 and pRb S807/811, according to RPPA 
analysis. Values represent log2-median centered values. The p-value was calculated by 
Mann-Whitney U-Test. (B) Change in cell number determined by MTT assay for 76NE6, 
MDA-MB-231, and MDA-MB-157 treated with 0, 2, 4 nM NE for 48 hours (C) 76NE6, 
MDA-MB-231, and MDA-MB-157 cell were treated with 10µM NE and subjected to 
western blot for pRb, pERK, pp90RSK, and EGR-1. Actin, loading control. 
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NE Knockout Reduces Tumor Growth and Proliferation in the C3(1)TAg Model of 
TNBC 
Genetically engineered mouse models can recapitulate the progression of 
human breast cancer. Many molecular, histological, and genetic similarities exist, 
however mouse models fail to completely reproduce the molecular heterogeneity of 
human breast tumors (779-781). Based on the relatively high concentration of NE in 
NE-positive TAN observed in human TNBC patients, a mouse model of TNBC was 
considered ideal to test the hypothesis that NE plays a role in breast tumorigenesis. 
Relatively few mouse models of TNBC exist, due in part to the use of hormone 
responsive promoters to target oncogenes to the mammary epithelium. 
The C3(1)TAg mouse model has been shown to give rise to TNBC and is 
molecularly similar to basal-like breast cancer in humans (778, 779, 782, 783). In this 
model, the expression of SV40 large tumor antigen is directed to the mammary gland by 
the promoter of rat prostatic binding protein C3 (1) (Pbpc3). This results in the 
downregulation of p53 and Rb tumor suppressor pathways in the mammary epithelium. 
Atypia of the mammary ductal epithelium develops at about eight weeks of age, which 
progress to mammary intraepithelial neoplasia (resembling DCIS) at about twelve 
weeks of age.  Invasive carcinomas develop at about sixteen weeks of age in one-
hundred-percent of female mice (male mice get prostate cancer). Lung metastasis 
develop in ten to fifteen-percent of tumor bearing mice. C3(1)TAg mice are a useful and 
predictable model of TNBC development (778, 782).  
C3(1)TAg mice were crossed with the previously established NE knockout mice 
(500). C3(1)TAg x NE+/+ and C3(1)TAg x NE-/- cohorts were followed for tumor 
development for approximately 6 months, at which point all mice had developed tumors 
(Figure 43A). No statistically significant difference was found in tumor incidence 
between the C3(1)TAg x NE+/+ and C3(1)TAg x NE-/- cohorts (Figure 43A).  
Following tumor initiation, growth was followed until the tumor exceeded the 
maximal allowable size of 1.5 cm along the greatest tumor axis (Figure 43B). Doubling 
time was calculated by application of an exponential growth model. C3(1)TAg x NE-/-  
tumors demonstrated a significantly slower tumor growth rate compared to C3(1)TAg x 
NE+/+ mice (Figure 43C). To determine if the difference in tumor growth rate was due 
to altered proliferation, tumors were subjected to immunohistochemical analysis of BrdU 
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incorporation (mice were injected with 100 mg BrdU/kg body weight two hours prior to 
sacrifice) (Figure 44A). Quantification reveals significantly less proliferation in C3(1)TAg 
x NE-/- compared to C3(1)TAg x NE+/+ tumors (Figure 44B). To determine if 
differences in apoptotic cell death contribute to the observed difference in tumor growth 
between genotypes, the tumors were subjected to immunohistochemical analysis for 
cleaved caspase 3 (Figure 45A). No statistically significant difference in the number of 
cleaved caspase 3 positive cells was observed between genotypes following 
quantification (Figure 45B).  
The mammary glands of C3(1)TAg x NE-/- and C3(1)TAg x NE+/+ genotype 
mice sacrificed at two months of age were subjected to immunohistochemical analysis 
of BrdU incorporation (Figure 46A). No statistically significant difference in the 
percentage of BrdU positive cells was observed (Figure 46B). Immunohistochemical 
analysis of BrdU incorporation was also preformed in the contralateral mammary gland 
of tumor bearing mice (Figure 46C). Quantification reveals significantly lower levels of 
proliferation in the contralateral mammary glands of C3(1)TAg x NE-/- compared to  
C3(1)TAg x NE+/+ (Figure 46D). These results suggest that NE activity may be an 
important factor in the growth of pre-invasive lesion in the mammary gland. 
NE is a component of the inflammatory response. Deregulated NE activity is 
known to promote inflammatory gene expression. Deregulated inflammatory signalling 
is a critical driver of tumor proliferation, therefore we examined the expression of 
inflammatory gene expression in C3(1)TAg x NE-/- and C3(1)TAg x NE+/+ tumors 
(Figure 47). Proliferation-associated genes, Melk and Mki67, were significantly 
downregulated in C3(1)TAg x NE-/- compared to  C3(1)TAg x NE+/+ when evaluated by 
quantitative RT-PCR (Figure 47). However, evaluation of inflammatory-associated 
genes, Tnf, Il1b, Il6, Csf2, Cxcl1, Ccl3, Mmp9, and Ccl2 does not reveal a statistically 
significant difference between C3(1)TAg x NE-/- and C3(1)TAg x NE+/+ genotypes 
(Figure 47). Hierarchical clustering of inflammatory gene expression identifies a cluster 
of C3(1)TAg tumors with relatively high levels of inflammatory gene expression and a 
cluster of C3(1)TAg tumors with relatively low inflammatory gene expression. However, 
clustering based on these failed to differentiate tumors based on the NE-/- or NE+/+ 
genotype (Figure 48). Taken together these results suggest that NE may have a 
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specific role in promoting breast tumor cell growth, but not in the inflammatory 
microenvironment. 
To assure that decreased proliferation in C3(1)TAg x NE-/-  was not due to a 
decrease in the infiltration of neutrophils, immunohistochemical analysis of Ly6G (Gr-1) 
was performed (Figure 49A). Quantification of Ly6G positive neutrophils revealed no 
statistically significant difference between C3(1)TAg x NE-/- and C3(1)TAg x NE+/+ 
groups (Figure 49B). Macrophages are an abundant inflammatory component of the 
tumor microenvironment. Immunohistochemical analysis of F4/80 was performed to 
assess the concentration of macrophages within the tumor stroma where macrophages 
predominately localized (Figure 49C). Quantification of peritumoral macrophages 
reveals no statistically significant difference between the C3(1)TAg x NE-/- and 
C3(1)TAg x NE+/+ genotypes (Figure 49D).  
Western blot analysis was preformed on lysates from twelve tumors from both 
the C3(1)TAg NE+/+ and C3(1)TAg NE-/- genotypes. Several tumors from NE knockout 
mice demonstrated slightly higher levels of the NE substrate Irs-1, however the levels 
were not consistently different between genotypes and no correlation was seen with the 
phosphorylation of Akt (Ser473) or the Akt substrate GSK3β (Ser9), as previously 
reported in a lung cancer model (542). Phosphorylated Erk (Thr202/Try204), Erk 
catalyzed phosphorylation of p90RSK (Thr359/Ser363), and the Erk regulated 
transcription factor Egr-1 demonstrated no consistent difference in expression between 
the C3(1)TAg NE+/+ and C3(1)TAg NE-/- tumors. Tlr4, an extracellular receptor 
activated by NE, was consistently expressed in all samples independent of tumor 
genotype. The NF-κB pathway inhibitor IκB was not differentially expressed in C3(1)TAg 
NE+/+ and C3(1)TAg NE-/- tumors. SV40 large T-antigen was expressed at equal 
levels in both tumor genotypes suggesting that the absence of NE did not compromise 
the integrity of the C3(1)TAg model (Figure 50). 
Taken together the results presented here suggest that NE contributes to tumor 
growth and proliferation, but is not dependent on upregulation of inflammatory 
mediators.  
 
 
 192 
 
Figure 43: Tumor Incidence and Growth in C3(1)TAg x NE+/+ and C3(1)TAg x NE-/- Genotype 
Mice. 
 
(A) Kaplan-Meier analysis of tumor incidence in C3(1)TAg NE+/+ and C3(1)TAg NE-/- 
cohorts. (B) Growth kinetics for individual C3(1)TAg NE+/+ (left panel) and C3(1)TAg 
NE-/- (right panel). (C) Doubling time was calculated for all C3(1)TAg NE+/+ and 
C3(1)TAg NE-/- tumors by fitting an exponential growth model. 
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Figure 44: BrdU Incorporation in C3(1)TAg x NE+/+ and C3(1)TAg x NE-/- Genotype Tumors. 
 
(A) C3(1)TAg NE+/+ and C3(1)TAg NE-/- tumors were subjected to 
immunohistochemical analysis of BrdU incorporation. (B) BrdU positive cells were 
counted as a percentage of total cells in three representative high magnification fields 
per tumor, a total of six tumors were examined per group.  
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Figure 45: Cleaved Caspase 3 in C3(1)TAg x NE+/+ and C3(1)TAg x NE-/- Genotype Tumors. 
 
(A) C3(1)TAg NE+/+ and C3(1)TAg NE-/- tumors were subjected to 
immunohistochemical analysis of cleaved caspase 3. (B) Cleaved caspase 3 positive 
cells were counted in six representative high magnification fields per tumor, a total of six 
tumors were examined per group 
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Figure 46: BrdU Incorporation in C3(1)TAg x NE+/+ and C3(1)TAg x NE-/- Genotype Mammary 
Glands.  
 
(A) C3(1)TAg NE+/+ and C3(1)TAg NE-/- mammary gland from two month old mice 
were subjected to immunohistochemical analysis of BrdU incorporation. (B) BrdU 
positive cells were counted as a percentage of total cells in ten representative high 
magnification fields per section, a total of six sections were examined per group. (C) 
C3(1)TAg NE+/+ and C3(1)TAg NE-/- mammary gland contralateral to the tumors 
examined in Figure 39A were subjected to immunohistochemical analysis of BrdU 
incorporation. (D) BrdU positive cells were counted as a percentage of total cells in ten 
representative high magnification fields per section, a total of six sections were 
examined per group. 
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Figure 47: Quantitative PCR of Proliferation and Inflammatory Gene Expression in C3(1)TAg x 
NE+/+ and C3(1)TAg x NE-/- Genotype Tumors. 
 
(A) Quantitative RT-PCR was used to evaluated the levels of proliferation and 
inflammation-associated gene expression in C3(1)TAg NE+/+ and C3(1)TAg NE-/- 
tumors; twelve tumors were examined per group. Values were normalized to Actin 
expression and are represented relative to mean C3(1)TAg NE+/+ expression.  
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Figure 48: Inflammatory qRT-PCR Gene Signature in C3(1) TAg Tumors 
 
Quantitative RT-PCR was used to evaluated the levels of inflammation associated gene 
expression in C3(1)TAg NE+/+ and C3(1)TAg NE-/- tumors (some presented in Figure 
47). Hierarchical clustering was performed on the log2-median centered values by 
Pearson correlation (centered) using the Cluster 3.0 software (Eisen Lab) and 
visualized as a heatmap using treeview (Eisen Lab). 
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Figure 49: Neutrophil and Macrophage Infiltration in C3(1)TAg x NE+/+ and C3(1)TAg x NE-/- 
Genotype Tumors. 
 
(A) C3(1)TAg NE+/+ and C3(1)TAg NE-/- tumors were subjected to 
immunohistochemical analysis of Ly6G a specific marker of neutrophils. (B) Ly6G 
positive cells were counted in ten representative high magnification fields per tumor, a 
total of six tumors were examined per group. (C) C3(1)TAg NE+/+ and C3(1)TAg NE-/- 
tumors were subjected to immunohistochemical analysis of F4/80, a specific marker of 
macrophages. (D) F4/80 positive cells were counted in ten representative high 
magnification fields per tumor, a total of six tumors were examined per group. 
Macrophages accumulate in the peritumoral stroma, therefore representative fields 
were choose directly adjacent to the tumor epithelium. 
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Figure 50: Western Blot Analysis of Signaling Pathways Implicated in NE-Induced Proliferation in 
C3(1)TAg x NE+/+ and C3(1)TAg x NE-/- Genotype Tumors. 
 
Whole tumor lysates from 12 C3(1)TAg NE+/+ and 12 C3(1)TAg NE-/- genotype mice 
were subjected to western blot analysis for Irs-1, pAkt (Ser473), pGSK3β (Ser9), pERK 
(Thr202/Try204), Egr-1, p90RSK (Thr359/Ser363), Tlr4, IκB, SV40 large T-antigen. 
Actin, loading control. 
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DISCUSSION 
NE expression is restricted to the myeloid lineage. In normal blood, NE 
immunohistochemistry strongly stains neutrophils and only very weakly stains a 
subpopulation of monocytes. NE immunohistochemistry also stains neutrophil 
precursors in the bone marrow and can be used to identify acute myeloid leukemia cells 
(784). Tumor-promoting myeloid derived suppressor cells, a heterogeneous population 
of undifferentiated granulocytes often observed in the tumor microenvironment, have 
been reported to express NE at the mRNA level (785) and may be detected by NE 
immunohistochemistry performed on tumor sections 
Downregulation of elafin in breast tumors suggests increased sensitivity to the 
growth promoting effect of NE. NE is largely contributed by TAN within the tumor 
microenvironment (616). The ability of tumor cells to recruit and manipulate 
nonmalignant cell types, including fibroblasts, endothelial cells, and leukocytes, governs 
their malignant growth potential (786). Immunohistochemical analysis of NE in a breast 
tumor specimens revealed that high levels of NE-expressing TAN (Figure 40A). High 
levels of NE-expressing TAN were prognostic of poor RFS, high tumor grade, and a 
TNBC phenotype (Figure 40B). These results are consistent with previous studies that 
found a correlation between high levels of NE measured by ELISA and poor patient 
survival (12, 599-601). The expression of the endogenous NE inhibitor elafin was also 
evaluated by immunohistochemistry in this patient cohort. Using the cutoffs established 
in Chapter Two (Figure 10) elafin expression was found to be downregulated in the 
majority of invasive breast tumors, validating these results (Figure 39). Therefore, 
deregulated NE-activity in breast tumors is likely multifactorial, resulting from both the 
downregulation of endogenous protease inhibitors and the increased concentration of 
NE secreted by TAN during tumor progression.  
RPPA analysis of cancer cell signaling pathways revealed the enrichment of 
ERK catalyzed phosphorylation of p90RSK at T359/S363 (787) and phosphorylation of 
Rb at S807/811 in tumors with TAN (NE-positive) compared to tumors without TAN 
(NE-negative) (Figure 42A). In Chapter two, TLR4-dependent ERK activation and 
proliferation was observed following the addition of exogenous NE to G0-arrested 
HMECs. Treatment of breast cancer cell lines and immortalized HMECs with NE is 
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capable of inducing phosphorylation of p90RSK at T359/S363 and phosphorylation of 
Rb at S807/811 (Figure 42C), indicating that NE is a TAN-secreted factor capable of 
enhancing the phosphorylation of these proteins. TAN secrete an array of growth 
factors, proteases, cytokines, and ROS into the tumor microenvironment 
In our analysis, we used a cut-off of 15 TAN per high-magnification field, which 
is higher than the cut-off used to interrogate the correlation with cell signaling pathways 
by RPPA (5 TAN per high-power field). Chronic inflammation is known to be an 
important contributing factor to breast cancer recurrence (367). Use of the higher cut-off 
to identify the prognostic significance of NE-expressing TAN may identify a group of 
highly inflammatory tumors. NE-induced TLR4 activation has been shown to induce the 
expression of pro-inflammatory cytokines/chemokines (590, 737) and may have a role 
in amplifying the inflammatory response within this subset of breast tumors.  
NE-positive TAN were shown to be enriched in TNBC and high-grade tumors 
(Table 9). NE levels (measure by ELISA) have previously been shown to correlate with 
ER and PR negative status (12). TNBC highly expresses chemokines critical to the 
recruitment of TAN, especially IL-8, which may account for the increased number of 
TAN in these tumors (773-776).  
The C3(1)TAg mouse model has been shown to give rise to TNBC tumors that 
are molecularly similar to basal-like breast cancer in humans (778, 779, 782, 783). 
Therefore we utilized the C3(1)Tag model of TNBC to test the mitogenic role of NE in 
vivo. No direct homolog of elafin exists within the mouse genome (639), therefore the 
contribution of elafin downregulation to breast tumorigenesis could not be directly tested 
in vivo. NE knockout were previously generated to study the role of NE in immunity and 
inflammation (500). NE knockout was shown to limit tumor growth and progression in 
the loxP-Stop-loxP K-rasG12D mouse model of lung cancer (542). We found that NE 
knockout does not slow the kinetics of tumor progression in the C3(1)TAg model (Figure 
43A), however NE knockout does reduce tumor growth (Figure 38C) and proliferation 
(Figure 39A,B). 
C3(1)TAg tumors in NE knockout mice demonstrated significantly reduced tumor 
growth (Figure 43) and proliferation (Figure 44) compared to NE expressing controls. 
No difference in the level of TAN (Figure 49 A, B), tumor-associated macrophages 
(Figure S49 C, D), or inflammatory gene expression (Figure 47) was observed between 
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C3(1)TAg-induced tumors in NE+/+ and NE-/- genotype mice. In this model system, NE 
has a specific role in the proliferation of tumor cells, but does not appear to alter 
inflammatory signaling or the recruitment of leukocytes. A study comparing NE 
knockout and NE/PR3 dual knockout mice found that the ability of NE to cleave the anti-
inflammatory factor progranulin and enhance the inflammatory response could be 
compensated for by PR3 (538). In humans, elafin inhibits both NE and PR3 (13), 
therefore downregulation of elafin may more broadly sensitize tumors to changes in 
inflammatory signaling.  
The data presented here and elsewhere (508, 542) demonstrate a role of 
deregulated NE activity in tumor growth and progression, suggesting that NE is an 
important therapeutic target in cancer 
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Chapter 5: General Discussion 
 
Elafin is Downregulated During Breast Cancer Progression 
Inducible and Systemic Protease Inhibitors 
Elafin is an endogenous inhibitor of the serine proteases NE and PR3. Epithelial 
cells are known to express high levels of elafin in response to pro-inflammatory 
cytokines (i.e IL-1β and TNF-α) (13, 647). The p38 MAPK, c-JUN, and NF-κB pathways 
are essential to inducible elafin expression (646, 648, 649). In contrast, systemic serine 
protease inhibitors, such as α1-antitrypsin and α1-antichymotrypsin, are constitutively 
expressed by the liver and diffuse into tissues from the circulatory system. Systemic 
protease inhibitors provide essential baseline control of NE activity; however, they are 
insufficient to control the high concentrations of neutrophil-secreted NE at sites of 
inflammation. In this context, elafin is an essential barrier against the deleterious effects 
of excessive NE activity and necessary for the normal resolution of inflammation (645, 
646).  
Elafin Expression in Human Tissue Under Normal and Disease Conditions 
The normal epidermis does not express elafin (647), however inflammation 
associated with the hyperproliferative disease psoriasis or experimental wounding was 
found to enhance elafin expression (650-653). Elafin expression can be detected in 
bronchial secretions and is hypothesized to be a biomarker of inflammatory lung 
disease (788, 789). Elafin may also be a biomarker of autoimmune graft versus host 
disease based on the expression of elafin in the skin rash characteristic of the disease 
(790). In the endometrium, elafin is highly upregulated during menstruation, suggesting 
that elafin has a role in physiological tissue remodeling (655). Constitutive elafin 
expression has been observed at mucosal surfaces, including the tongue, tonsils, 
gingiva, epiglottis, esophagus, vagina, and pharynx (647). In addition to its protease 
inhibitory capacity, elafin also has anti-microbial and immune functions, which likely 
underlies its constitutive expression at mucosal surfaces. Immunohistochemical 
analysis of elafin expression was performed on several normal human tissues, in 
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parallel with specimens of normal breast tissue, DCIS, and invasive breast presented in 
figure 10. This analysis revealed that elafin was expressed by the normal endometrium, 
kidney, spleen, colon, and mammary gland, but not the prostate (Figure 51).  
Inadequate expression or absence of elafin has been observed in disease states 
characterized by chronic or excessive inflammation, including acute respiratory distress 
syndrome (14), inflammatory bowel disease (15), and acute lung injury (16). These 
studies suggest that deregulated NE plays an important role in the pathogenesis of 
inflammatory disease. NE has been shown to participate in tissue destruction and 
fibrosis associated with several inflammatory diseases. In COPD and emphysema, NE 
is viewed as a critical therapeutic target in preventing tissue destruction in inflammatory 
lung diseases(791). 
The tumor microenvironment is characterized by extensive recruitment of 
inflammatory cells and altered production of inflammatory mediators. The inflammatory 
components of the tumor microenvironment are indispensible to tumor progression(9). 
Several studies suggest that loss of elafin-mediated control of NE-activity is a feature of 
malignant growth. Elafin is downregulated in poorly differentiated squamous cell 
carcinomas of the skin, head/neck, and esophagus compared to well-differentiated 
tumors (21, 22). In the majority of melanoma and breast cancer cell lines elafin is 
downregulated compared to normal HMECs and melanocytes (23, 26). These studies 
served as the rationale to examine elafin expression in human tumors 
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Figure 51: Immunohistochemical Analaysis of Elafin in Normal Human Tissues. 
 
Elafin expression was evaluated by immunohistochemistry in the normal endometrium 
(A), kidney (B), prostate (C), spleen (D), colon (E), and mammary gland (F). 
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Immunohistochemical Analysis of Elafin Expression During Breast and Ovarian 
Cancer Progression 
As a first step in establishing a role for elafin in tumorigenesis, 
immunohistochemical analysis of elafin was performed on normal breast tissue from 
reduction mammoplasty, DCIS, and invasive breast carcinoma specimens (701). This 
analysis revealed that elafin is highly expressed in the normal mammary epithelium, but 
downregulated in the majority of invasive tumors and a subset of DCIS (Figure 10). To 
determine if elafin downregulation is a generalizable event during tumorigenesis, elafin 
immunohistochemical analysis was performed on normal fallopian tube, ovarian 
cystadenomas, borderline tumors, and invasive ovarian carcinoma specimens (792). 
The majority of ovarian cystadenomas and borderline tumors examined maintained 
elafin expression at levels similar to the normal epithelium, however elafin expression 
was downregulated in the majority of invasive ovarian tumors (Figure 12). 
Elafin loss in the majority of invasive breast tumors compared to pre-invasive 
tumors suggests that elafin is specifically switched off as tumors achieve a malignant 
phenotype. This expression pattern suggests that elafin has tumor suppressive 
properties early during breast cancer development. Maspin, a member of the serpin 
family of serine protease inhibitors, was previously reported to have tumor suppressive 
properties in breast cancer (741, 746, 747). Similar to elafin, maspin expression was 
originally identified as highly expressed in HMECs, but downregulated in breast tumor 
cell lines (740, 741). Immunohistochemical studies observed mapsin downregulation in 
melanoma, breast, prostate, and gastric cancers (742-745). Continued research is 
necessary to determine if elafin has a bona fide tumor suppressive role in breast 
tumorigenesis similar to maspin. 
Future Direction: Evaluating Elafin as a Prognostic Biomarker in DCIS 
In this study elafin expression was not prognostic of survival in breast or ovarian 
cancer patients (Figure 11 and 13). However, given the preponderant loss of elafin in 
invasive compared to pre-invasive tumors, elafin downregulation may identify early 
neoplasias likely to progress to invasive carcinoma. We were unable to evaluate the 
prognostic significance of elafin in pre-invasive lesions using the patient cohorts 
presented due to insufficient statistical power and inadequate follow-up. Elafin 
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downregulation as a prognostic marker of progression in pre-invasive breast DCIS is a 
particularly interesting hypothesis to be tested if an adequate patient cohort becomes 
available.  
Over the last several decades, increased mammographic screening has 
contemporaneously led to an increased frequency of DCIS diagnosis. The risk of a 
subsequent invasive tumor event, following diagnosis of DCIS, is not associated with 
patient age, race, menopausal status, or a family history of breast cancer. Detection of 
DCIS by palpation rather than mammography is associated with an increased risk of 
developing invasive breast cancer. Large tumor size (greater than 10 mm), positive 
margins, high/intermediate nuclear grade, and the extent or type (comedo) of necrosis 
are also associated with an increased risk of developing invasive breast cancer. There 
are currently no reliable molecular biomarkers capable of identifying women diagnosed 
with DCIS at high risk of developing subsequent invasive carcinoma. Such a prognostic 
marker could be utilized to better stratify DCIS patients into a cohort requiring extensive 
therapy and a cohort better served by limited intervention (793).  
Following lumpectomy alone approximately 8% of women diagnosed with DCIS 
will develop ipsilateral invasive breast cancer within 5-years. The addition of radiation 
therapy reduces the rate of a subsequent invasive event to approximately 3% (794). 
The low rate of progression limits the ability to develop a sufficiently powered cohort of 
DCIS patients for the identification of prognostic markers. Very few studies have 
overcome this barrier to the study of prognostic markers in DCIS. A recently published 
exception examined a cohort of 1162 women diagnosed (between 1983 and 1994) with 
DCIS and treated by lumpectomy alone. Specimens from these patients were subjected 
to immunohistochemical analysis for ER, PR, Ki67, p53, p16, HER2, and COX-2. This 
study reveals differences in the prognostic factors that are associated with DCIS 
recurrence and progression to invasive disease. High Ki67, p16, and COX-2 were 
shown to be associated (independently and together) with increased risk of invasive 
breast cancer (793).  
Elafin may have prognostic significance in DCIS patients that could be evaluated 
through by immunohistochemical evaluation of elafin downregulation in a large cohort of 
DCIS patients with sufficient follow-up.  
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Future Direction: Evaluating the Impact of Polymorphism in the PI3 (Elafin) and 
ELA2 (NE) Genes on Breast Cancer Incidence 
The majority of hereditary breast cancer risk is dependent on the combinatorial 
effect of several moderate and low penetrance gene variants. Polymorphisms in the PI3 
and ELA2 genes have never been examined in a cohort of breast cancer patients 
versus controls. The hypothesis that an association exists between polymorphisms in 
these genes and breast cancer incidence could be tested to evaluate an etiological role 
for deregulated NE activity in breast cancer 
Variants in the PI3 gene encoding elafin are associated with the incidence of 
acute respiratory distress syndrome (ARDS), an disease of excessive lung 
inflammation. Comparing 449 ARDS patients with 1031 controls a significant 
association between ARDS and rs2664581 (resulting in an amino acid substitution, 
elafin T34P). The rs2664581 polymorphism in PI3 was associated with a lower serum 
concentration of elafin (666).  
Polymorphisms in the promoter region of the ELA2 gene encoding NE are 
associated with lung cancer incidence. Comparing 348 lung cancer patients and 299 
controls identified an association between lung cancer and two polymorphisms in the 
ELA2 promoter -903T/G and -741G/A. A genotype of -903TT was associated with a 2.3 
fold greater risk of developing lung cancer, while the -741GG genotype was associated 
with a 1.4 fold higher risk. Luciferase reporter analysis of both polymorphisms found 
that they substantially increase ELA2 promoter activity (604). A subsequent study 
confirmed this association and identified additional polymorphisms in the ELA2 
promoter, including -832G/T and -789C/T, that are associated with lung cancer 
development(795). Another study found no association between polymorphism in the 
ELA2 gene/promoter and either lung cancer or COPD (796). Polymorphisms in the 
ELA2 have also been identified as associated with coronary heart disease (797). 
A Novel Role for Elafin in Growth Control by Opposing Deregulated NE-Activity 
Conventionally Understood Role of Elafin in Inflammatory Disease 
Mouse models of elafin overexpression are protected from tissue destruction 
associated with experimental colitis (667), resistant to acute lung injury (20), 
demonstrate reduced pulmonary hypertension following chronic hypoxia (19), and 
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improved heart function after viral myocarditis (18) or myocardial infarction (17). The 
protease inhibitory capacity of elafin is essential to its anti-inflammatory role in mouse 
models of emphysema (636). Elafin also has anti-inflammatory properties independent 
of its anti-protease activity. Elafin directly reduces NF-κB activation in monocytes 
exposed to LPS through a protease-independent effect on the ubiquitination of NF-κB 
pathway inhibitor IκB (673). Inducible elafin expression is critical to attenuation of 
inflammation, prevention of tissue destruction, and preservation of organ function. 
Inflammation in the Normal Mammary Gland and Tumorigenesis 
Inflammatory signaling networks and cell types play essential roles in the 
growth, development, and function of the mammary gland. The NF-κB pathway is 
essential to lobuloaveolar proliferation and differentiation (232). Csf-1 knockout mice 
are deficient in macrophages and demonstrate impaired branching morphogenesis 
(217). Mmp-2 knockout mice are incapable of invasion at TEBs and Mmp-3 knockout 
mice are deficient in lateral side branching (186). Cytokine signaling through Stat3 
initiates involution of the mammary epithelium, a process characterized by the 
infiltration of macrophages and neutrophils (244, 798).  
Perturbations in inflammatory signaling and the integrity of ECM are involved in 
mammary tumorigenesis (8). In mouse models, inflammatory cells are recruited to early 
adenomas and non-invasive mammary intraductal neoplasia (799) and are detected 
throughout tumor progression (800). The recruitment of leukocytes is essential to early 
breast tumorigenesis, growth, and progression (344, 386, 398, 801). Sub-clinical, 
chronic inflammation is a significant risk factor for the development of human breast 
cancer (127, 128). Examination of normal breast tissue obtained from reduction 
mammoplasty confirms that neutrophils (CD15+CD11b+CD49d-) are abundantly present 
even in the absence of neoplasia (802). High levels of NE in breast tumors correlates 
with poor patient outcome and resistance to therapy (12, 599-601). Studies examining 
the presence of neutrophils within normal breast tissue and during breast cancer 
progression are limited. However, the available evidence suggests that neutrophils 
localize to the mammary gland and are present throughout breast tumorigenesis. The 
role of neutrophils in the normal mammary gland and during breast tumorigenesis is 
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poorly understood. A role for the NE activity has never been considered in breast 
tumorigenesis.  
A Role for Elafin in Growth Control  
Immunohistochemical analysis revealed that elafin was highly expressed in the 
normal mammary epithelium. Corroborating this result, HMECs were previously found 
to express high levels of elafin in cell culture experiments (23). Elafin is downregulated 
during breast tumorigenesis. To understand the role of elafin in the mammary 
epithelium and the impetus for its downregulation during tumorigenesis we employed 
HMECs as a model system.  
Elafin is highly expressed by growth factor deprived G0 HMECs compared to 
HMECs proliferating in growth factor containing media or arrested within the cell cycle 
(Figure 14 and 15). This result suggests a previously unrecognized role for elafin in 
growth control. Elimination of G1/G0 checkpoint control by downregulation of the Rb 
tumor suppressor results eliminates the ability of HMECs to enter G0 and upregulate 
elafin (Figure 18 and 20). C/EBP β sites (24) in the elafin promoter are also necessary 
for expression of elafin in G0 HMECs (Figure 17). The integrity of the Rb and C/EBP β 
pathways are likely essential to the constitutive expression of elafin in the normal breast 
epithelium. Dominant negative C/EBP β is predominately expressed (as a ratio to full-
length, activating isoforms) in a large proportion of breast tumors (24). The Rb tumor 
suppressor is inactivated by directly by mutation and allelic loss and indirectly by 
alteration in proteins controlling Rb levels and activity(85). 
Elafin knockdown HMECs fail to maintain G0-arrest during long-term growth 
factor deprivation. The elafin protease inhibitory domain is essential to its anti-mitogenic 
capacity (Figure 21). Elafin knockdown HMECs demonstrate increased sensitivity to the 
growth promoting effect of exogenous NE (Figure 22). Several published studies have 
demonstrated increased proliferation following addition of exogenous NE (542, 676, 
736). In vivo the application of NE to the mouse epidermis results in proliferation, 
whereas application of elafin can prevent epidermal proliferation (676). Mechanistically, 
TLR4 dependent ERK activation is essential to the growth promoting effect of NE 
(Figure 25). Overall, these results suggest that elafin is an essential component of 
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epithelial growth control as a critical counterbalance against mitogenic effect of NE in 
normal epithelial cells.  
Future Direction: In Vivo Role of Protease Inhibitors in Breast Tumorigenesis 
Mice do not have a direct elafin homolog. However, secretory leukocyte 
peptidase inhibitor (Slpi) shares structural similarity with the elafin WAP domain and has 
the capacity to inhibit NE. Unlike elafin, Slpi is incapable of inhibiting Pr3 and can inhibit 
trypsin, chymotrypsin, and cathepsin G.  
Experimental evidence from mouse models of inflammatory disease suggests 
that Slpi is a critical counterbalance against deregulated NE activity. The colonic 
epithelium of thymic stromal lymphopoetin (Tslp) knockout mice orally administered 
dextran sodium sulfate (DSS) failed to upregulate Slpi, demonstrated high NE activity, 
and were unable to recover from colitis compared to controls. Administration of 
recombinant Slpi or the NE inhibitor sivelestat enhanced recovery from DSS-induced 
colitis in Tslp knockout mice (803). Slpi knockout mice demonstrate impaired healing 
following cutaneous wounding. Wounding healing in Slpi knockout mice was 
characterized by increased inflammation, excessive production of Tgfβ, and high NE 
activity (804). Progranulin (also known as proepithelin) is a critical growth and 
regulatory factor in the wound healing response. NE cleaves progranulin into a form that 
is detrimental to normal wound healing. Addition of full-length progranulin to the wounds 
of Slpi knockout mice restores the wound healing response (539). Roles for Slpi in 
inflammation and immunity have also been identified independent of its anti-protease 
capacity (805, 806). 
Studies investigating the role of SLPI in cancer have often arrived at seemingly 
incompatible conclusions. SLPI has been shown to have tumor promoting (760-763) 
and tumor suppressive effects (761, 764, 765) in xenograft mouse models. In these 
experiments, SLPI was overexpressed in tumor-derived cell types prior to ortotopic or 
sub-cutaneous injection. The pro-tumor effects of SLPI overexpression appear to be 
independent of its anti-protease activity (760) and highly dependent on the tumor type 
being examined (761). Anti-tumor effects were exclusively observed in mammary tumor 
xenografts (761). 
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A more complete understanding of Slpi-mediated protease inhibition could be 
obtained by crossing the Slpi knockout mouse with transgenic breast tumor models. 
This experiment would test the hypothesis that disequilibrium between NE and its 
inhibitor Slpi promotes breast tumorigenesis and progression in vivo. The contribution of 
inflammatory processes to breast tumorigenesis has previously been examined in the 
MMTV-PyMT transgenic mouse model. MMTV-PyMT tumors demonstrate abundant 
infiltration of neutrophils (presumably expressing NE). The progression of MMTV-PyMT 
tumors has been carefully delineated making it possible to examine the effects of 
changes in NE activity throughout tumor progression (800). MMTV-PyMT tumors are 
also highly metastatic, making this transgenic model ideal for the study of deregulated 
NE in metastatic breast cancer. In chapter 4, the C3(1)TAg model was utilized to 
understand the role of NE in TNBC. In this model, NE knockout significantly reduced the 
level of proliferation (Figure 44). Knockout of Slpi in these mice may enhance 
proliferation in tumors and pre-invasive lesion. C3(1)TAg are not highly metastatic, a 
major drawback to this model.  
Future Direction: The Role of TLR4 in Breast Tumorigenesis 
TLRs recognize molecules derived from invading microbes, termed pathogen-
associated molecular patterns, and are essential to the innate immune response. TLR4 
specifically recognizes lipopolysaccharide (LPS). Activation of TLR4 by LPS requires 
several auxiliary proteins, including LBP and CD14, and the co-receptor MD-2. 
Stimulation of TLR4 by LPS results in the intracellular recruitment of adaptor proteins 
MyD88 and TRIF, which activates of the NF-κB, ERK, and JNK pathways leading to the 
expression of pro-inflammatory cytokines and interferons (807). Treatment of murine 
macrophages with NE resulted in the upregulation of cytokines Tnfa, Il1b, Cxcl1, and 
Il6, while Tlr4 knockout macrophages are incapable of upregulating these cytokines 
upon NE stimulation (597). In bronchial epithelial cells NE induced IL-8 expression 
through TLR4 activation (590). Direct proteolysis of TLR4 by NE has been reported 
(737). However, the NE cleavage sites on TLR4 have not been identified. Mapping the 
cleavage of TLR4 by mass spectrometry or another biochemical technique is important 
to the development of a complete understanding of NE-induced TLR4 activation. The 
effect of NE-mediated cleavage on the recruitment of auxiliary proteins and the 
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activation of downstream signaling must also be resolved by biochemical analysis. The 
relevance of NE-mediated cleavage of TLR4 to human breast tumorigenesis is an 
important question. Antibodies that identify cleaved and uncleaved TLR4 could facilitate 
detection of truncated forms in tumors (737).  
Tumor cells have been shown to express TLR4, however the expression of 
TLR4 is highest in macrophages, dendritic cells, and other immune cell types within the 
tumor microenvironment (808, 809). TLR4 activation can result in the activation of 
iNOS, IL-6, uPA, IL-10, IL-8, TGFβ, and VEGF (809, 810), factors with known roles in 
tumor growth and progression suggesting that TLR4 has pro-tumorigenic properties. In 
chronic liver disease, intestinal bacterial infiltrate the liver and result in the activation of 
TLR4. Activation of TLR4 in the liver is critical to the development and progression of 
heptacellular carcinoma in mouse models (811). In experimental models of breast and 
ovarian cancer, downregulation of TLR4 has been shown to reduce the growth and 
progression of xenograft tumors (812, 813). 
Microbial-derived TLR4 ligands are not found at many sites of tumor initiation, 
including breast and ovarian cancer (808). Endogenous ligands of TLR4 are believed to 
play an important role in the activation of TLR4 in these tumors. High-mobility group 
box-1 (HMGB1) has been identified as an endogenous ligand of TLR4 (809). HMGB1 is 
a nuclear protein that is secreted by necrotic cells (814, 815). NE may be an important 
instigator of TLR4 activation during inflammatory conditions (590, 597).  
TLR4 can also play a role in anti-tumor immunity. In breast cancer patients 
treated with chemotherapy or radiotherapy, HMGB1 released by dying cells activates 
TLR4 expressing dendritic cells resulting in an anti-tumor immune response. Patients 
with a TLR4 loss of function allele relapse earlier following chemotherapy or 
radiotherapy compared to patients with fully functional TLR4 indicating that initiation of 
an innate immune response is an indispensible component of cancer therapy (816).  
The available evidence suggests that TLR4 activation can dramatically enhance 
pro-tumorigenic cytokine and growth factor signaling or initiate anti-tumor immunity 
depending on context and the cell type affected. Mice bearing a point mutation to the 
third exon of Tlr4 (resulting in a proline to histidine substitution at position 712) have 
been developed. These mice demonstrated defective Tlr4 activation following LPS 
stimulation and extreme susceptibility to bacterial sepsis (817). To test the hypothesis 
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that epithelial Tlr4 promotes tumorigenesis, the mammary epithelium from mice 
transgenic for MMTV-PyMT and mutant TLR4 can be transplanted into the cleared 
mammary fat pad of wild type. To test the hypothesis that Tlr4 in the stromal 
compartment accelerates tumorigenesis the MMTV-PyMT transgenic mammary gland 
expressing wild type Tlr4 can be transplanted into the cleared mammary fat pad of Tlr4 
mutant mice. Adoptive transfer of TLR4 mutant bone marrow into MMTV-PyMT 
transgenic mice could be used to test the hypothesis that Tlr4 activation leukocytes 
promotes tumorigenesis. Alternatively, to test the hypothesis that leukocyte Tlr4 is 
essential to the anti-tumor response these mice could be treated by irradiation or 
chemotherapy and evaluation of tumor regression. 
Conditional TLR4 knockout mice have been recently developed (818) providing an 
alternative model to specifically eliminate TLR4 expression from the mammary 
epithelium and specific cell types within the bone marrow or stromal compartments.  
Elafin has Tumor Suppressive Properties 
Published studies have observed downregulation of elafin in breast tumor 
derived cell lines compared to HMECs (23, 24). To test the hypothesis that elafin has 
tumor suppressive properties, elafin was expressed in breast tumor-derived cell lines 
using an adenoviral vector. Elafin expression caused cell cycle arrest in breast cancer 
cell lines expressing the Rb tumor suppressor. However, in breast cancer cell lines 
lacking Rb, elafin expression induces apoptotic cell death (Figure 31). Elafin expression 
does not affect HMECs, which endogenously express elafin. However, HMECs with a 
compromised Rb-dependent, G1-checkpoint fail to express endogenous elafin and are 
sensitive to the adenoviral elafin-induced apoptotic cell death (Figure 30). Overall, the 
expression of elafin causes cell cycle arrest or apoptosis in breast tumor derived cell 
lines depending on Rb status, but does not affect normal HMECs with an intact G1 
checkpoint Elafin represents a candidate therapeutic capable of specifically targeting 
tumor cells with disruption of the G1 checkpoint with no toxicity in normally dividing 
cells. 
Since the publication of this work (678), intratumoral injection of adenoviral elafin 
into MDA-MB-468 xenograft tumors was shown to reduce tumor burden and prolong the 
survival of mice (25). Elafin re-expression using a tet-inducible system resulted in 
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apoptotic cell death in melanoma cells, but not normal melanocyte. In melanoma 
xenografts, expression of elafin significantly reduced tumor size (27). 
Future Direction: Identification of the Mechanism by which Elafin Induces 
Apoptotic Cell Death 
The work presented here and elsewhere (25-27), reporting the ability of elafin to 
induce apoptosis in breast and melanoma cell lines, does not address if the apoptotic 
effect of elafin is protease dependent or independent. NE expression has previously 
been characterized in tumor cell lines (25, 617, 735). In experimental models, 
pharmacological NE inhibitors were able to attenuate the development of skin tumors, 
reduce growth and metastasis in a lung xenograft model, and inhibit 
proliferation/chemotaxis of pancreatic cells (603, 606, 607, 609). Knockdown of NE has 
been shown to decrease migration and growth of breast tumor cell lines (25, 617). In 
these experiments no effect was observed on cell survival, however MDA-MB-231 cells 
were the predominately utilized model system. In Figure 34, MDA-MB-231 cells were 
not sensitive to the apoptotic effect of elafin unless Rb was experimentally 
downregulated. To address the hypothesis that the apoptotic effect of elafin on breast 
cancer is protease dependent, previously reported mutations to the protease inhibitor 
domain of elafin that inactivate its anti-protease activity should be utilized (636). 
Inducible expression of these mutants elafin M25G and elafin M25K should be 
evaluated by TUNEL and BrdU incorporation in the panel of cell lines that are sensitive 
to elafin-induced growth arrest (MCF-7, ZR75-1, and T47D) and apoptosis (MDA-MB-
157, MDA-MB-436, and MDA-MB-468). 
Future Direction: Therapeutic Reactivation of Elafin in Breast Tumors 
In xenograft models, adenovirus was directly injected into tumors (25), while this 
is an excellent proof of principle it is unlikely to be a viable clinical strategy given the 
clinical restraints on gene therapy. However, a pharmacologically active compound 
capable of inducing elafin re-expression in tumor cells could be a clinically translatable.  
In melanoma cell lines, normally lacking elafin expression, treatment with a DNA 
methyltransferase inhibitor induced the expression of elafin. The elafin promoter was 
not directly methylated in melanoma cells. Demethylation of the FOXA2 promoter 
resulted in restoration of FOXA2 levels and elafin transcripiton. In these experiments, 
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elafin knockdown melanoma cells demonstrate reduced sensitivity to apoptotic cell 
death induced by DNA methyltranferase inhibitor (26). This experiment suggest that 
elafin reactivation by therapeutics may be an important determinate of cytotoxicity.  
Oltipraz is a chemopreventative agent that has been shown to induce C/EBP β 
DNA binding and activation of gene transcription both in vivo and in vitro (819-824). 
Oltipraz has been used in clinical trials as both a chemopreventative agent (825) and in 
the treatment of patients with liver fibrosis and cirrhosis (821), however the results of 
these studies are inconclusive. C/EBP β is essential to the expression of elafin in 
HMECs and deregulation of C/EBP β is responsible for elafin downregulation in breast 
cancer cell lines (24). Therefore, oltipraz may be capable of enhancing the transcription 
of elafin in breast tumor cells and may be a promising anti-cancer agent. 
The ability of oltipraz to induce elafin expression should be examined, 
particularly in Rb-negative breast cancer cell lines. To determine if oltipraz can induce 
apoptotic cell death through elafin upregulation, Rb-negative breast cancer cell lines 
expressing elafin shRNA can be treated with the oltipraz. If these experiments, prove 
successful, pre-clinical models combining elafin-inducing oltipraz with traditional 
chemotherapy or targeted therapies could be tested.  
More specific elafin-inducing drugs could be identified using the previously 
established elafin luciferase reporter system (24). This system consists of a firefly-
luciferase promoter constructs containing the 440 bp proximal elafin promoter 
(pSPL440) and the 440 bp proximal elafin promoter with mutations to C/EBPβ binding 
sites 4 and 5 (pSPL440m4/5), which are critical to elafin transcription. Breast cancer cell 
lines stably incorporating these plasmids could be used to screen for drugs that potently 
induce elafin expression specifically through C/EBPβ. NF-κB-dependent (717) 
expression of elafin has been described in response to pro-inflammatory cytokines, 
especially IL-1β and TNF-α (646, 647). Avoiding drugs that induce elafin through this 
pathway is important given the tumor promoting effect of NF-κB. 
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Neutrophil Elastase Promotes Breast Cancer Growth In Vivo 
Conventionally Understood Role of NE in Inflammation and Tumorigenesis 
NE is normally sequestered within the azurophilic granules of neutrophils and is 
essential to the intracellular destruction of pathogens following phagocytosis at sites of 
infection (500). Activated neutrophils secrete NE into the extracellular environment. 
Extracellular NE activity is associated with degradation of the ECM and disruption of cell 
adhesion, which plays a role in tumor invasion and metastasis. NE has also been 
implicated in the alteration of cytokine and chemokine signaling resulting in increased 
infiltration and activation of pro-inflammatory cell types. The conventionally understood 
role of NE in tumor progression emphasizes the importance of NE in cell invasion and 
metastasis, through ECM degradation and the cleavage of adhesion molecules (610). 
Role of NE in Intracellular Signaling 
Several groups have demonstrated a role for NE in intracellular signaling. NE 
activates cell surface receptors, including TLR4 (590), proteinase-activated receptor 2 
(PAR2) (521), and epidermal growth factor receptor (EGFR) (681), either directly 
through proteolysis of the extracellular domain or indirectly through the 
liberation/activation of latent ligands within the ECM (506). These pathways have never 
been studied in tumorigenesis and are largely known from examining the role of NE in 
inflammatory lung disease. Tumor cells demonstrate the capacity to endocytos NE from 
the extracellular microenvironment. Intracellular NE was shown to enhance 
phosphoinositide 3-kinase (PI3K) activity following the degradation of insulin receptor 
substrate-1 (542). NE has also been implicated in cleavage of cyclin E into low-
molecular weight isoforms capable of hyperactivating cyclin-dependent kinase 2 and 
inducing tumor formation in mouse models (541, 624).  
Tumor Associated Neutrophils and NE in Tumorigenesis and Progression 
Tumor-infiltrating neutrophils (TAN) are recruited by cancer cell-derived 
chemokines (368) and are prognostic of poor patient outcome in several tumor types 
(410, 826). Depletion of neutrophils or disruption of neutrophil chemotaxis inhibits tumor 
growth, angiogenesis, and metastasis in mouse models of tumor progression (415-417). 
NE knockout in the loxP-Stop-loxP K-rasG12D mouse model of lung cancer severely 
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limits tumor growth and proliferation, providing direct in vivo evidence of a role for NE in 
lung tumorigenesis (542). NE-mutant mice ware protected from skin carcinogenesis 
following ultraviolet irradiation and benzopyrene exposure (609).  
The evaluation of NE by immunohistochemistry reveals that high levels of NE-
expressing, tumor-associated neutrophils were prognostic of poor recurrence-free 
survival and correlate with intracellular signaling events. This observation is consistent 
with several previous studies that measure NE in breast tumors by ELISA, which found 
a strong correlation between high levels of NE and poor patient outcome (12, 599-601).  
Reverse phase protein array (RPPA) analysis of critical signaling pathways 
revealed a correlation between NE-expressing neutrophils and phosphorylation 
p90RSK (ERK-dependent) and Rb. In chapter 2, TLR4 dependent ERK activation was 
found to be essential to the growth promoting effect of NE. Previously published studies 
have also observed that NE can induce ERK signaling. (681). An enrichment of ERK-
specific phosphorylation of p90RSK in NE-positive tumors suggests that this 
observation is an important downstream effector of TAN capable of inducing ERK 
signaling and cell proliferation.  
NE-positive TAN were associated with TNBC and high-grade tumors. High NE 
expression (determined by ELISA) was previously shown to negatively correlate with 
tumor ER and PR status (12). TNBC highly expresses chemokines critical to the 
recruitment and activation of TAN, including IL-8 and IL-6 (773-776). Based on the high 
concentration of NE-positive TAN in TNBC we chose to examine the role of NE in a 
mouse model of TNBC. The C3(1)TAg mouse model has been shown to give rise to 
TNBC tumors (778, 779, 782, 783). NE knockout does not slow the kinetics of tumor 
progression in the C3(1)TAg model (Figure 43A), however NE knockout does reduce 
tumor growth (Figure 38C) and proliferation (Figure 39 A, B).  
By extending the role of NE beyond tumor cell invasion, our results argue that the 
application of therapeutic modalities targeting NE activity could inhibit multiple elements 
of tumor growth and progression. NE inhibitors are currently under development for the 
treatment of chronic inflammatory lung diseases. This study positively contributes to the 
rationale for examination of these inhibitors as anti-cancer agents. Many studies 
suggest that the recruitment of non-malignant cell types is an essential component of 
breast tumor progression. Targeting essential crosstalk between the tumor epithelial 
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compartment and the stromal microenvironment is a promising approach to anti-cancer 
therapy. 
The NE inhibitor sivelestat, was able to reduce the proliferation, motility, and 
chemotaxis of the pancreatic cancer cell line Capan-1 in vitro (603). In a mouse 
xenograft model of non-small cell lung cancer using the EBC-1 and PC-1 cell lines, 
sivelestat attenuates proliferation and metastasis (606). Sivelestat also inhibited 
spontaneous metastasis of EBC-1 xenograft tumors (607). Beige mice are deficient in 
NE (608). Pharmacological inhibitors of NE, 2,4,6-trinitrochlorobenzene and oxazolone 
were able to attenuate the development of skin tumors following ultraviolet irradiation 
(609). 
Future Directions: Alternatives to the C3(1)TAg Model to Determine a Role for NE 
in Metastatic Breast Cancer 
C3(1)TAg tumors were poorly metastatic. The lungs of C3(1)TAg tumor bearing 
mice were inflated with formalin, fixed, paraffin-embedded, and sectioned for 
immunohistochemical analysis. Following staining with an antibody specific to SV40 
large T-Antigen (data not shown) only 4 out of 49 mice had metastatic lesions (two were 
of the NE+/+ genotype and two of the NE-/- genotype). Interestingly, the NE+/+ mice 
with metastatic lung lesions had a greater number of foci and larger lesion size than 
NE-/- mice, however no conclusions could can be drawn about the influence of NE on 
metastasis in this model. The MMTV-Wnt1 mouse models and the BRCAfl/flp53+/- also 
generate tumors with a TNBC phenotype, however they are also poorly metastatic (827, 
828). To test a role for NE in metastatic breast cancer the NE knockout could be 
examined in the MMTV-PyMT transgenic model, which is highly metastatic (404, 779). 
Alternatively, in vivo passaging of the C3(1)TAg tumors could be performed to create 
transplantable mouse tumors with increased metastatic proclivity and then injected into 
the mammary fat pads of NE+/+ and NE-/-. 
Future Directions: Development of Pre-Clinical Models of NE-Inhibition in Breast 
Cancer. 
AZD9668, a pharmacological NE inhibitor, was well tolerated by healthy 
individuals and was found to possess favorable pharmacokinetics in phase I clinical 
trials (829). In phase II clinical trials, AZD9668 did not alleviate the symptoms of COPD 
patients (598, 830) and had limited benefit in patients with bronchiectasis and cystic 
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fibrosis (831, 832). AZD9668 diminished levels of pro-inflammatory biomarkers in the 
bloodstream and levels of NE specific elastin catabolites, desmosine and isodesmosine 
in the urine (831, 832). Collectively, these studies suggest that AZD9668 is not an 
effective therapy in inflammatory lung disease. However, these studies were relatively 
short term (less than one month) and the results of future long term clinical trials should 
be considered. 
AZD9668 is capable of inhibiting NE-activity in human patients (831, 832) and 
patient derived neutrophils (833). Oral administration of AZD9668 to rats or mice 
prevented NE-induced lung injury and reduced inflammation following exposure to 
cigarette smoke (833). AZD9668 may be an effective inhibitor of NE in tumor models.  
NE knockout reduces tumor growth (Figure 38C) and proliferation (Figure 
39A,B) in the C3(1)TAg of TNBC. The MMTV-PyMT breast tumor model has been 
suggested throughout this discussion as a possible alternative to examine the role of 
NE in metastatic breast cancer largely based on the abundant infiltration of neutrophils 
in MMTV-PyMT (800). To testing the efficacy of AZD9668 in breast cancer, C3(1)TAg 
and MMTV-PyMT transgenic mice could be orally administered AZD9668 following 
tumor initiation at approximately 4 months, proliferation, absolute growth delay, and 
metastasis as primary endpoints. As a preventative therapy AZD9668 could be 
administered beginning at four weeks of age with tumor-free survival as the primary end 
point.  
Chemotherapeutic agents activate tumor fibroblast resulting the production of 
inflammatory cytokines and chemokines resulting in a robust inflammatory resoponse 
and the recruitment of neutrophils and macrophages (348, 834). TAN in the tumor 
microenvironment likely contribute NE, which may have a role in chemoresistance and 
recurrence based on the results presented within this dissertation. Therefore 
combination of cytotoxic chemotherapy with AZD9668 may be an effective anti-tumor 
strategy. This hypothesis could be tested in traditional cell line xenograft models of 
breast cancer or in patient specimen derived explant models which are more 
representative of human tumors. In these models, tumor regression, survival, and 
recurrence could be examined following co-administration of AZD9668 and cytotoxic 
chemotherapeutics, such as doxorubincin. 
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Conclusions 
The interdependency of tumor cells and the microenvironment in which they 
evolve (7) provides a strong rationale for the therapeutic targeting of essential crosstalk. 
The cellular constituents of the tumor microenvironment are not susceptible to the 
selective pressures driving therapeutic resistance in tumor cells; therefore, therapeutic 
modalities targeting critical microenvironmental factors may yield durable antitumor 
responses.  
The data presented here suggests that NE is an important downstream effector 
of TAN capable of inducing ERK signaling and cell proliferation. The absence of elafin 
in the majority of breast tumor enhances sensitivity to the mitogenic effects of NE. Elafin 
has tumor suppressive properties in vitro. The absence of NE significantly decreased 
tumor growth and proliferation in vivo. A therapeutic approach directed specifically at 
controlling deregulated NE-activity may therefore be an effective therapy in breast 
cancer. Effective inhibitors of NE have been developed for the treatment of 
inflammatory lung disease (11). 
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